Robert C. Bast, M.D.

Peer-Reviewed Articles

1. Guo, J, Wang, C, Luo, N, Wu, Y, Huang, W, Zhu, J, Shi, W, Ding, J, Ge, Y, Liu, C, Lu, Z, Bast RC, Ai, GH, Yang, W, Wang, R, Li, C, Chen, R, Liu, S, Jin, H, Zhao, B, Cheng, Z. IL-2-free tumor-infiltrating lymphocyte therapy with PD-1 blockade demonstrates potent efficacy in advanced gynecologic cancer. BMC medicine 22(1), 2024. PMID: 38769543.
2. Fahrmann, JF, Ghasemi, SM, Han, CY, Wu, R, Dennison, JB, Vykoukal, JV, Celestino, J, Lu, KH, Lu, Z, Drescher, CW, Do, K, Hanash, SM, Bast Jr, RC, Irajizad, E. A metabolite-based liquid biopsy for detection of ovarian cancer. Biomarker Research 12(1), 2024. PMID: 39192316.
3. Santiago-O'Farrill JM, Blessing Bollu A, Yang H, Orellana V, Pina M, Zhang X, Liu J, Bast RC Jr, Lu Z. Crizotinib Enhances PARP Inhibitor Efficacy in Ovarian Cancer Cells and Xenograft Models by Inducing Autophagy. Mol Cancer Res 22(9):840-851, 2024. PMID: 38780897.
4. Han CY, Lu KH, Corrigan G, Perez A, Kohring SD, Celestino J, Bedi D, Bedia E, Bevers T, Boruta D, Carlson M, Holman L, Leeds L, Mathews C, McCann G, Moore RG, Schlumbrecht M, Slomovitz B, Tobias D, Williams-Brown Y, Bevers MW, Liu J, Gornet TG, Handy BC, Lu Z, Bedia JS, Skates SJ, Bast RC Jr. Normal Risk Ovarian Screening Study: 21-Year Update. J Clin Oncol 42(10):1102-1109, 2024. PMID: 38194613.
5. Wang F, Yu X, Qian J, Cao Y, Dong S, Zhan S, Lu Z, Bast RC Jr, Song Q, Chen Y, Zhang Y, Zhou J. A novel SIK2 inhibitor SIC-19 exhibits synthetic lethality with PARP inhibitors in ovarian cancer. Drug Resist Updat 74:101077, 2024. PMID: 38518726.
6. Bildik G, Gray JP, Mao W, Yang H, Ozyurt R, Orellana VR, De Wever O, Carey MS, Bast RC, Lu Z. DIRAS3 induces autophagy and enhances sensitivity to anti-autophagic therapy in KRAS-driven pancreatic and ovarian carcinomas. Autophagy 20(3):675-691, 2024. PMID: 38169324.
7. Han YC, Bedia JS, Yang WL, Hawley SJ, Bergan L, Hopper M, Celestino J, Guo J, Gornet TG, Soosaipillai A, Yang H, Doskocil SD, Lokshin AE, Handy BC, Diamandis EP, Moore RG, Lu KH, Lu Z, Anderson KS, Drescher CW, Skates SJ, Bast RC Jr. Autoantibodies, antigen-autoantibody complexes and antigens complement CA125 for early detection of ovarian cancer. Br J Cancer 130(5):861-868, 2024. PMID: 38195887.
8. Liang X, Jung SY, Fong LW, Bildik G, Gray JP, Mao W, Zhang S, Millward SW, Gorfe AA, Zhou Y, Lu Z, Bast RC Jr. Membrane anchoring of the DIRAS3 N-terminal extension permits tumor suppressor function. iScience 26(11):108151, 2023. PMID: 37915607.
9. Heinzl N, Maritschnegg E, Koziel K, Schilhart-Wallisch C, Heinze G, Yang WL, Bast RC, Sehouli J, Braicu EI, Vergote I, Van Gorp T, Mahner S, Paspalj V, Grimm C, Obermayr E, Schuster E, Holzer B, Rousseau F, Schymkowitz J, Concin N, Zeillinger R. Amyloid-like p53 as prognostic biomarker in serous ovarian cancer-a study of the OVCAD consortium. Oncogene 42(33):2473-2484, 2023. e-Pub 2023. PMID: 37402882.
10. Irajizad E, Han CY, Celestino J, Wu R, Murage E, Spencer R, Dennison JB, Vykoukal J, Long JP, Do KA, Drescher C, Lu K, Lu Z, Bast RC, Hanash S, Fahrmann JF. A blood-based metabolite panel for distinguishing ovarian cancer from benign pelvic masses. Clin Cancer Res 28(21):4669-4676, 2022. e-Pub 2022. PMID: 36037307.
11. Handley KF, Sims TT, Bateman NW, Glassman D, Foster KI, Lee S, Yao J, Yao H, Fellman BM, Liu J, Lu Z, Conrads KA, Hood BL, Barakat W, Zhao L, Zhang J, Westin SN, Celestino J, Rangel KM, Badal S, Pereira I, Ram PT, Maxwell GL, Eberlin LS, Futreal PA, Bast RC, Fleming ND, Conrads TP, Sood AK. Classification of High-Grade Serous Ovarian Cancer Using Tumor Morphologic Characteristics. JAMA Netw Open 5(10):e2236626, 2022. e-Pub 2022. PMID: 36239936.
12. Brown H, Chung M, Üffing A, Batistatou N, Tsang T, Doskocil S, Mao W, Willbold D, Bast RC, Lu Z, Weiergräber OH, Kritzer JA. Structure-Based Design of Stapled Peptides That Bind GABARAP and Inhibit Autophagy. J Am Chem Soc 144(32):14687-14697, 2022. e-Pub 2022. PMID: 35917476.
13. Shi X, Yu X, Wang J, Bian S, Li Q, Fu F, Zou X, Zhang L, Bast RC, Lu Z, Guo L, Chen Y, Zhou J. SIK2 promotes ovarian cancer cell motility and metastasis by phosphorylating MYLK. Mol Oncol 16(13):2558-2574, 2022. e-Pub 2022. PMID: 35278271.
14. Boylan KLM, Petersen A, Starr TK, Pu X, Geller MA, Bast RC, Lu KH, Cavallaro U, Connolly DC, Elias KM, Cramer DW, Pejovic T, Skubitz APN. Development of a multi-protein classifier for the detection of early stage ovarian cancer. Cancers (Basel) 14(13), 2022. e-Pub 2022. PMID: 35804849.
15. Grindel BJ, Engel BJ, Ong JN, Srinivasamani A, Liang X, Zacharias NM, Bast RC, Curran MA, Takahashi TT, Roberts RW, Millward SW. Directed Evolution of PD-L1-Targeted Affibodies by mRNA Display. ACS Chem Biol 17(6):1543-1555, 2022. e-Pub 2022. PMID: 35611948.
16. Zheng Y, Sethi R, Mangala LS, Taylor C, Goldsmith J, Wang M, Masuda K, Carrami EM, Mannion D, Miranda F, Herrero-Gonzalez S, Hellner K, Chen F, Alsaadi A, Albukhari A, Fotso DC, Yau C, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Knapp S, Gray NS, Campo L, Myers KA, Dhar S, Ferguson D, Bast RC, Sood AK, von Delft F, Ahmed AA. Author Correction: Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation. Nat Commun 13(1):3352, 2022. e-Pub 2022. PMID: 35688808.
17. Lu Z, Mao W, Yang H, Santiago-O'Farrill JM, Rask PJ, Mondal J, Chen H, Ivan C, Liu X, Liu CG, Xi Y, Masuda K, Carrami EM, Chen M, Tang Y, Pang L, Lakomy DS, Calin GA, Liang H, Ahmed AA, Vankayalapati H, Bast RC. SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers. J Clin Invest 132(11), 2022. PMID: 35642638.
18. Kim CS, Nevozhay D, Aburto RR, Pehere A, Pang L, Dillard R, Wang Z, Smith C, Mathieu KB, Zhang M, Hazle JD, Bast RC, Sokolov K. One-Pot, One-Step Synthesis of Drug-Loaded Magnetic Multimicelle Aggregates. Bioconjug Chem 33(5):969-981, 2022. e-Pub 2022. PMID: 35522527.
19. Niu N, Yao J, Bast RC, Sood AK, Liu J. IL-6 promotes drug resistance through formation of polyploid giant cancer cells and stromal fibroblast reprogramming. Oncogenesis 10(9):65, 2021. e-Pub 2021. PMID: 34588424.
20. Han CY, Patten DA, Kim SI, Lim JJ, Chan DW, Siu MKY, Han Y, Carmona E, Parks RJ, Lee C, Di LJ, Lu Z, Chan KKL, Ku JL, Macdonald EA, Vanderhyden BC, Mes-Masson AM, Ngan HYS, Cheung ANY, Song YS, Bast RC, Harper ME, Tsang BK. Nuclear HKII-P-p53 (Ser15) Interaction is a Prognostic Biomarker for Chemoresponsiveness and Glycolytic Regulation in Epithelial Ovarian Cancer. Cancers (Basel) 13(14), 2021. e-Pub 2021. PMID: 34298618.
21. Niu N, Shen W, Zhong Y, Bast RC, Jazaeri A, Sood AK, Liu J. Expression of B7-H4 and IDO1 is associated with drug resistance and poor prognosis in high-grade serous ovarian carcinomas. Hum Pathol 113:20-27, 2021. e-Pub 2021. PMID: 33887301.
22. Artibani M, Masuda K, Hu Z, Rauher PC, Mallett G, Wietek N, Morotti M, Chong K, KaramiNejadRanjbar M, Zois CE, Dhar S, El-Sahhar S, Campo L, Blagden SP, Damato S, Pathiraja PN, Nicum S, Gleeson F, Laios A, Alsaadi A, Santana Gonzalez L, Motohara T, Albukhari A, Lu Z, Bast RC, Harris AL, Ejsing CS, Klemm RW, Yau C, Sauka-Spengler T, Ahmed AA. Adipocyte-like signature in ovarian cancer minimal residual disease identifies metabolic vulnerabilities of tumor initiating cells. JCI Insight 6(11):e147929, 2021. e-Pub 2021. PMID: 33945502.
23. Fahrmann JF, Irajizad E, Kobayashi M, Vykoukal J, Dennison JB, Murage E, Wu R, Long JP, Do KA, Celestino J, Lu KH, Lu Z, Bast RC, Hanash S. A MYC-Driven Plasma Polyamine Signature for Early Detection of Ovarian Cancer. Cancers (Basel) 13(4):1-22, 2021. e-Pub 2021. PMID: 33671595.
24. Lokshin A, Bast RC, Rodland K. Circulating Cancer Biomarkers. Cancers (Basel) 13(4):1-5, 2021. e-Pub 2021. PMID: 33671847.
25. Fan D, Yang H, Mao W, Rask PJ, Pang L, Xu C, Vankayalapat H, Ahmed AA, Bast RC, Lu Z. A novel salt inducible kinase 2 inhibitor, ARN-3261, sensitizes ovarian cancer cell lines and xenografts to carboplatin. Cancers (Basel) 13(3):1-15, 2021. e-Pub 2021. PMID: 33503955.
26. Gray JP, Uddin MN, Chaudhari R, Sutton MN, Yang H, Rask P, Locke H, Engel BJ, Batistatou N, Wang J, Grindel BJ, Bhattacharya P, Gammon ST, Zhang S, Piwnica-Worms D, Kritzer JA, Lu Z, Bast RC, Millward SW. Directed evolution of cyclic peptides for inhibition of autophagy. Chem Sci 12(10):3526-3543, 2021. e-Pub 2021. PMID: 34163626.
27. Klionsky DJ, Abdel-Aziz AK, Abdelfatah S, Abdellatif M, Abdoli A, Abel S, Abeliovich H, Abildgaard MH, Abudu YP, Acevedo-Arozena A, Adamopoulos IE, Adeli K, Adolph TE, Adornetto A, Aflaki E, Agam G, Agarwal A, Aggarwal BB, Agnello M, Agostinis P, Agrewala JN, Agrotis A, Aguilar PV, Ahmad ST, Ahmed ZM, Ahumada-Castro U, Aits S, Aizawa S, Akkoc Y, Akoumianaki T, Akpinar HA, Al-Abd AM, Al-Akra L, Al-Gharaibeh A, Alaoui-Jamali MA, Alberti S, Alcocer-Gómez E, Alessandri C, Ali M, Alim Al-Bari MA, Aliwaini S, Alizadeh J, Almacellas E, Almasan A, Alonso A, Alonso GD, Altan-Bonnet N, Altieri DC, ÉMC Á, Alves S, Alves da Costa C, Alzaharna MM, Amadio M, Amantini C, Amaral C, Ambrosio S, Amer AO, Ammanathan V, An Z, Andersen SU, Andrabi SA, Andrade-Silva M, Andres AM, Angelini S, Ann D, Anozie UC, Ansari MY, Antas P, Antebi A, Antón Z, Anwar T, Apetoh L, Apostolova N, Araki T, Araki Y, Arasaki K, Araújo WL, Araya J, Arden C, Arévalo MA, Arguelles S, Arias E, Arikkath J, Arimoto H, Ariosa AR, Armstrong-James D, Arnauné-Pelloquin L, Aroca A, Arroyo DS, Arsov I, Artero R, Asaro DML, Aschner M, Ashrafizadeh M, Ashur-Fabian O, Atanasov AG, Au AK, Auberger P, Auner HW, Aurelian L, Autelli R, Avagliano L, Ávalos Y, Aveic S, Aveleira CA, Avin-Wittenberg T, Aydin Y, Ayton S, Ayyadevara S, Azzopardi M, Baba M, Backer JM, Backues SK, Bae DH, Bae ON, Bae SH, Baehrecke EH, Baek A, Baek SH, Baek SH, Bagetta G, Bagniewska-Zadworna A, Bai H, Bai J, Bai X, Bai Y, Bairagi N, Baksi S, Balbi T, Baldari CT, Balduini W, Ballabio A, Ballester M, Balazadeh S, Balzan R, Bandopadhyay R, Banerjee S, Banerjee S, Á B, Bao Y, Baptista MS, Baracca A, Barbati C, Bargiela A, Barilà D, Barlow PG, Barmada SJ, Barreiro E, Barreto GE, Bartek J, Bartel B, Bartolome A, Barve GR, Basagoudanavar SH, Bassham DC, Bast RC, Basu A, Batoko H, Batten I, Baulieu EE, Baumgarner BL, Bayry J, Beale R, Beau I, Beaumatin F, Bechara LRG, Beck GR, Beers MF, Begun J, Behrends C, Behrens GMN, Bei R, Bejarano E, Bel S, B. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition). Autophagy 17(1):1-382, 2021. e-Pub 2021. PMID: 33634751.
28. Blackman A, Mitchell J, Rowswell-Turner R, Singh R, Kim KK, Eklund E, Skates S, Bast RC, Messerlian G, Miller MC, Moore RG. Analysis of serum HE4 levels in various histologic subtypes of epithelial ovarian cancer and other malignant tumors. Tumour Biol 43(1):355-365, 2021. PMID: 34957977.
29. Bast RC, Han CY, Lu Z, Lu KH. Next steps in the early detection of ovarian cancer. Commun Med (Lond) 1(1):36, 2021. e-Pub 2021. PMID: 34676377.
30. Kim O, Park EY, Kwon SY, Shin S, Emerson RE, Shin YH, DeMayo FJ, Lydon JP, Coffey DM, Hawkins SM, Quilliam LA, Cheon DJ, Fernández FM, Nephew KP, Karpf AR, Widschwendter M, Sood AK, Bast RC, Godwin AK, Miller KD, Cho CH, Kim J. Targeting progesterone signaling prevents metastatic ovarian cancer. Proc Natl Acad Sci U S A 117(50):31993-32004, 2020. e-Pub 2020. PMID: 33262282.
31. Bast RC, Lu Z, Han CY, Lu KH, Anderson KS, Drescher CW, Skates SJ. Biomarkers and Strategies for Early Detection of Ovarian Cancer. Cancer Epidemiol Biomarkers Prev 29(12):2504-2512, 2020. e-Pub 2020. PMID: 33051337.
32. Bast RC, Srivastava S. The National Cancer Institute Early Detection Research Network: Two Decades of Progress. Cancer Epidemiol Biomarkers Prev 29(12):2396-2400, 2020. PMID: 33262198.
33. Blessing AM, Santiago-O'Farrill JM, Mao W, Pang L, Ning J, Pak D, Bollu LR, Rask P, Iles L, Yang H, Tran S, Elmir E, Bartholomeusz G, Langley R, Lu Z, Bast RC. Elimination of dormant, autophagic ovarian cancer cells and xenografts through enhanced sensitivity to anaplastic lymphoma kinase inhibition. Cancer 126(15):3579-3592, 2020. e-Pub 2020. PMID: 32484926.
34. Gentry-Maharaj A, Blyuss O, Ryan A, Burnell M, Karpinskyj C, Gunu R, Kalsi JK, Dawnay A, Marino IP, Manchanda R, Lu K, Yang WL, Timms JF, Parmar M, Skates SJ, Bast RC, Jacobs IJ, Zaikin A, Menon U. Multi-Marker Longitudinal Algorithms Incorporating HE4 and CA125 in Ovarian Cancer Screening of Postmenopausal Women. Cancers (Basel) 12(7), 2020. e-Pub 2020. PMID: 32708856.
35. Li YC, Lytle NK, Gammon ST, Wang L, Hayes TK, Sutton MN, Bast RC, Der CJ, Piwnica-Worms D, McCormick F, Wahl GM. Analysis of RAS protein in living cells reveals a mechanism for pan-RAS depletion by membrane-targeted RAS binders. Proc Natl Acad Sci U S A 117(22):12121-12130, 2020. e-Pub 2020. PMID: 32424096.
36. Kim O, Park EY, Klinkebiel DL, Pack SD, Shin YH, Abdullaev Z, Emerson RE, Coffey DM, Kwon SY, Creighton CJ, Kwon S, Chang EC, Chiang T, Yatsenko AN, Chien J, Cheon DJ, Yang-Hartwich Y, Nakshatri H, Nephew KP, Behringer RR, Fernández FM, Cho CH, Vanderhyden B, Drapkin R, Bast RC, Miller KD, Karpf AR, Kim J. In vivo modeling of metastatic human high-grade serous ovarian cancer in mice. PLoS Genet 16(6):e1008808, 2020. e-Pub 2020. PMID: 32497036.
37. Lyu T, Jiang Y, Jia N, Che X, Li Q, Yu Y, Hua K, Bast RC, Feng W. SMYD3 promotes implant metastasis of ovarian cancer via H3K4 trimethylation of integrin promoters. Int J Cancer 146(6):1553-1567, 2020. e-Pub 2019. PMID: 31503345.
38. Kobayashi M, Katayama H, Irajizad E, Vykoukal JV, Fahrmann JF, Kundnani DL, Yu CY, Cai Y, Hsiao FC, Yang WL, Lu Z, Celestino J, Long JP, Do KA, Lu KH, Ladd JJ, Urban N, Bast RC, Hanash SM. Proteome Profiling Uncovers an Autoimmune Response Signature That Reflects Ovarian Cancer Pathogenesis. Cancers (Basel) 12(2):485, 2020. e-Pub 2020. PMID: 32092936.
39. Santiago-O'Farrill JM, Weroha SJ, Hou X, Oberg AL, Heinzen EP, Maurer MJ, Pang L, Rask P, Amaravadi RK, Becker SE, Romero I, Rubio MJ, Matias-Guiu X, Santacana M, Llombart-Cussac A, Poveda A, Lu Z, Bast RC. Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models. Cancer 126(4):894-907, 2020. e-Pub 2019. PMID: 31714594.
40. Yang WL, Lu Z, Guo J, Fellman BM, Ning J, Lu KH, Menon U, Kobayashi M, Hanash SM, Celestino J, Skates SJ, Bast RC. Human epididymis protein 4 antigen-autoantibody complexes complement cancer antigen 125 for detecting early-stage ovarian cancer. Cancer 126(4):725-736, 2020. e-Pub 2019. PMID: 31714597.
41. Sutton MN, Lu Z, Li YC, Zhou Y, Huang T, Reger AS, Hurwitz AM, Palzkill T, Logsdon C, Liang X, Gray JW, Nan X, Hancock J, Wahl GM, Bast RC. DIRAS3 (ARHI) blocks RAS/MAPK signaling by binding directly to Ras and disrupting Ras clusters. Cell Rep 29(11):3448-3459.e6, 2019. e-Pub 2019. PMID: 31825828.
42. Guo J, Lu Z, Bast RC. Reply to Comment on "Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancer" Cancers 2019, 11, 596: Markers for Early Detection of Ovarian Cancer. Cancers (Basel) 11(9):None, 2019. e-Pub 2019. PMID: 31540545.
43. Yang H, Shu Z, Jiang Y, Mao W, Pang L, Redwood A, Jeter-Jones SL, Jennings NB, Ornelas A, Zhou J, Rodriguez-Aguayo C, Bartholomeusz G, Iles LR, Zacharias NM, Millward SW, Lopez-Berestein G, Le XF, Ahmed AA, Piwnica-Worms H, Sood AK, Bast RC, Lu Z. 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers. Clin Cancer Res 25(18):5702-5716, 2019. e-Pub 2019. PMID: 31391192.
44. Karuturi MS, Holmes HM, Lei X, Johnson M, Barcenas CH, Cantor SB, Gallick GE, Bast RC, Giordano SH. Potentially inappropriate medications defined by STOPP criteria in older patients with breast and colorectal cancer. J Geriatr Oncol 10(5):pii: S1879-4068(18)30284-4, 2019. e-Pub 2019. PMID: 30795923.
45. Andre F, Ismaila N, Henry NL, Somerfield MR, Bast RC, Barlow W, Collyar DE, Hammond ME, Kuderer NM, Liu MC, Van Poznak C, Wolff AC, Stearns V. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results from TAILORx. J Clin Oncol 37(22):JCO1900945, 2019. e-Pub 2019. PMID: 31150316.
46. Nebgen DR, Lu KH, Bast RC. Novel approaches to ovarian cancer screening. Curr Oncol Rep 21(8):75, 2019. e-Pub 2019. PMID: 31346778.
47. Bast RC, Matulonis UA, Sood AK, Ahmed AA, Amobi AE, Balkwill FR, Wielgos-Bonvallet M, Bowtell DDL, Brenton JD, Brugge JS, Coleman RL, Draetta GF, Doberstein K, Drapkin RI, Eckert MA, Edwards RP, Elias KM, Ennis D, Futreal A, Gershenson DM, Greenberg RA, Huntsman DG, Ji JXY, Kohn EC, Iavarone C, Lengyel ER, Levine DA, Lord CJ, Lu Z, Mills GB, Modugno F, Nelson BH, Odunsi K, Pilsworth JA, Rottapel RK, Powell DJ, Shen L, Shih IM, Spriggs DR, Walton J, Zhang K, Zhang R, Zou L. Critical Questions in Ovarian Cancer Research and Treatment: Report of an American Association for Cancer Research Special Conference. Cancer 125(12):1963-1972, 2019. e-Pub 2019. PMID: 30835824.
48. Simmons AR, Fourkala EO, Gentry-Maharaj A, Ryan A, Sutton MN, Baggerly K, Zheng H, Lu KH, Jacobs I, Skates S, Menon U, Bast RC. Complementary longitudinal serum biomarkers to CA125 for early detection of ovarian cancer. Cancer Prev Res (Phila) 12(6):391-400, 2019. e-Pub 2019. PMID: 30967390.
49. Sutton MN, Huang GY, Zhou J, Mao W, Langley R, Lu Z, Bast RC. Amino Acid Deprivation-Induced Autophagy Requires Upregulation of DIRAS3 through Reduction of E2F1 and E2F4 Transcriptional Repression. Cancers (Basel) 11(5):pii: E603, 2019. e-Pub 2019. PMID: 31052266.
50. Guo J, Yang WL, Pak D, Celestino J, Lu KH, Ning J, Lokshin AE, Cheng Z, Lu Z, Bast RC. Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancer. Cancers (Basel) 11(5):pii: E596, 2019. e-Pub 2019. PMID: 31035430.
51. Sutton MN, Huang GY, Liang X, Sharma R, Reger AS, Mao W, Pang L, Rask PJ, Lee K, Gray JP, Hurwitz AM, Palzkill T, Millward SW, Kim C, Lu Z, Bast RC. DIRAS3-Derived Peptide Inhibits Autophagy in Ovarian Cancer Cells by Binding to Beclin1. Cancers (Basel) 11(4):pii: E557, 2019. e-Pub 2019. PMID: 31003488.
52. Mao W, Peters HL, Sutton MN, Orozco AF, Pang L, Yang H, Lu Z, Bast RC. The role of vascular endothelial growth factor, interleukin 8, and insulinlike growth factor in sustaining autophagic DIRAS3-induced dormant ovarian cancer xenografts. Cancer 125(8):1267-1280, 2019. e-Pub 2019. PMID: 30620384.
53. Skubitz APN, Boylan KLM, Geschwind K, Cao Q, Starr TK, Geller MA, Celestino J, Bast RC, Lu KH, Koopmeiners JS. Simultaneous Measurement of 92 Serum Protein Biomarkers for the Development of a Multi-Protein Classifier for Ovarian Cancer Detection. Cancer Prev Res (Phila) 12(3):171-184, 2019. e-Pub 2019. PMID: 30709840.
54. Yam C, Murthy RK, Rauch GM, Murray JL, Walters RS, Valero V, Brewster AM, Bast RC, Booser DJ, Giordano SH, Esteva FJ, Yang W, Hortobagyi GN, Moulder SL, Arun B. A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-β. Invest New Drugs 36(6):1103-1109, 2018. e-Pub 2018. PMID: 30311036.
55. Yang H, Mao W, Rodriguez-Aguayo C, Mangala LS, Bartholomeusz G, Iles LR, Jennings NB, Ahmed AA, Sood AK, Lopez-Berestein G, Lu Z, Bast RC. Paclitaxel Sensitivity of Ovarian Cancer can be enhanced by knocking down Pairs of Kinases that regulate MAP4 Phosphorylation and Microtubule Stability. Clin Cancer Res 24(20):5072-5084, 2018. e-Pub 2018. PMID: 30084832.
56. Engel BJ, Gammon ST, Chaudhari R, Lu Z, Pisaneschi F, Yang H, Ornelas A, Yan V, Kelderhouse L, Najjar AM, Tong WP, Zhang S, Piwnica-Worms D, Bast RC, Millward SW. Caspase-3 Substrates for Noninvasive Pharmacodynamic Imaging of Apoptosis by PET/CT. Bioconjug Chem 29(9):3180-3195, 2018. e-Pub 2018. PMID: 30168713.
57. Karuturi MS, Holmes HM, Lei X, Johnson M, Barcenas CH, Cantor SB, Gallick GE, Bast RC, Giordano SH. Potentially inappropriate medication use in older patients with breast and colorectal cancer. Cancer 124(14):3000-3007, 2018. e-Pub 2018. PMID: 29689595.
58. Mathieu KB, Bedi DG, Thrower SL, Qayyum A, Bast RC. Screening for ovarian cancer: imaging challenges and opportunities for improvement. Ultrasound Obstet Gynecol 51(3):293-303, 2018. e-Pub 2017. PMID: 28639753.
59. Zheng Y, Sethi R, Mangala LS, Taylor C, Goldsmith J, Wang M, Masuda K, Karaminejadranjbar M, Mannion D, Miranda F, Herrero-Gonzalez S, Hellner K, Chen F, Alsaadi A, Albukhari A, Fotso DC, Yau C, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Knapp S, Gray NS, Campo L, Myers KA, Dhar S, Ferguson D, Bast RC, Sood AK, von Delft F, Ahmed AA. Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation. Nat Commun 9(1):476, 2018. e-Pub 2018. PMID: 29396402.
60. Sutton MN, Yang H, Huang GY, Fu C, Pontikos M, Wang Y, Mao W, Pang L, Yang M, Liu J, Parker-Thornburg J, Lu Z, Bast RC. RAS-related GTPases DIRAS1 and DIRAS2 induce autophagic cancer cell death and are required for autophagy in murine ovarian cancer cells. Autophagy 14(4):637-53, 2018. e-Pub 2018. PMID: 29368982.
61. Lin CW, Yang H, Sanchez SR, Mao W, Pang L, Beckingham KM, Bast RC, Weisman RB. In Vivo Optical Detection and Spectral Triangulation of Carbon Nanotubes. ACS Appl Mater Interfaces 9(48):41680-41690, 2017. e-Pub 2017. PMID: 29131572.
62. Yang WL, Gentry-Maharaj A, Simmons A, Ryan A, Fourkala EO, Lu Z, Baggerly KA, Zhao Y, Lu KH, Bowtell D, Jacobs I, Skates SJ, He WW, Menon U, Bast RC, Group AS. Elevation of TP53 Autoantibody Prior to CA125 in Preclinical Invasive Epithelial Ovarian Cancer. Clin Cancer Res 23(19):5912-5922, 2017. e-Pub 2017. PMID: 28637689.
63. Krop I, Ismaila N, Andre F, Bast RC, Barlow W, Collyar DE, Hammond ME, Kuderer NM, Liu MC, Mennel RG, Van Poznak C, Wolff AC, Stearns V. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. J Clin Oncol 35(24):2838-2847, 2017. e-Pub 2017. PMID: 28692382.
64. Yang WL, Lu Z, Bast RC. The role of biomarkers in the management of epithelial ovarian cancer. Expert Rev Mol Diagn 17(6):577-591, 2017. e-Pub 2017. PMID: 28468520.
65. Zhou J, Alfraidi A, Zhang S, Santiago-O'Farrill JM, Yerramreddy Reddy VK, Alsaadi A, Ahmed AA, Yang H, Liu J, Mao W, Wang Y, Takemori H, Vankayalapati H, Lu Z, Bast RC. A novel compound ARN-3236 inhibits Salt Inducible Kinase 2 and sensitizes ovarian cancer cell lines and xenografts to paclitaxel. Clin Cancer Res 23(8):1945-1954, 2017. e-Pub 2016. PMID: 27678456.
66. Taylor C, Mannion D, Miranda F, Karaminejadranjbar M, Herrero-Gonzalez S, Hellner K, Zheng Y, Bartholomeusz G, Bast RC, Ahmed AA. Loss of PFKFB4 induces cell death in mitotically arrested ovarian cancer cells. Oncotarget 8(11):17960-17980, 2017. e-Pub 2017. PMID: 28152500.
67. Blessing AM, Rajapakshe K, Reddy Bollu L, Shi Y, White MA, Pham AH, Lin C, Jonsson P, Cortes CJ, Cheung E, La Spada AR, Bast RC, Merchant FA, Coarfa C, Frigo DE. Transcriptional Regulation of Core Autophagy and Lysosomal Genes by the Androgen Receptor Promotes Prostate Cancer Progression. Autophagy 13(3):506-21, 2017. e-Pub 2016. PMID: 27977328.
68. Niu N, Zhang J, Zhang N, Mercado-Uribe I, Tao F, Han Z, Pathak S, Multani AS, Kuang J, Yao J, Bast RC, Sood AK, Hung MC, Liu J. Linking genomic reorganization to tumor initiation via the giant cell cycle. Oncogenesis 5(12):e281, 2016. e-Pub 2016. PMID: 27991913.
69. Ornelas A, McCullough CR, Lu Z, Zacharias NM, Kelderhouse LE, Gray J, Yang H, Engel BJ, Wang Y, Mao W, Sutton MN, Bhattacharya PK, Bast RC, Millward SW. Induction of autophagy by ARHI (DIRAS3) alters fundamental metabolic pathways in ovarian cancer models. BMC Cancer 16(1):824, 2016. e-Pub 2016. PMID: 27784287.
70. Leung F, Bernardini MQ, Brown MD, Zheng Y, Molina R, Bast RC, Davis G, Serra S, Diamandis EP, Kulasingam V. Validation of a novel biomarker panel for the detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev 25(9):1333-40, 2016. e-Pub 2016. PMID: 27448593.
71. Miranda F, Mannion D, Liu S, Zheng Y, Mangala LS, Redondo C, Herrero-Gonzalez S, Xu R, Taylor C, Chedom DF, Karaminejadranjbar M, Albukhari A, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Salah E, Abdul Azeez KR, Elkins JM, Campo L, Myers KA, Klotz D, Bivona S, Dhar S, Bast RC, Saya H, Choi HG, Gray NS, Fischer R, Kessler BM, Yau C, Sood AK, Motohara T, Knapp S, Ahmed AA. Salt-Inducible Kinase 2 Couples Ovarian Cancer Cell Metabolism with Survival at the Adipocyte-Rich Metastatic Niche. Cancer Cell 30(2):273-289, 2016. e-Pub 2016. PMID: 27478041.
72. Hellner K, Miranda F, Fotso Chedom D, Herrero-Gonzalez S, Hayden DM, Tearle R, Artibani M, KaramiNejadRanjbar M, Williams R, Gaitskell K, Elorbany S, Xu R, Laios A, Buiga P, Ahmed K, Dhar S, Zhang RY, Campo L, Myers KA, Lozano M, Ruiz-Miró M, Gatius S, Mota A, Moreno-Bueno G, Matias-Guiu X, Benítez J, Witty L, McVean G, Leedham S, Tomlinson I, Drmanac R, Cazier JB, Klein R, Dunne K, Bast RC, Kennedy SH, Hassan B, Lise S, Garcia MJ, Peters BA, Yau C, Sauka-Spengler T, Ahmed AA. Premalignant SOX2 overexpression in the fallopian tubes of ovarian cancer patients: Discovery and validation studies. EBioMedicine 10:137-49, 2016. e-Pub 2016. PMID: 27492892.
73. Simmons AR, Clarke CH, Badgwell DB, Lu Z, Sokoll LJ, Lu KH, Zhang Z, Bast RC, Skates SJ. Validation of a biomarker panel and longitudinal biomarker performance for early detection of ovarian cancer. Int J Gynecol Cancer 26(6):1070-7, 2016. e-Pub 2016. PMID: 27206285.
74. Gao M, Ma Y, Bast RC, Li Y, Wan L, Liu Y, Sun Y, Fang Z, Zhang L, Wang X, Wei Z. Epac1 knockdown inhibits the proliferation of ovarian cancer cells by inactivating AKT/Cyclin D1/CDK4 pathway in vitro and in vivo. Med Oncol 33(7):73, 2016. e-Pub 2016. PMID: 27277757.
75. Chen J, Bai M, Ning C, Xie B, Zhang J, Liao H, Xiong J, Tao X, Yan D, Xi X, Chen X, Yu Y, Bast RC, Zhang Z, Feng Y, Zheng W. Gankyrin facilitates follicle-stimulating hormone-driven ovarian cancer cell proliferation through the PI3K/AKT/HIF-1α/cyclin D1 pathway. Oncogene 35(19):2506-17, 2016. e-Pub 2015. PMID: 26364616.
76. Harris LN, Ismaila N, McShane LM, Andre F, Collyar DE, Gonzalez-Angulo AM, Hammond EH, Kuderer NM, Liu MC, Mennel RG, Van Poznak C, Bast RC, Hayes DF, Clinical Oncology ASO. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women with Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 34(10):1134-50, 2016. e-Pub 2016. PMID: 26858339.
77. Ejaz A, Mitterberger MC, Lu Z, Mattesich M, Zwierzina ME, Hörl S, Kaiser A, Viertler HP, Rostek U, Meryk A, Khalid S, Pierer G, Bast RC, Zwerschke W. Weight Loss Upregulates the Small GTPase DIRAS3 in Human White Adipose Progenitor Cells, Which Negatively Regulates Adipogenesis and Activates Autophagy via Akt-mTOR Inhibition. EBioMedicine 6:149-61, 2016. e-Pub 2016. PMID: 27211557.
78. Morgado M, Sutton MN, Simmons M, Warren CR, Lu Z, Constantinou PE, Liu J, Francis LL, Conlan RS, Bast RC, Carson DD. Tumor necrosis factor-α and interferon-γ stimulate MUC16 (CA125) expression in breast, endometrial and ovarian cancers through NFκB. Oncotarget 7(12):14871-84, 2016. e-Pub 2016. PMID: 26918940.
79. Zhang S, Mercado-Uribe I, Sood A, Bast RC, Liu J. Coevolution of neoplastic epithelial cells and multilineage stroma via polyploid giant cells during immortalization and transformation of mullerian epithelial cells. Genes Cancer 7(3-4):60-72, 2016. PMID: 27382431.
80. Redis RS, Vela LE, Lu W, Ferreira de Oliveira J, Ivan C, Rodriguez-Aguayo C, Adamoski D, Pasculli B, Taguchi A, Chen Y, Fernandez AF, Valledor L, Van Roosbroeck K, Chang S, Shah M, Kinnebrew G, Han L, Atlasi Y, Cheung LH, Huang GY, Monroig P, Ramirez MS, Catela Ivkovic T, Van L, Ling H, Gafà R, Kapitanovic S, Lanza G, Bankson JA, Huang P, Lai SY, Bast RC, Rosenblum MG, Radovich M, Ivan M, Bartholomeusz G, Liang H, Fraga MF, Widger WR, Hanash S, Berindan-Neagoe I, Lopez-Berestein G, Ambrosio ALB, Gomes Dias SM, Calin GA. Allele-specific reprogramming of cancer metabolism by the long non-coding RNA, CCAT2. Mol Cell 61(4):520-34, 2016. e-Pub 2016. PMID: 26853146.
81. Yang H, Das P, Yu Y, Mao W, Wang Y, Baggerly K, Wang Y, Marquez RT, Bedi A, Liu J, Fishman D, Lu Z, Bast RC. NDN is an imprinted tumor suppressor gene that is downregulated in ovarian cancers through genetic and epigenetic mechanisms. Oncotarget 7(3):3018-32, 2016. e-Pub 2015. PMID: 26689988.
82. Sölétormos G, Duffy MJ, Othman Abu Hassan S, Verheijen RH, Tholander B, Bast RC, Gaarenstroom KN, Sturgeon CM, Bonfrer JM, Petersen PH, Troonen H, CarloTorre G, Kanty Kulpa J, Tuxen MK, Molina R. Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers. Int J Gynecol Cancer 26(1):43-51, 2016. PMID: 26588231.
83. Ma Y, Wei Z, Bast RC, Wang Z, Li Y, Gao M, Liu Y, Wang X, Guo C, Zhang L, Wang X. Downregulation of TRIM27 expression inhibits the proliferation of ovarian cancer cells in vitro and in vivo. Lab Invest 96(1):37-48, 2016. e-Pub 2015. PMID: 26568293.
84. Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD, Adeli K, Adhihetty PJ, Adler SG, Agam G, Agarwal R, Aghi MK, Agnello M, Agostinis P, Aguilar PV, Aguirre-Ghiso J, Airoldi EM, Ait-Si-Ali S, Akematsu T, Akporiaye ET, Al-Rubeai M, Albaiceta GM, Albanese C, Albani D, Albert ML, Aldudo J, Algül H, Alirezaei M, Alloza I, Almasan A, Almonte-Beceril M, Alnemri ES, Alonso C, Altan-Bonnet N, Altieri DC, Alvarez S, Alvarez-Erviti L, Alves S, Amadoro G, Amano A, Amantini C, Ambrosio S, Amelio I, Amer AO, Amessou M, Amon A, An Z, Anania FA, Andersen SU, Andley UP, Andreadi CK, Andrieu-Abadie N, Anel A, Ann DK, Anoopkumar-Dukie S, Antonioli M, Aoki H, Apostolova N, Aquila S, Aquilano K, Araki K, Arama E, Aranda A, Araya J, Arcaro A, Arias E, Arimoto H, Ariosa AR, Armstrong JL, Arnould T, Arsov I, Asanuma K, Askanas V, Asselin E, Atarashi R, Atherton SS, Atkin JD, Attardi LD, Auberger P, Auburger G, Aurelian L, Autelli R, Avagliano L, Avantaggiati ML, Avrahami L, Awale S, Azad N, Bachetti T, Backer JM, Bae DH, Bae JS, Bae ON, Bae SH, Baehrecke EH, Baek SH, Baghdiguian S, Bagniewska-Zadworna A, Bai H, Bai J, Bai XY, Bailly Y, Balaji KN, Balduini W, Ballabio A, Balzan R, Banerjee R, Bánhegyi G, Bao H, Barbeau B, Barrachina MD, Barreiro E, Bartel B, Bartolomé A, Bassham DC, Bassi MT, Bast RC, Basu A, Batista MT, Batoko H, Battino M, Bauckman K, Baumgarner BL, Bayer KU, Beale R, Beaulieu JF, Beck GR, Becker C, Beckham JD, Bédard PA, Bednarski PJ, Begley TJ, Behl C, Behrends C, Behrens GM, Behrns KE, Bejarano E, Belaid A, Belleudi F, Bénard G, Berchem G, Bergamaschi D, Bergami M, Berkhout B, Berliocchi L, Bernard A, Bernard M, Bernassola F, Bertolotti A, Bess AS, Besteiro S, Bettuzzi S, Bhalla S, Bhattacharyya S, Bhutia SK, Biagosch C, Bianchi MW, Biard-Piechaczyk M, Billes V, Bincoletto C, Bingol B, Bird SW, Bitoun M, Bjedov I, Blackstone C, Blanc L, Blanco GA, Blomhoff HK, Boada-Romero E, Böckler S, Boes M, Boesze-Battaglia. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy 12(1):1-222, 2016. PMID: 26799652.
85. Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ, Bast RC, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, Brenton JD, Chiappinelli KB, Martins FC, Coukos G, Drapkin R, Edmondson R, Fotopoulou C, Gabra H, Galon J, Gourley C, Heong V, Huntsman DG, Iwanicki M, Karlan BY, Kaye A, Lengyel E, Levine DA, Lu KH, McNeish IA, Menon U, Narod SA, Nelson BH, Nephew KP, Pharoah P, Powell DJ, Ramos P, Romero IL, Scott CL, Sood AK, Stronach EA, Balkwill FR. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer 15(11):668-79, 2015. PMID: 26493647.
86. Abu Hassan SO, Nielsen DL, Tuxen MK, Jr BR, Soletormos G. Systematic review of criteria to interpret CA125 increments during monitoring of patients with advanced epithelial ovarian cancer. J Oncol Med Pract 1(1):1000101 (1-11), 2015. PMID: None.
87. Van Poznak C, Somerfield MR, Bast RC, Cristofanilli M, Goetz MP, Gonzalez-Angulo AM, Hicks DG, Hill EG, Liu MC, Lucas W, Mayer IA, Mennel RG, Symmans WF, Hayes DF, Harris LN. Use of Biomarkers to Guide Decisions on Systemic Therapy for Women with Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 33(24):2695-704, 2015. e-Pub 2015. PMID: 26195705.
88. Washington MN, Suh G, Orozco AF, Sutton MN, Yang H, Wang Y, Mao W, Millward S, Ornelas A, Atkinson N, Liao W, Bast RC, Lu Z. ARHI (DIRAS3)-mediated autophagy-associated cell death enhances chemosensitivity to cisplatin in ovarian cancer cell lines and xenografts. Cell Death Dis 6:e1836, 2015. e-Pub 2015. PMID: 26247722.
89. Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC, Bennett JM, Benz EJ, Berliner N, Bertino J, Bhatia R, Bhatia S, Bhojwani D, Blanke CD, Bloomfield CD, Bosserman L, Broxmeyer HE, Byrd JC, Cabanillas F, Canellos GP, Chabner BA, Chanan-Khan A, Cheson B, Clarkson B, Cohn SL, Colon-Otero G, Cortes J, Coutre S, Cristofanilli M, Curran WJ, Daley GQ, DeAngelo DJ, Deeg HJ, Einhorn LH, Erba HP, Esteva FJ, Estey E, Fidler IJ, Foran J, Forman S, Freireich E, Fuchs C, George JN, Gertz MA, Giralt S, Golomb H, Greenberg P, Gutterman J, Handin RI, Hellman S, Hoff PM, Hoffman R, Hong WK, Horowitz M, Hortobagyi GN, Hudis C, Issa JP, Johnson BE, Kantoff PW, Kaushansky K, Khayat D, Khuri FR, Kipps TJ, Kripke M, Kyle RA, Larson RA, Lawrence TS, Levine R, Link MP, Lippman SM, Lonial S, Lyman GH, Markman M, Mendelsohn J, Meropol NJ, Messinger Y, Mulvey TM, O'Brien S, Perez-Soler R, Pollock R, Prchal J, Press O, Radich J, Rai K, Rosenberg SA, Rowe JM, Rugo H, Runowicz CD, Sandmaier BM, Saven A, Schafer AI, Schiffer C, Sekeres MA, Silver RT, Siu LL, Steensma DP, Stewart FM, Stock W, Stone R, Storb R, Strong LC, Tallman MS, Thompson M, Ueno NT, Van Etten RA, Vose JM, Wiernik PH, Winer EP, Younes A, Zelenetz AD, LeMaistre CA. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc 90(8):996-1000, 2015. e-Pub 2015. PMID: 26211600.
90. Pickering CR, Bast RC, Keyomarsi K. How will we recruit, train, and retain physicians and scientists to conduct translational cancer research?. Cancer 121(6):806-16, 2015. e-Pub 2014. PMID: 25355050.
91. Zhang S, Lu Z, Unruh AK, Ivan C, Baggerly KA, Calin GA, Li Z, Bast RC, Le XF. Clinically relevant microRNAs in ovarian cancer. Mol Cancer Res 13(3):393-401, 2015. e-Pub 2014. PMID: 25304686.
92. Shadfan BH, Simmons AR, Simmons GW, Ho A, Wong J, Lu KH, Bast RC, McDevitt JT. A multiplexable, microfluidic platform for the rapid quantitation of a biomarker panel for early ovarian cancer detection at the point-of-care. Cancer Prev Res (Phila) 8(1):37-48, 2015. e-Pub 2014. PMID: 25388014.
93. Zhang S, Lu Z, Mao W, Ahmed AA, Yang H, Zhou J, Jennings N, Rodriguez-Aguayo C, Lopez-Berestein G, Miranda R, Qiao W, Baladandayuthapani V, Li Z, Sood AK, Liu J, Le XF, Bast RC. CDK5 regulates paclitaxel sensitivity in ovarian cancer cells by modulating AKT activation, p21Cip1- and p27Kip1-mediated G1 cell cycle arrest and apoptosis. PLoS One 10(7):e0131833, 2015. e-Pub 2015. PMID: 26146988.
94. Deniger DC, Maiti SN, Mi T, Switzer KC, Ramachandran V, Hurton LV, Ang S, Olivares S, Rabinovich BA, Huls MH, Lee DA, Bast RC, Champlin RE, Cooper LJ. Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies. Clin Cancer Res 20(22):5708-19, 2014. e-Pub 2014. PMID: 24833662.
95. Bilen MA, Reyes A, Bhowmick D, Maa A, Bast R, Pisters LL, Lin SH, Logothetis CJ, Tu SM. Variant prostate carcinoma and elevated serum CA-125. Can J Urol 21(5):7442-8, 2014. PMID: 25347368.
96. Lu Z, Yang H, Sutton MN, Yang M, Clarke CH, Liao WS, Bast RC. ARHI (DIRAS3) induces autophagy in ovarian cancer cells by downregulating the epidermal growth factor receptor, inhibiting PI3K and Ras/MAP signaling and activating the FOXo3a-mediated induction of Rab7. Cell Death Differ 21(8):1275-89, 2014. e-Pub 2014. PMID: 24769729.
97. Lu Z, Baquero MT, Yang H, Yang M, Reger AS, Kim C, Levine DA, Clarke CH, Liao WS, Bast RC. DIRAS3 regulates the autophagosome initiation complex in dormant ovarian cancer cells. Autophagy 10(6):1071-1092, 2014. PMID: 24879154.
98. Holman LL, Lu KH, Bast RC, Hernandez MA, Bodurka DC, Skates S, Sun CC. Risk Perception, Worry, and Test Acceptance in Average-Risk Women Undergoing Ovarian Cancer Screening. Am J Obstet Gynecol 210(3):257.e1-6, 2014. e-Pub 2013. PMID: 24246524.
99. Lyu T, Jia N, Wang J, Yan X, Yu Y, Lu Z, Bast RC, Hua K, Feng W. Expression and epigenetic regulation of angiogenesis related factors during dormancy and recurrent growth of ovarian carcinoma. Epigenetics 8(12):1330-46, 2013. e-Pub 2013. PMID: 24135786.
100. Lu KH, Skates S, Hernandez MA, Bedi D, Bevers T, Leeds L, Moore R, Granai C, Harris S, Newland W, Adeyinka O, Geffen J, Deavers MT, Sun CC, Horick N, Fritsche H, Bast RC. A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value. Cancer 119(19):3454-61, 2013. e-Pub 2013. PMID: 23983047.
101. Zhang Z, Zhu Y, Lai Y, Wu X, Feng Z, Yu Y, Bast RC, Wan X, Xi X, Feng Y. Follicle-stimulating hormone inhibits apoptosis in ovarian cancer cells by regulating the OCT4 stem cell signaling pathway. Int J Oncol 43(4):1194-204, 2013. e-Pub 2013. PMID: 23921511.
102. Romero I, Sun CC, Wong KK, Bast RC, Gershenson DM. Low-Grade Serous Carcinoma: New Concepts and Emerging Therapies. Gynecol Oncol 130(3):660-6, 2013. e-Pub 2013. PMID: 23707670.
103. Simmons AR, Baggerly K, Bast RC. The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomas. Oncology (Williston Park) 27(6):548-56, 2013. PMID: 23909069.
104. Chen X, Zhang J, Cheng W, Chang DY, Huang J, Wang X, Jia L, Rosen DG, Zhang W, Yang D, Gershenson DM, Sood AK, Bast RC, Liu J. CA125 level as a prognostic indicator in type I and type II epithelial ovarian cancer. Int J Gynecol Cancer 23(5):815-822, 2013. e-Pub 2013. PMID: 23669443.
105. Tao X, Zhao N, Jin H, Zhang Z, Liu Y, Wu J, Bast RC, Yu Y, Feng Y. Follicle-stimulating hormone enhances the proliferation of ovarian cancer cells by activating transient receptor potential channel C3. Endocr Relat Cancer 20(3):415-429, 2013. e-Pub 2013. PMID: 23580589.
106. Lu Z, Bast RC. The tumor suppressor gene ARHI (DIRAS3) inhibits ovarian cancer cell migration through multiple mechanisms. Cell Adh Migr 7(2):232-6, 2013. e-Pub 2013. PMID: 23357870.
107. Diamandis EP, Bast RC, Lopez-Otín C. Conquering Cancer in Our Lifetime: New Diagnostic and Therapeutic Trends. Clin Chem 59(1):1-3, 2013. e-Pub 2012. PMID: 23204223.
108. Diamandis EP, Bast RC, Gold P, Chu TM, Magnani JL. Reflection on the Discovery of Carcinoembryonic Antigen, Prostate-Specific Antigen, and Cancer Antigens CA125 and CA19-9. Clin Chem 59(1):22-31, 2013. e-Pub 2012. PMID: 23204222.
109. Li Y, Liu T, Ivan C, Huang J, Shen DY, Kavanagh JJ, Bast RC, Fu S, Hu W, Sood AK. Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells. Front Oncol 3:58, 2013. e-Pub 2013. PMID: 23519775.
110. Jia L, Zhang S, Ye Y, Li X, Mercado-Uribe I, Bast RC, Liu J. Paclitaxel Inhibits Ovarian Tumor Growth by Inducing Epithelial Cancer Cells to Benign Fibroblast-like cells. Cancer Lett 326(2):176-82, 2012. e-Pub 2012. PMID: 22902993.
111. Fu S, Li Y, Huang J, Liu T, Hong Z, Chen A, Bast RC, Kavanagh JJ, Gershenson DM, Sood AK, Hu W. Aurora kinase inhibitor VE 465 synergistically enhances cytotoxicity of carboplatin in ovarian cancer cells through induction of apoptosis and downregulation of histone 3. Cancer Biol Ther 13(11):1034-41, 2012. e-Pub 2012. PMID: 22895067.
112. Fu S, Hennessy BT, Ng CS, Ju Z, Coombes KR, Wolf JK, Sood AK, Levenback CF, Coleman RL, Kavanagh JJ, Gershenson DM, Markman M, Dice K, Howard A, Li J, Li Y, Stemke-Hale K, Dyer M, Atkinson E, Jackson E, Kundra V, Kurzrock R, Bast RC, Mills GB. Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. Gynecol Oncol 126(1):47-53, 2012. e-Pub 2012. PMID: 22487539.
113. Xu J, Shetty PB, Feng W, Chenault C, Bast RC, Issa JP, Hilsenbeck SG, Yu Y. Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancer is associated with clinical characteristics, but only RASSF1A methylation is associated with outcome. BMC Cancer 12(1):243, 2012. e-Pub 2012. PMID: 22695491.
114. Jung EJ, Santarpia L, Kim J, Esteva FJ, Moretti E, Buzdar AU, Di Leo A, Le XF, Bast RC, Park ST, Pusztai L, Calin GA. Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer 118(10):2603-14, 2012. e-Pub 2011. PMID: 22370716.
115. Russell P, Hennessy BT, Li J, Carey MS, Bast RC, Freeman T, Venkitaraman AR. Cyclin G1 regulates the outcome of taxane-induced mitotic checkpoint arrest. Oncogene 31(19):2450-60, 2012. e-Pub 2011. PMID: 22056875.
116. Bast RC, Skates S, Lokshin A, Moore RG. Differential diagnosis of a pelvic mass: Improved algorithms and novel biomarkers. Int J Gynecol Cancer 22(10 Suppl 1):S5-8, 2012. PMID: 22543921.
117. Raamanathan A, Simmons GW, Christodoulides N, Floriano PN, Furmaga WB, Redding SW, Lu KH, Bast RC, McDevitt JT. Programmable Bio-Nano-Chip Systems for Serum CA125 Quantification: Towards Ovarian Cancer Diagnostics at the Point-of-Care. Cancer Prev Res (Phila) 5(5):706-16, 2012. e-Pub 2012. PMID: 22490510.
118. Moore RG, Miller MC, Eklund EE, Lu KH, Bast RC, Lambert-Messerlian G. Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age. Am J Obstet Gynecol 206(4):349.e1-7, 2012. e-Pub 2011. PMID: 22301440.
119. Moore RG, Miller MC, Steinhoff MM, Skates SJ, Lu KH, Lambert-Messerlian G, Bast RC. Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders. Am J Obstet Gynecol 206(4):351.e1-8, 2012. e-Pub 2011. PMID: 22284961.
120. Romero I, Bast RC. Minireview: Human Ovarian Cancer: Biology, Current Management, and Paths to Personalizing Therapy. Endocrinology 153(4):1593-602, 2012. e-Pub 2012. PMID: 22416079.
121. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA, Ahn HJ, Ait-Mohamed O, Ait-Si-Ali S, Akematsu T, Akira S, Al-Younes HM, Al-Zeer MA, Albert ML, Albin RL, Alegre-Abarrategui J, Aleo MF, Alirezaei M, Almasan A, Almonte-Becerril M, Amano A, Amaravadi R, Amarnath S, Amer AO, Andrieu-Abadie N, Anantharam V, Ann DK, Anoopkumar-Dukie S, Aoki H, Apostolova N, Arancia G, Aris JP, Asanuma K, Asare NY, Ashida H, Askanas V, Askew DS, Auberger P, Baba M, Backues SK, Baehrecke EH, Bahr BA, Bai XY, Bailly Y, Baiocchi R, Baldini G, Balduini W, Ballabio A, Bamber BA, Bampton ET, Bánhegyi G, Bartholomew CR, Bassham DC, Bast RC, Batoko H, Bay BH, Beau I, Béchet DM, Begley TJ, Behl C, Behrends C, Bekri S, Bellaire B, Bendall LJ, Benetti L, Berliocchi L, Bernardi H, Bernassola F, Besteiro S, Bhatia-Kissova I, Bi X, Biard-Piechaczyk M, Blum JS, Boise LH, Bonaldo P, Boone DL, Bornhauser BC, Bortoluci KR, Bossis I, Bost F, Bourquin JP, Boya P, Boyer-Guittaut M, Bozhkov PV, Brady NR, Brancolini C, Brech A, Brenman JE, Brennand A, Bresnick EH, Brest P, Bridges D, Bristol ML, Brookes PS, Brown EJ, Brumell JH, Brunetti-Pierri N, Brunk UT, Bulman DE, Bultman SJ, Bultynck G, Burbulla LF, Bursch W, Butchar JP, Buzgariu W, Bydlowski SP, Cadwell K, Cahová M, Cai D, Cai J, Cai Q, Calabretta B, Calvo-Garrido J, Camougrand N, Campanella M, Campos-Salinas J, Candi E, Cao L, Caplan AB, Carding SR, Cardoso SM, Carew JS, Carlin CR, Carmignac V, Carneiro LA, Carra S, Caruso RA, Casari G, Casas C, Castino R, Cebollero E, Cecconi F, Celli J, Chaachouay H, Chae HJ, Chai CY, Chan DC, Chan EY, Chang RC, Che CM, Chen CC, Chen GC, Chen GQ, Chen M, Chen Q, Chen SS, Chen W, Chen X, Chen X, Chen X, Chen YG, Chen Y, Chen Y, Chen YJ, Chen Z, Cheng A, Cheng CH, Cheng Y, Cheong H, Cheong JH, Cherry S, Chess-Williams R, Cheung ZH, Chevet E, Chiang HL, Chiarelli R, Chiba T, Chin LS, Chiou SH, Chisari FV, Cho CH, Cho DH, Choi AM, Choi D, Cho. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 8(4):445-544, 2012. PMID: 22966490.
122. Badgwell DB, Lu Z, Le K, Gao F, Yang M, Suh GK, Bao JJ, Das P, Andreeff M, Chen W, Yu Y, Ahmed AA, S-L Liao W, Bast RC. The tumor-suppressor gene ARHI (DIRAS3) suppresses ovarian cancer cell migration through inhibition of the Stat3 and FAK/Rho signaling pathways. Oncogene 31(1):68-79, 2012. e-Pub 2011. PMID: 21643014.
123. Moore LE, Pfeiffer RM, Zhang Z, Lu KH, Fung ET, Bast RC. Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial. Cancer 118(1):91-100, 2012. e-Pub 2011. PMID: 21717433.
124. Auzenne EJ, Klostergaard J, Mandal PK, Liao WS, Lu Z, Gao F, Bast RC, Robertson FM, McMurray JS. A phosphopeptide mimetic prodrug targeting the SH2 domain of Stat3 inhibits tumor growth and angiogenesis. J Exp Ther Oncol 10(2):155-62, 2012. PMID: 23350355.
125. Le XF, Almeida MI, Mao W, Spizzo R, Rossi S, Nicoloso MS, Zhang S, Wu Y, Calin GA, Bast RC. Modulation of microRNA-194 and Cell Migration by HER2-targeting Trastuzumab in Breast Cancer. PLoS One 7(7):e41170, 2012. e-Pub 2012. PMID: 22829924.
126. Su JL, Cheng X, Yamaguchi H, Chang YW, Hou CF, Lee DF, Ko HW, Hua KT, Wang YN, Hsiao M, Chen PB, Hsu JM, Bast RC, Hortobagyi GN, Hung MC. FOXO3a dependent mechanism of E1A-Induced chemosensitization. Cancer Res 71(21):6878-87, 2011. e-Pub 2011. PMID: 21911455.
127. Chen MY, Liao WS, Lu Z, Bornmann WG, Hennessey V, Washington MN, Rosner GL, Yu Y, Ahmed AA, Bast RC. Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2M arrest and autophagy. Cancer 117(19):4424-38, 2011. e-Pub 2011. PMID: 21491416.
128. Ahmed AA, Goldsmith J, Fokt I, Le XF, Krzysko KA, Lesyng B, Bast RC, Priebe W. A genistein derivative, ITB-301, induces microtubule depolymerization and mitotic arrest in multidrug-resistant ovarian cancer. Cancer Chemother Pharmacol 68(4):1033-44, 2011. e-Pub 2011. PMID: 21340606.
129. Vaughan S, Coward JI, Bast RC, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, Levine DA, McNeish IA, Menon U, Mills GB, Nephew KP, Oza AM, Sood AK, Stronach EA, Walczak H, Bowtell DD, Balkwill FR. Rethinking ovarian cancer: Recommendations for improving outcomes. Nat Rev Cancer 11(10):719-725, 2011. e-Pub 2011. PMID: 21941283.
130. Le XF, Mao W, He G, Claret FX, Xia W, Ahmed AA, Hung MC, Siddik ZH, Bast RC. The Role of p27Kip1 in Dasatinib-Enhanced Paclitaxel Cytotoxicity in Human Ovarian Cancer Cells. J Natl Cancer Inst 103(18):1403-22, 2011. e-Pub 2011. PMID: 21813412.
131. Ahmed AA, Wang X, Lu Z, Goldsmith J, Le XF, Grandjean G, Bartholomeusz G, Broom B, Bast RC. Modulating microtubule stability enhances the cytotoxic response of cancer cells to paclitaxel. Cancer Res 71(17):5806-17, 2011. e-Pub 2011. PMID: 21775522.
132. Clarke CH, Yip C, Badgwell D, Fung ET, Coombes KR, Zhang Z, Lu KH, Bast RC. Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer. Gynecol Oncol 122(3):548-53, 2011. e-Pub 2011. PMID: 21708402.
133. Le XF, Bast RC. Src Family Kinases and paclitaxel sensitivity. Cancer Biol Ther 12(4):260-9, 2011. e-Pub 2011. PMID: 21646863.
134. Mandal PK, Gao F, Lu Z, Ren Z, Ramesh R, Birtwistle JS, Kaluarachchi KK, Chen X, Bast RC, Liao WS, McMurray JS. Potent and Selective Phosphopeptide Mimetic Prodrugs Targeted to the Src Homology 2 (SH2) Domain of Signal Transducer and Activator of Transcription 3. J Med Chem 54(10):3549-63, 2011. e-Pub 2011. PMID: 21486047.
135. Fu S, Hu W, Iyer R, Kavanagh JJ, Coleman RL, Levenback CF, Sood AK, Wolf JK, Gershenson DM, Markman M, Hennessy BT, Kurzrock R, Bast RC. Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer 117(8):1661-9, 2011. e-Pub 2010. PMID: 21472713.
136. Diao L, Clarke CH, Coombes KR, Hamilton SR, Roth J, Mao L, Czerniak B, Baggerly KA, Morris JS, Fung ET, Bast RC. Reproducibility of SELDI spectra across time and laboratories. Cancer Inform 10:45-64, 2011. e-Pub 2011. PMID: 21552492.
137. Cramer DW, Bast RC, Berg CD, Diamandis EP, Godwin AK, Hartge P, Lokshin AE, Lu KH, McIntosh MW, Mor G, Patriotis C, Pinsky PF, Thornquist MD, Scholler N, Skates SJ, Sluss PM, Srivastava S, Ward DC, Zhang Z, Zhu CS, Urban N. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res (Phila) 4(3):365-74, 2011. PMID: 21372036.
138. Zhu CS, Pinsky PF, Cramer DW, Ransohoff DF, Hartge P, Pfeiffer RM, Urban N, Mor G, Bast RC, Moore LE, Lokshin AE, McIntosh MW, Skates SJ, Vitonis A, Zhang Z, Ward DC, Symanowski JT, Lomakin A, Fung ET, Sluss PM, Scholler N, Lu KH, Marrangoni AM, Patriotis C, Srivastava S, Buys SS, Berg CD, Team PP. A Framework for Evaluating Biomarkers for Early Detection: Validation of Biomarker Panels for Ovarian Cancer. Cancer Prev Res (Phila) 4(3):375-383, 2011. PMID: 21372037.
139. Zou CF, Jia L, Jin H, Yao M, Zhao N, Huan J, Lu Z, Bast RC, Feng Y, Yu Y. Re-expression of ARHI (DIRAS3) induces autophagy in breast cancer cells and enhances the inhibitory effect of paclitaxel. BMC Cancer 11(1):22, 2011. e-Pub 2011. PMID: 21244707.
140. Yu Y, Feng W, Lu Z, Jr BR. PEG3 (paternally expressed 3). Atlas Genet Cytogenet Oncol Haematol 15(5):422-4, 2011. PMID: None.
141. Landen CN, Goodman B, Katre AA, Steg AD, Nick AM, Stone RL, Miller LD, Mejia PV, Jennings NB, Gershenson DM, Bast RC, Coleman RL, Lopez-Berestein G, Sood AK. Targeting Aldehyde Dehydrogenase Cancer Stem Cells in Ovarian Cancer. Mol Cancer Ther 9(12):3186-99, 2010. e-Pub 2010. PMID: 20889728.
142. Hennessey VG, Rosner GL, Bast RC, Chen MY. A Bayesian approach to dose-response assessment and synergy and its application to in vitro dose response studies. Biometrics 66(4):1275-83, 2010. e-Pub 2010. PMID: 20337630.
143. Le XF, Mao W, Lu Z, Carter BZ, Bast RC. Dasatinib induces autophagic cell death in human ovarian cancer. Cancer 116(21):4980-90, 2010. e-Pub 2010. PMID: 20629079.
144. Moore RG, Jabre-Raughley M, Brown AK, Robison KM, Miller MC, Allard WJ, Kurman RJ, Bast RC, Skates SJ. Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol 203(3):228.e1-6, 2010. e-Pub 2010. PMID: 20471625.
145. Ahmed AA, Lu Z, Jennings NB, Etemadmoghadam D, Capalbo L, Jacamo RO, Barbosa-Morais N, Le XF, Study Group AOC, Vivas-Mejia P, Lopez-Berestein G, Grandjean G, Bartholomeusz G, Liao W, Andreeff M, Bowtell D, Glover DM, Sood AK, Bast RC. SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer. Cancer Cell 18(2):109-121, 2010. PMID: 20708153.
146. Feng W, Orlandi R, Zhao N, Carcangiu ML, Tagliabue E, Xu J, Bast RC, Yu Y. Tumor suppressor genes are frequently methylated in lymph node metastases of breast cancers. BMC Cancer 10(1):378, 2010. e-Pub 2010. PMID: 20642860.
147. Khleif SN, Doroshow JH, Hait WN, [Bast RC] ACBC. AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development. Clin Cancer Res 16(13):3299-318, 2010. e-Pub 2010. PMID: 20501613.
148. Yang H, Lu X, Qian J, Xu F, Hu Y, Yu Y, Bast RC, Li J. Imprinted tumor suppressor gene ARHI induces apoptosis correlated with changes in DNA methylation in pancreatic cancer cells. Mol Med Rep 3(4):581-7, 2010. PMID: 21472283.
149. Bast RC. CA 125 and the detection of recurrent ovarian cancer: a reasonably accurate biomarker for a difficult disease. Cancer 116(12):2850-3, 2010. PMID: 20564390.
150. Liu G, Yang G, Chang B, Mercado-Uribe I, Huang M, Zheng J, Bast RC, Lin SH, Liu J. Stanniocalcin 1 and Ovarian Tumorigenesis. J Natl Cancer Inst 102(11):812-27, 2010. e-Pub 2010. PMID: 20484106.
151. Nolen B, Velikokhatnaya L, Marrangoni A, De Geest K, Lomakin A, Bast RC, Lokshin A. Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol Oncol 117(3):440-5, 2010. e-Pub 2010. PMID: 20334903.
152. Donach M, Yu Y, Artioli G, Banna G, Feng W, Bast RC, Zhang Z, Nicoletto MO. Combined use of biomarkers for detection of ovarian cancer in high-risk women. Tumour Biol 31(3):209-15, 2010. e-Pub 2010. PMID: 20393825.
153. Huang S, Chang IS, Lin W, Ye W, Luo RZ, Lu Z, Lu Y, Zhang K, Liao WS, Tao T, Bast RC, Chen X, Yu Y. ARHI (DIRAS3), an imprinted tumour suppressor gene, binds to importins and blocks nuclear import of cargo proteins. Biosci Rep 30(3):159-68, 2010. e-Pub 2009. PMID: 19435463.
154. Yurkovetsky Z, Skates S, Lomakin A, Nolen B, Pulsipher T, Modugno F, Marks J, Godwin A, Gorelik E, Jacobs I, Menon U, Lu K, Badgwell D, Bast RC, Lokshin AE. Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol 28(13):2159-66, 2010. e-Pub 2010. PMID: 20368574.
155. Kavanagh JJ, Levenback CF, Ramirez PT, Wolf JL, Moore CL, Jones MR, Meng L, Brown GL, Bast RC. Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer. J Hematol Oncol 3(1):9, 2010. e-Pub 2010. PMID: 20222977.
156. Le XF, Merchant O, Bast RC, Calin GA. The Roles of MicroRNAs in the Cancer Invasion-Metastasis Cascade. Cancer Microenviron 3(1):137-47, 2010. e-Pub 2010. PMID: 21209780.
157. Zheng J, Mercado-Uribe I, Rosen DG, Chang B, Liu P, Yang G, Malpica A, Naora H, Auersperg N, Mills GB, Bast RC, Liu J. Induction of papillary carcinoma in human ovarian surface epithelial cells using combined genetic elements and peritoneal microenvironment. Cell Cycle 9(1):140-6, 2010. e-Pub 2010. PMID: 20016289.
158. Yu Y, Lu Z, Luo RZ, Jr BR. DIRAS3 (DIRAS family, GTP binding RAS-like 3). Atlas Genet Cytogenet Oncol Haematol 14(8):714-6, 2010. PMID: None.
159. Thigpen JT, Alberts D, Birrer M, Copeland L, Coleman RL, Markman M, Jr BR, Eisenhauer EL, Fleming G, Fracasso PM, Gershenson DM, Herzog T, Monk B, Ozols RF, Rustin G, Shrader M, Ranganathan A. Current Challenges and Future Directions in the Management of Ovarian Cancer: Proceedings of the First Global Workshop on Ovarian Cancer. Clinical Ovarian Cancer 3:81-97, 2010. PMID: None.
160. Kurzrock R, Pilat S, Bartolazzi M, Sanders D, Van Wart Hood J, Tucker SD, Webster K, Mallamaci MA, Strand S, Babcock E, Bast RC. Project zero delay: A process for accelerating the activation of cancer clinical trials. J Clin Oncol 27(26):4433-40, 2009. e-Pub 2009. PMID: 19652061.
161. Samanta AK, Huang HJ, Le XF, Mao W, Lu KH, Bast RC, Liao WS. MEKK3 expression correlates with nuclear factor kappa B activity and with expression of antiapoptotic genes in serous ovarian carcinoma. Cancer 115(17):3897-908, 2009. e-Pub 2009. PMID: 19517469.
162. Xie X, Hsu JL, Choi MG, Xia W, Yamaguchi H, Chen CT, Trinh BQ, Lu Z, Ueno NT, Wolf JK, Bast RC, Hung MC. A novel hTERT promoter-driven E1A therapeutic for ovarian cancer. Mol Cancer Ther 8(8):2375-82, 2009. e-Pub 2009. PMID: 19671744.
163. Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, Gajewski W, Kurman R, Bast RC, Skates SJ. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 112(1):40-46, 2009. e-Pub 2008. PMID: 18851871.
164. Anderson NS, Bermudez Y, Badgwell D, Chen R, Nicosia SV, Bast RC, Kruk PA. Urinary levels of Bcl-2 are elevated in ovarian cancer patients. Gynecol Oncol 112(1):60-67, 2009. e-Pub 2008. PMID: 19007973.
165. Cheon DJ, Wang Y, Deng JM, Lu Z, Xiao L, Chen CM, Bast RC, Behringer RR. CA125/MUC16 is dispensable for mouse development and reproduction. PLoS One 4(3):e4675, 2009. e-Pub 2009. PMID: 19262696.
166. Le XF, Mao W, Lu C, Thornton A, Heymach JV, Sood AK, Bast RC. Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2. Cell Cycle 7(23):3747-58, 2008. e-Pub 2008. PMID: 19029832.
167. Wang Y, Cheon DJ, Lu Z, Cunningham SL, Chen CM, Luo RZ, Xing D, Orsulic S, Bast RC, Behringer RR. MUC16 expression during embryogenesis, in adult tissues, and ovarian cancer in the mouse. Differentiation 76(10):1081-1092, 2008. e-Pub 2008. PMID: 18637025.
168. Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brünner N, Chan DW, Babaian R, Bast RC, Dowell B, Esteva FJ, Haglund C, Harbeck N, Hayes DF, Holten-Andersen M, Klee GG, Lamerz R, Looijenga LH, Molina R, Nielsen HJ, Rittenhouse H, Semjonow A, IeM S, Sibley P, Sölétormos G, Stephan C, Sokoll L, Hoffman BR, Diamandis EP, Clinical Biochemistry NAO. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 54(12):e11-79, 2008. PMID: 19042984.
169. Lu Z, Luo RZ, Lu Y, Zhang X, Yu Q, Khare S, Kondo S, Kondo Y, Yu Y, Mills GB, Liao WS, Bast RC. The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. J Clin Invest 118(12):3917-29, 2008. e-Pub 2008. PMID: 19033662.
170. Wei Y, Xia W, Zhang Z, Liu J, Wang H, Adsay NV, Albarracin C, Yu D, Abbruzzese JL, Mills GB, Bast RC, Hortobagyi GN, Hung MC. Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian and pancreatic cancers. Mol Carcinog 47(9):701-706, 2008. PMID: 18176935.
171. Moore RG, Brown AK, Miller MC, Badgwell D, Lu Z, Allard WJ, Granai CO, Bast RC, Lu K. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol 110(2):196-201, 2008. e-Pub 2008. PMID: 18495222.
172. Das PM, Bast RC. Early detection of ovarian cancer. Biomark Med 2(3):291-303, 2008. PMID: 20477415.
173. Feng W, Marquez RT, Lu Z, Liu J, Lu KH, Issa JP, Fishman DM, Yu Y, Bast RC. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. Cancer 112(7):1489-502, 2008. PMID: 18286529.
174. Ashworth A, Balkwill F, Bast RC, Berek JS, Kaye A, Boyd JA, Mills G, Weinstein JN, Woolley K, Workman P. Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian Cancer Action/HHMT Forum, Lake Como, March 2007. Gynecol Oncol 108(3):652-657, 2008. e-Pub 2007. PMID: 18096210.
175. Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, Steinhoff M, Messerlian G, DiSilvestro P, Granai CO, Bast RC. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 108(2):402-408, 2008. e-Pub 2007. PMID: 18061248.
176. Zhang Z, Yu Y, Xu F, Berchuck A, van Haaften-Day C, Havrilesky LJ, de Bruijn HW, van der Zee AG, Woolas RP, Jacobs IJ, Skates S, Chan DW, Bast RC. Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. Gynecol Oncol 107(3):526-531, 2007. e-Pub 2007. PMID: 17920110.
177. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC, Clinical Oncology ASO. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25(33):5287-312, 2007. e-Pub 2007. PMID: 17954709.
178. Bast RC, Thigpen JT, Arbuck SG, Basen-Engquist K, Burke LB, Freedman R, Horning SJ, Ozols R, Rustin GJ, Spriggs D, Wenzel LB, Pazdur R. Clinical trial endpoints in ovarian cancer: Report of an FDA/ASCO/AACR Public Workshop. Gynecol Oncol 107(2):173-6, 2007. PMID: 17950384.
179. Le XF, Arachchige-Don AS, Mao W, Horne MC, Bast RC. Roles of human epidermal growth factor receptor 2, c-jun NH2-terminal kinase, phosphoinositide 3-kinase, and p70 S6 kinase pathways in regulation of cyclin G2 expression in human breast cancer cells. Mol Cancer Ther 6(11):2843-57, 2007. PMID: 18025271.
180. Badgwell D, Lu Z, Cole L, Fritsche H, Atkinson EN, Somers E, Allard J, Moore RG, Lu KH, Bast RC. Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment. Gynecol Oncol 106(3):490-497, 2007. e-Pub 2007. PMID: 17532030.
181. Yang G, Rosen DG, Mercado-Uribe I, Colacino JA, Mills GB, Bast RC, Zhou C, Liu J. Knockdown of p53 combined with expression of the catalytic subunit of telomerase is sufficient to immortalize primary human ovarian surface epithelial cells. Carcinogenesis 28(1):174-82, 2007. e-Pub 2006. PMID: 16829690.
182. Feng W, Shen L, Wen S, Rosen DG, Jelinek J, Hu X, Huan S, Huang M, Liu J, Sahin AA, Hunt KK, Bast RC, Shen Y, Issa JP, Yu Y. Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res 9(4):R57, 2007. PMID: 17764565.
183. Brewer M, Ranger-Moore J, Satterfield W, Hao Z, Wang J, Brewer E, Wharton JT, Bast R, Zou C. Combination of 4-HPR and oral contraceptive in monkey model of chemoprevention of ovarian cancer. Front Biosci 12:2260-8, 2007. e-Pub 2007. PMID: 17127462.
184. Rosen DG, Mercado-Uribe I, Yang G, Bast RC, Amin HM, Lai R, Liu J. The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis. Cancer 107(11):2730-2740, 2006. PMID: 17063503.
185. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, Hayes DF, Bast RC, ASCO. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24(33):5313-5327, 2006. e-Pub 2006. PMID: 17060676.
186. Wen XF, Yang G, Mao W, Thornton A, Liu J, Bast RC, Le XF. HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy. Oncogene 25(52):6986-6996, 2006. e-Pub 2006. PMID: 16715132.
187. Farley J, Bast RC, Birrer MJ. Biomarkers and clinical trial design. Gynecol Oncol 103(2 Suppl 1):S3-5, 2006. e-Pub 2006. PMID: 17027069.
188. Yang G, Rosen DG, Zhang Z, Bast RC, Mills GB, Colacino JA, Mercado-Uribe I, Liu J. The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc Natl Acad Sci U S A 103(44):16472-16477, 2006. e-Pub 2006. PMID: 17060621.
189. Brewer M, Kirkpatrick ND, Wharton JT, Wang J, Hatch K, Auersperg N, Utzinger U, Gershenson D, Bast R, Zou C. 4-HPR modulates gene expression in ovarian cells. Int J Cancer 119(5):1005-1013, 2006. PMID: 16570282.
190. Le XF, Bedrosian I, Mao W, Murray M, Lu Z, Keyomarsi K, Lee MH, Zhao J, Bast RC. Anti-HER2 antibody trastuzumab inhibits CDK2-mediated NPAT and Histone H4 expression via the PI3K pathway. Cell Cycle 5(15):1654-1661, 2006. e-Pub 2006. PMID: 16861913.
191. Lu Z, Luo RZ, Peng H, Rosen DG, Atkinson EN, Warneke C, Huang M, Nishmoto A, Liu J, Liao WS, Yu Y, Bast RC. Transcriptional and posttranscriptional down-regulation of the imprinted tumor suppressor gene ARHI (DRAS3) in ovarian cancer. Clin Cancer Res 12(8):2404-2413, 2006. PMID: 16638845.
192. Balkwill FR, Ashworth A, Bast RC, Berek JS, Boyd J, Disis ML, Gabra H, Gore ME, Hamilton TC, Jacobs IJ, Kaye SB, Kohn EC, Mills GB, Urban ND. 10th Biennial Helene Harris Memorial Trust Meeting. Cancer Res 66(6):2904-2906, 2006. PMID: 16540635.
193. Lee Z, Swaby RF, Liang Y, Yu S, Liu S, Lu KH, Bast RC, Mills GB, Fang X. Lysophosphatidic acid is a major regulator of growth-regulated oncogene alpha in ovarian cancer. Cancer Res 66(5):2740-8, 2006. PMID: 16510595.
194. Menon U, Skates SJ, Lewis S, Rosenthal AN, Rufford B, Sibley K, Macdonald N, Dawnay A, Jeyarajah A, Bast RC, Oram D, Jacobs IJ. Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J Clin Oncol 23(31):7919-7926, 2005. PMID: 16258091.
195. Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, Hellstrom I, Mok SC, Liu J, Bast RC. Potential markers that complement expression of CA 125 in epithelial ovarian cancer. Gynecol Oncol 99(2):267-277, 2005. e-Pub 2005. PMID: 16061277.
196. Young T, Mei F, Liu J, Bast RC, Kurosky A, Cheng X. Proteomics analysis of H-RAS-mediated oncogenic transformation in a genetically defined human ovarian cancer model. Oncogene 24(40):6174-6184, 2005. PMID: 15940260.
197. Marquez RT, Baggerly KA, Patterson AP, Liu J, Broaddus R, Frumovitz M, Atkinson EN, Smith DI, Hartmann L, Fishman D, Berchuck A, Whitaker R, Gershenson DM, Mills GB, Bast RC, Lu KH. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium and colon. Clin Cancer Res 11(17):6116-6126, 2005. PMID: 16144910.
198. Nishimoto A, Yu Y, Lu Z, Mao X, Ren Z, Watowich SS, Mills GB, Liao WS, Chen X, Bast RC, Luo RZ. A Ras homologue member I directly inhibits signal transducers and activators of transcription 3 translocation and activity in human breast and ovarian cancer cells. Cancer Res 65(15):6701-6710, 2005. PMID: 16061651.
199. Brewer M, Wharton JT, Wang J, McWatters A, Auersperg N, Gershenson D, Bast R, Zou C. In vitro model of normal, immortalized ovarian surface epithelial and ovarian cancer cells for chemoprevention of ovarian cancer. Gynecol Oncol 98(2):182-192, 2005. PMID: 15907982.
200. Hartmann LC, Lu KH, Linette GP, Cliby WA, Kalli KR, Gershenson D, Bast RC, Stec J, Iartchouk N, Smith DI, Ross JS, Hoersch S, Shridhar V, Lillie J, Kaufmann SH, Clark EA, Damokosh AI. Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clin Cancer Res 11(6):2149-2155, 2005. PMID: 15788660.
201. Le XF, Lammayot A, Gold D, Lu Y, Mao W, Chang T, Patel A, Mills GB, Bast RC. Genes affecting the cell cycle, growth, maintenance, and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signaling. J Biol Chem 280(3):2092-2104, 2005. e-Pub 2004. PMID: 15504738.
202. Rosen DG, Yang G, Cai KQ, Bast RC, Gershenson DM, Silva EG, Liu J. Subcellular localization of p27KIP1 expression predicts poor prognosis in human ovarian cancer. Clin Cancer Res 11(2 Pt 1):632-637, 2005. PMID: 15701850.
203. Le XF, Pruefer F, Bast RC. HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways. Cell Cycle 4(1):87-95, 2005. e-Pub 2005. PMID: 15611642.
204. Skates SJ, Horick N, Yu Y, Xu FJ, Berchuck A, Havrilesky LJ, de Bruijn HW, van der Zee AG, Woolas RP, Jacobs IJ, Zhang Z, Bast RC. Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J Clin Oncol 22(20):4059-4066, 2004. e-Pub 2004. PMID: 15381683.
205. Rosen DG, Wang L, Jain AN, Lu KH, Luo RZ, Yu Y, Liu J, Bast RC. Expression of the tumor suppressor gene ARHI in epithelial ovarian cancer is associated with increased expression of p21WAF1/CIP1 and prolonged progression-free survival. Clin Cancer Res 10(19):6559-6566, 2004. PMID: 15475444.
206. Zhang Z, Bast RC, Yu Y, Li J, Sokoll LJ, Rai AJ, Rosenzweig JM, Cameron B, Wang YY, Meng XY, Berchuck A, Van Haaften-Day C, Hacker NF, de Bruijn HW, van der Zee AG, Jacobs IJ, Fung ET, Chan DW. Three Biomarkers Identified from Serum Proteomic Analysis for the Detection of Early Stage Ovarian Cancer. Cancer Res 64(16):5882-5890, 2004. PMID: 15313933.
207. Donato ML, Aleman A, Champlin RE, Saliba RM, Wharton JT, Burke TW, Bodurka DC, Bevers MW, Levenback CF, Wolf JK, Bast RC, Freedman RS, Ippoliti C, Brewer M, Gajewski JL, Gershenson DM. Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation. Bone Marrow Transplant 33(12):1219-1224, 2004. PMID: 15122311.
208. Lu KH, Patterson AP, Wang L, Marquez RT, Atkinson EN, Baggerly KA, Ramoth LR, Rosen DG, Liu J, Hellstrom I, Smith D, Hartmann L, Fishman D, Berchuck A, Schmandt R, Whitaker R, Gershenson DM, Mills GB, Bast RC. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res 10(10):3291-3300, 2004. PMID: 15161682.
209. Fang X, Yu S, Bast RC, Liu S, Xu HJ, Hu SX, LaPushin R, Claret FX, Aggarwal BB, Lu Y, Mills GB. Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. J Biol Chem 279(10):9653-9661, 2004. e-Pub 2003. PMID: 14670967.
210. Liu J, Yang G, Thompson-Lanza JA, Glassman A, Hayes K, Patterson A, Marquez RT, Auersperg N, Yu Y, Hahn WC, Mills GB, Bast RC. A genetically defined model for human ovarian cancer. Cancer Res 64(5):1655-1663, 2004. PMID: 14996724.
211. Samanta AK, Huang HJ, Bast RC, Liao WS. Overexpression of MEKK3 confers resistance to apoptosis through activation of NFκB. J Biol Chem 279(9):7576-7583, 2004. e-Pub 2003. PMID: 14662759.
212. Yang G, Cai KQ, Thompson-Lanza JA, Bast RC, Liu J. Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression. J Biol Chem 279(6):4339-4345, 2004. e-Pub 2003. PMID: 14625284.
213. Pusztai L, Krishnamurti S, Perez Cardona J, Sneige N, Esteva FJ, Volchenok M, Breitenfelder P, Kau SW, Takayama S, Krajewski S, Reed JC, Bast RC, Hortobagyi GN. Expression of BAG-1 and BcL-2 proteins before and after neoadjuvant chemotherapy of locally advanced breast cancer. Cancer Invest 22(2):248-256, 2004. PMID: 15199607.
214. Tanyi JL, Hasegawa Y, Lapushin R, Morris AJ, Wolf JK, Berchuck A, Lu K, Smith DI, Kalli K, Hartmann LC, McCune K, Fishman D, Broaddus R, Cheng KW, Atkinson EN, Yamal JM, Bast RC, Felix EA, Newman RA, Mills GB. Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer. Clin Cancer Res 9(10 Pt 1):3534-3545, 2003. PMID: 14506139.
215. Wang L, Hoque A, Luo RZ, Yuan J, Lu Z, Nishimoto A, Liu J, Sahin AA, Lippman SM, Bast RC, Yu Y. Loss of the expression of the tumor suppressor gene ARHI is associated with progression of breast cancer. Clin Cancer Res 9(10 Pt 1):3660-3666, 2003. PMID: 14506155.
216. Balkwill F, Bast RC, Berek J, Chenevix-Trench G, Gore M, Hamilton T, Jacobs I, Mills G, Souhami R, Urban N, Orsulic S, Smyth J, Ursulic S. Current research and treatment for epithelial ovarian cancer. A Position Paper from the Helene Harris Memorial Trust. Eur J Cancer 39(13):1818-1827, 2003. PMID: 12932658.
217. Fujii S, Luo RZ, Yuan J, Kadota M, Oshimura M, Dent SR, Kondo Y, Issa JP, Bast RC, Yu Y. Reactivation of the silenced and imprinted alleles of ARHI is associated with increased histone H3 acetylation and decreased histone H3 lysine 9 methylation. Hum Mol Genet 12(15):1791-1800, 2003. PMID: 12874100.
218. Yuan J, Luo RZ, Fujii S, Wang L, Hu W, Andreeff M, Pan Y, Kadota M, Oshimura M, Sahin AA, Issa JP, Bast RC, Yu Y. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers. Cancer Res 63(14):4174-4180, 2003. PMID: 12874023.
219. Nakamori M, Fu X, Meng F, Jin A, Tao L, Bast RC, Zhang X. Effective therapy of metastatic ovarian cancer with an oncolytic herpes simplex virus incorporating two membrane fusion mechanisms. Clin Cancer Res 9(7):2727-2733, 2003. PMID: 12855653.
220. Shvartsman HS, Lu KH, Lee J, Lillie J, Deavers MT, Clifford S, Wolf JK, Mills GB, Bast RC, Gershenson DM, Schmandt R. Overexpression of kallikrein 10 in epithelial ovarian carcinomas. Gynecol Oncol 90(1):44-50, 2003. PMID: 12821340.
221. Le XF, Claret FX, Lammayot A, Tian L, Deshpande D, LaPushin R, Tari AM, Bast RC. The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition. J Biol Chem 278(26):23441-23450, 2003. e-Pub 2003. PMID: 12700233.
222. Cannistra SA, Bast RC, Berek JS, Bookman MA, Crum CP, DePriest PD, Garber JE, Koh WJ, Markman M, McGuire WP, Rose PG, Rowinsky EK, Rustin GJ, Skates SJ, Vasey PA, King L. Progress in the management of gynecologic cancer: consensus summary statement. J Clin Oncol 21(10 Suppl):129s-132s, 2003. PMID: 12743127.
223. Luo RZ, Fang X, Marquez R, Liu SY, Mills GB, Liao WS, Yu Y, Bast RC. ARHI is a Ras-related small G-protein with a novel N-terminal extension that inhibits growth of ovarian and breast cancers. Oncogene 22(19):2897-2909, 2003. PMID: 12771940.
224. Bast RC. Status of tumor markers in ovarian cancer screening. J Clin Oncol 21(10 Suppl):200-205, 2003. PMID: 12743135.
225. Verschraegen CF, Hu W, Du Y, Mendoza J, Early J, Deavers M, Freedman RS, Bast RC, Kudelka AP, Kavanagh JJ, Giovanella BC. Establishment and characterization of cancer cell cultures and xenografts derived from primary or metastatic Mullerian cancers. Clin Cancer Res 9(2):845-852, 2003. PMID: 12576458.
226. Le XF, Hittelman WN, Liu J, McWatters A, Li C, Mills GB, Bast RC. Paclitaxel induces inactivation of p70 S6 kinase and phosphorylation of Thr421 and Ser424 via multiple signaling pathways in mitosis. Oncogene 22(4):484-497, 2003. PMID: 12555062.
227. Mills GB, Fang X, Lu Y, Hasegawa Y, Eder A, Tanyi J, Tabassam FH, Mao M, Wang H, Cheng KW, Nakayama Y, Kuo W, Erickson J, Gershenson D, Kohn EC, Jaffe R, Bast RC, Gray J. Specific keynote: Molecular Therapeutics in Ovarian Cancer. Gynecol Oncol 88(1 Pt 2):S88-S92, 2003. PMID: 12586094.
228. Wiener JR, Windham TC, Estrella VC, Parikh NU, Thall PF, Deavers MT, Bast RC, Mills GB, Gallick GE. Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. Gynecol Oncol 88(1):73-79, 2003. PMID: 12504632.
229. Bao JJ, Le XF, Wang RY, Yuan J, Wang L, Atkinson EN, LaPushin R, Andreeff M, Fang B, Yu Y, Bast RC. Reexpression of the tumor suppressor gene ARHI induces apoptosis in ovarian and breast cancer cells through a caspase-independent calpain-dependent pathway. Cancer Res 62(24):7264-7272, 2002. PMID: 12499268.
230. Le XF, Varela CR, Bast RC. Heregulin-induced apoptosis. Apoptosis 7(6):483-491, 2002. PMID: 12370490.
231. Brewer M, Utzinger U, Li Y, Atkinson EN, Satterfield W, Auersperg N, Richards-Kortum R, Follen M, Bast R. Fluorescence spectroscopy as a biomarker in a cell culture and in a nonhuman primate model for ovarian cancer chemopreventive agents. J Biomed Opt 7(1):20-26, 2002. PMID: 11818008.
232. Kramer S, Yu Y, Jager W, Lang N, Bast RC, Beckmann MW. Characterization of the ARHI tumor suppressor as a target for gene therapy in ovarian cancer. Geburtsh Frauenheilk 62:870-876, 2002. PMID: None.
233. Le XF, Marcelli M, McWatters A, Nan B, Mills GB, O'Brian CA, Bast RC. Heregulin-induced apoptosis is mediated by down-regulation of Bcl-2 and activation of caspase-7 and is potentiated by impairment of protein kinase C α activity. Oncogene 20(57):8258-8269, 2001. PMID: 11781840.
234. van Haaften-Day C, Shen Y, Xu F, Yu Y, Berchuck A, Havrilesky LJ, de Bruijn HW, van der Zee AG, Bast RC, Hacker NF. OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal. Cancer 92(11):2837-2844, 2001. PMID: 11753957.
235. Bast RC, Mills GB, Young RC. Translational research - traffic on the bridge. Biomed Pharmacother 55(9-10):565-571, 2001. PMID: 11769968.
236. Donato ML, Gershenson DM, Wharton JT, Ippoliti CM, Aleman AS, Bodurka-Bevers D, Bevers MW, Burke TW, Levenback CF, Wolf JK, Freedman RS, Bast RC, Gajewski JL, Champlin RE. High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer. Gynecol Oncol 82(3):420-426, 2001. PMID: 11520135.
237. Shridhar V, Lee J, Pandita A, Iturria S, Avula R, Staub J, Morrissey M, Calhoun E, Sen A, Kalli K, Keeney G, Roche P, Cliby W, Lu K, Schmandt R, Mills GB, Bast RC, James CD, Couch FJ, Hartmann LC, Lillie J, Smith DI. Genetic analysis of early- versus late-stage ovarian tumors. Cancer Res 61(15):5895-5904, 2001. PMID: 11479231.
238. Brewer M, Utzinger U, Satterfield W, Hill L, Gershenson D, Bast R, Wharton JT, Richards-Kortum R, Follen M. Biomarker modulation in a nonhuman rhesus primate model for ovarian cancer chemoprevention. Cancer Epidemiol Biomarkers Prev 10(8):889-893, 2001. PMID: 11489756.
239. Luo RZ, Peng H, Xu F, Bao J, Pang Y, Pershad R, Issa JP, Liao WS, Bast RC, Yu Y. Genomic structure and promoter characterization of an imprinted tumor suppressor gene ARHI. Biochim Biophys Acta 1519(3):216-222, 2001. PMID: 11418188.
240. Bast RC, Ravdin P, Hayes DF, Bates S, Fritsche H, Jessup JM, Kemeny N, Locker GY, Mennel RG, Somerfield MR, Expert Panel ASOCOTM. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19(6):1865-1878, 2001. PMID: 11251019.
241. Rivera E, Valero V, Syrewicz L, Rahman Z, Esteva FJ, Theriault RL, Rosales MM, Booser D, Murray JL, Bast RC, Hortobagyi GN, Esteva FL. Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer. J Clin Oncol 19(6):1716-22, 2001. PMID: 11251001.
242. Rodriguez GC, Haisley C, Hurteau J, Moser TL, Whitaker R, Bast RC, Stack MS. Regulation of invasion of epithelial ovarian cancer by transforming growth factor-β. Gynecol Oncol 80(2):245-253, 2001. PMID: 11161867.
243. Schmidt M, McWatters A, White RA, Groner B, Wels W, Fan Z, Bast RC. Synergistic interaction between an anti-p185HER-2 pseudomonas exotoxin fusion protein [scFv(FRP5)-ETA] and ionizing radiation for inhibiting growth of ovarian cancer cells that overexpress HER-2. Gynecol Oncol 80(2):145-155, 2001. PMID: 11161852.
244. Utzinger U, Brewer M, Silva E, Gershenson D, Jr BR, Mitchell MF, Richards-Kortum R. Reflectance spectroscopy for in vivo characterization of ovarian tissue. Lasers Surg Med 28(1):56-66, 2001. PMID: 11430444.
245. Brewer M, Utzinger U, Silva E, Gershenson D, Bast RC, Follen M, Richards-Kortum R. Fluorescence spectroscopy for in vivo characterization of ovarian tissue. Lasers Surg Med 29(2):128-135, 2001. PMID: 11553899.
246. Ibrahim NK, Valero V, Rahman Z, Theriault RL, Walters RS, Buzdar AU, Booser DJ, Holmes FA, Murray JL, Willey J, Bast R, Hortobagyi GN. Phase I-II vinorelbine (Navelbine) by continuous infusion in patients with metastatic breast cancer: cumulative toxicities limit dose escalation. Cancer Invest 19(5):459-466, 2001. PMID: 11458813.
247. Kruzelock RP, Cuevas BD, Wiener JR, Xu FJ, Yu Y, Cabeza-Arvelaiz Y, Pershouse M, Lovell MM, Killary AM, Mills GB, Bast RC. Functional evidence for an ovarian cancer tumor suppressor gene on chromosome 22 by microcell-mediated chromosome transfer. Oncogene 19(54):6277-6285, 2000. PMID: 11175342.
248. Mao M, Fang X, Lu Y, Lapushin R, Bast RC, Mills GB. Inhibition of growth-factor-induced phosphorylation and activation of protein kinase B/Akt by atypical protein kinase C in breast cancer cells. Biochem J 352 Pt 2:475-482, 2000. PMID: 11085941.
249. Einhorn N, Bast R, Knapp R, Nilsson B, Zurawski V, Sjövall K. Long-term follow-up of the Stockholm screening study on ovarian cancer. Gynecol Oncol 79(3):466-470, 2000. PMID: 11104621.
250. Hogdall EV, Høgdall CK, Tingulstad S, Hagen B, Nustad K, Xu FJ, Bast RC, Jacobs IJ. Predictive values of serum tumour markers tetranectin, OVX1, CASA and CA125 in patients with a pelvic mass. Int J Cancer 89(6):519-523, 2000. PMID: 11102897.
251. Fang X, Yu S, LaPushin R, Lu Y, Furui T, Penn LZ, Stokoe D, Erickson JR, Bast RC, Mills GB. Lysophosphatidic acid prevents apoptosis in fibroblasts via G(i)-protein-mediated activation of mitogen-activated protein kinase. Biochem J 352 Pt 1:135-143, 2000. PMID: 11062066.
252. Fang X, Yu SX, Lu Y, Bast RC, Woodgett JR, Mills GB. Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc Natl Acad Sci U S A 97(22):11960-11965, 2000. PMID: 11035810.
253. Xu F, Xia W, Luo RZ, Peng H, Zhao S, Dai J, Long Y, Zou L, Le W, Liu J, Parlow AF, Hung MC, Bast RC, Yu Y. The human ARHI tumor suppressor gene inhibits lactation and growth in transgenic mice. Cancer Res 60(17):4913-4920, 2000. PMID: 10987306.
254. Xu F, Leadon SA, Yu Y, Boyer CM, O'Briant K, Ward K, McWatters A, Zhao X, Bae DS, DeSombre K, Zalutsky MR, Bast RC. Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2. Clin Cancer Res 6(8):3334-3341, 2000. PMID: 10955821.
255. Le XF, Vadlamudi R, McWatters A, Bae DS, Mills GB, Kumar R, Bast RC. Differential signaling by an anti-p185(HER2) antibody and heregulin. Cancer Res 60(13):3522-3531, 2000. PMID: 10910064.
256. Peng H, Xu F, Pershad R, Hunt KK, Frazier ML, Berchuck A, Gray JW, Hogg D, Bast RC, Yu Y. ARHI is the center of allelic deletion on chromosome 1p31 in ovarian and breast cancers. Int J Cancer 86(5):690-694, 2000. PMID: 10797292.
257. Donato ML, Gershenson D, Ippoliti C, Wharton JT, Bast RC, Aleman A, Anderlini P, Gajewski JG, Giralt S, Molldrem J, Ueno N, Lauppe J, Korbling M, Boyer J, Bodurka-Bevers D, Bevers M, Burke T, Freedman R, Levenback C, Wolf J, Champlin RE. High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer. Bone Marrow Transplant 25(11):1137-40, 2000. PMID: 10849525.
258. Le XF, McWatters A, Wiener J, Wu JY, Mills GB, Bast RC. Anti-HER2 antibody and heregulin suppress growth of HER2-overexpressing human breast cancer cells through different mechanisms. Clin Cancer Res 6(1):260-270, 2000. PMID: 10656457.
259. Bast RC, Yu Y, Xu FJ, Le XF, Mills GB. Molecular approaches to management of epithelial ovarian cancer. Int J Gynecol Cancer 10(S1):2-7, 2000. PMID: 11240724.
260. Furui T, LaPushin R, Mao M, Khan H, Watt SR, Watt MA, Lu Y, Fang X, Tsutsui S, Siddik ZH, Bast RC, Mills GB. Overexpression of Edg-2/vzg-1 induces apoptosis and anoikis in ovarian cancer cells in a lysophosphatidic acid-independent manner. Clin Cancer Res 5(12):4308-4318, 1999. PMID: 10632375.
261. Gershenson DM, Deavers M, Diaz S, Tortolero-Luna G, Miller BE, Bast RC, Mills GB, Silva EG. Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors. Clin Cancer Res 5(12):4053-4058, 1999. PMID: 10632339.
262. Fang X, Yu S, Eder A, Mao M, Bast RC, Boyd D, Mills GB. Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway. Oncogene 18(48):6635-6640, 1999. PMID: 10597268.
263. Wolf JK, Mills GB, Bazzet L, Bast RC, Roth JA, Gershenson DM. Adenovirus-mediated p53 growth inhibition of ovarian cancer cells is independent of endogenous p53 status. Gynecol Oncol 75(2):261-266, 1999. PMID: 10525383.
264. Woolas RP, Oram DH, Jeyarajah AR, Bast RC, Jacobs IJ. Ovarian cancer identified through screening with serum markers but not by pelvic imaging. Int J Gynecol Cancer 9(6):497-501, 1999. PMID: 11240818.
265. Pustilnik TB, Estrella V, Wiener JR, Mao M, Eder A, Watt MA, Bast RC, Mills GB. Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells. Clin Cancer Res 5(11):3704-3710, 1999. PMID: 10589790.
266. Xu F, Yu Y, Le XF, Boyer C, Mills GB, Bast RC. The outcome of heregulin-induced activation of ovarian cancer cells depends on the relative levels of HER-2 and HER-3 expression. Clin Cancer Res 5(11):3653-3660, 1999. PMID: 10589783.
267. Ibrahim NK, Rahman Z, Valero V, Willey J, Theriault RL, Buzdar AU, Murray JL, Bast R, Hortobagyi GN. Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. Cancer 86(7):1251-1257, 1999. PMID: 10506711.
268. Zalutsky MR, Xu FJ, Yu Y, Foulon CF, Zhao XG, Slade SK, Affleck DJ, Bast RC. Radioiodinated antibody targeting of the HER-2/neu oncoprotein: effects of labeling method on cellular processing and tissue distribution. Nucl Med Biol 26(7):781-790, 1999. PMID: 10628557.
269. Baile WF, Kudelka AP, Beale EA, Glober GA, Myers EG, Greisinger AJ, Bast RC, Goldstein MG, Novack D, Lenzi R. Communication skills training in oncology. Description and preliminary outcomes of workshops on breaking bad news and managing patient reactions to illness. Cancer 86(5):887-897, 1999. PMID: 10463990.
270. Boyer CM, Pusztai L, Wiener JR, Xu FJ, Dean GS, Bast BS, O'Briant KC, Greenwald M, DeSombre KA, Bast RC. Relative cytotoxic activity of immunotoxins reactive with different epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185. Int J Cancer 82(4):525-531, 1999. PMID: 10404066.
271. Wiener JR, Nakano K, Kruzelock RP, Bucana CD, Bast RC, Gallick GE. Decreased Src tyrosine kinase activity inhibits malignant human ovarian cancer tumor growth in a nude mouse model. Clin Cancer Res 5(8):2164-2170, 1999. PMID: 10473101.
272. Hogdall EV, Hogdall CK, Kjaer SK, Xu F, Yu Y, Bast RC, Blaakaer J, Jacobs IJ. OVX1 radioimmunoassay results are dependent on the method of sample collection and storage. Clin Chem 45(5):692-694, 1999. PMID: 10222361.
273. Zhang Z, Barnhill SD, Zhang H, Xu F, Yu Y, Jacobs I, Woolas RP, Berchuck A, Madyastha KR, Bast RC. Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses. Gynecol Oncol 73(1):56-61, 1999. PMID: 10094881.
274. Hagopian GS, Mills GB, Khokhar AR, Bast RC, Siddik ZH. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: Modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV). Clin Cancer Res 5(3):655-664, 1999. PMID: 10100719.
275. Yu Y, Xu F, Peng H, Fang X, Zhao S, Li Y, Cuevas B, Kuo WL, Gray JW, Siciliano M, Mills GB, Bast RC. NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proc Natl Acad Sci U S A 96(1):214-219, 1999. PMID: 9874798.
276. Rahman Z, Kavanagh J, Champlin R, Giles R, Hanania E, Fu SQ, Zu Z, Mehra R, Holmes F, Kudelka A, Claxton D, Verschraegen C, Gajewski J, Andreeff M, Heimfeld S, Berenson R, Ellerson D, Calvert L, Mechetner E, Holzmayer T, Dayne A, Hamer J, Bachier C, Ostrove J, Przepiorka D, Burtness B, Cote R, Bast R, Hortobagyi G, Deisseroth A. Chemotherapy immediately following autologous stem-cell transplantation in patients with advanced breast cancer. Clin Cancer Res 4(11):2717-2721, 1998. PMID: 9829734.
277. Dean GS, Pusztai L, Xu FJ, O'Briant K, DeSombre K, Conaway M, Boyer CM, Mendelsohn J, Bast RC. Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cells. Clin Cancer Res 4(10):2545-2550, 1998. PMID: 9796989.
278. Gershenson DM, Burke TW, Morris M, Bast RC, Guaspari A, Hohneker J, Wharton JT. A phase I study of a daily x3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer. Gynecol Oncol 70(3):404-409, 1998. PMID: 9790795.
279. Bast RC, Pusztai L, Kerns BJ, MacDonald JA, Jordan P, Daly L, Boyer CM, Mendelsohn J, Berchuck A. Coexpression of the HER-2 gene product, p185HER-2, and epidermal growth factor receptor, p170EGF-R, on epithelial ovarian cancers and normal tissues. Hybridoma 17(4):313-321, 1998. PMID: 9790065.
280. Martell RE, Xu FJ, Davis WZ, Anselmino L, Yu YH, Daly L, Bast RC. OVX1 and CEA in patients with colon carcinoma, colon polyps and benign colon disorders. Int J Biol Markers 13(3):145-149, 1998. PMID: 10079388.
281. Boente MP, Berchuck A, Whitaker RS, Kalén A, Xu FJ, Clarke-Pearson DL, Bell RM, Bast RC. Suppression of diacylglycerol levels by antibodies reactive with the c-erbB-2 (HER-2/neu) gene product p185c-erbB-2 in breast and ovarian cancer cell lines. Gynecol Oncol 70(1):49-55, 1998. PMID: 9698473.
282. Patton SE, Martin ML, Nelsen LL, Fang X, Mills GB, Bast RC, Ostrowski MC. Activation of the ras-mitogen-activated protein kinase pathway and phosphorylation of ets-2 at position threonine 72 in human ovarian cancer cell lines. Cancer Res 58(10):2253-2259, 1998. PMID: 9605774.
283. Bast RC, Desch CE, Hayes DF, Kemeney NE, Ravdin P, Smith TJ. 1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. Adopted on November 7, 1997 by the American Society of Clinical Oncology. J Clin Oncol 16(2):793-5, 1998. PMID: 9469371.
284. Fang X, Jin X, Xu HJ, Liu L, Peng HQ, Hogg D, Roth JA, Yu Y, Xu F, Bast RC, Mills GB. Expression of p16 induces transcriptional downregulation of the RB gene. Oncogene 16(1):1-8, 1998. PMID: 9467937.
285. Bast RC. Summary of the first Emil J Freireich symposium. Clin Cancer Res 3(12 Pt 2):2708-2710, 1997. PMID: 10068278.
286. Xu HJ, Zhou Y, Ji W, Perng GS, Kruzelock R, Kong CT, Bast RC, Mills GB, Li J, Hu SX. Reexpression of the retinoblastoma protein in tumor cells induces senescence and telomerase inhibition. Oncogene 15(21):2589-2596, 1997. PMID: 9399646.
287. Xu FJ, Stack S, Boyer C, O'Briant K, Whitaker R, Mills GB, Yu YH, Bast RC. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis. Clin Cancer Res 3(9):1629-1634, 1997. PMID: 9815853.
288. Xu FJ, Yu YH, Bae DS, Zhao XG, Slade SK, Boyer CM, Bast RC, Zalutsky MR. Radioiodinated antibody targeting of the HER-2/neu oncoprotein. Nucl Med Biol 24(5):451-459, 1997. PMID: 9290082.
289. Vredenburgh JJ, Silva O, Broadwater G, Berry D, DeSombre K, Tyer C, Petros WP, Peters WP, Bast RC. The significance of tumor contamination in the bone marrow from high-risk primary breast cancer patients treated with high-dose chemotherapy and hematopoietic support. Biol Blood Marrow Transplant 3(2):91-97, 1997. PMID: 9267669.
290. Fang X, Gibson S, Flowers M, Furui T, Bast RC, Mills GB. Lysophosphatidylcholine stimulates activator protein 1 and the c-Jun N-terminal kinase activity. J Biol Chem 272(21):13683-13689, 1997. PMID: 9153219.
291. Beck EP, Wagner M, Anselmino L, Xu F, Bast RC, Jaeger W. Is OVX1 a suitable marker for endometrial cancer?. Gynecol Oncol 65(2):291-296, 1997. PMID: 9159340.
292. Baile WF, Lenzi R, Kudelka AP, Maguire P, Novack D, Goldstein M, Myers EG, Bast RC. Improving physician-patient communication in cancer care: outcome of a workshop for oncologists. J Cancer Educ 12(3):166-173, 1997. PMID: 9376255.
293. Jr BR, Knapp RC. CA 125: History, current status, and future prospects. McGill J Med 3:67-71, 1997. PMID: None.
294. Sharp F, Blackett AD, Berek JS, Jr BR. Conclusions and recommendations of the Helene Harris Memorial Trust Sixth Biennial International Forum on Ovarian Cancer. Int J Gynec Oncol, Los Angeles, California, USA 7(None):416-424, 1997. PMID: None.
295. Woolas RP, Jacobs IJ, Xu F, Berchuck A, Soper JT, Clarke-Pearson DL, Spence-Jones C, Oram DH, Hudson CN, Shepherd JH, Jr BR. Multiple tumor marker measurements to differentiate stage I ovarian cancer from the benign ovarian cyst. J Gynecol Techniques 3:123-126, 1997. PMID: None.
296. Hanania EG, Giles RE, Kavanaugh J, Ellerson D, Zu Z, Wang T, Su Y, Kudelka A, Rahman Z, Holmes F, Hortobagyi G, Claxton D, Bachier C, Hester J, Korbling M, Seong D, Cote R, Holzmayer T, Mechetner E, Heimfeld S, Berenson R, Burtness B, Edwards C, Bast R, Andreeff M, Champlin R, Deisseroth AB. Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy. Proc Natl Acad Sci U S A 93(26):15346-51, 1996. PMID: 8986814.
297. van den Brule FA, Buicu C, Berchuck A, Bast RC, Deprez M, Liu FT, Cooper DN, Pieters C, Sobel ME, Castronovo V. Expression of the 67-kD laminin receptor, galectin-1, and galectin-3 in advanced human uterine adenocarcinoma. Hum Pathol 27(11):1185-1191, 1996. PMID: 8912829.
298. Hayes DF, Bast RC, Desch CE, Fritsche H, Kemeny NE, Jessup JM, Locker GY, Macdonald JS, Mennel RG, Norton L, Ravdin P, Taube S, Winn RJ. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 88(20):1456-1466, 1996. PMID: 8841020.
299. Bast RC, Expert Panel TASOCOTM. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology. J Clin Oncol 14(10):2843-77, 1996. PMID: 8874347.
300. Young TN, Rodriguez GC, Rinehart AR, Bast RC, Pizzo SV, Stack MS. Characterization of gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: purification of matrix metalloproteinase 2. Gynecol Oncol 62(1):89-99, 1996. PMID: 8690299.
301. van Haaften-Day C, Russell P, Boyer CM, Kerns BJ, Wiener JR, Jensen DN, Bast RC, Hacker NF. Expression of cell regulatory proteins in ovarian borderline tumors. Cancer 77(10):2092-2098, 1996. PMID: 8640675.
302. Skubitz AP, Bast RC, Wayner EA, Letourneau PC, Wilke MS. Expression of α6 and β4 integrins in serous ovarian carcinoma correlates with expression of the basement membrane protein laminin. Am J Pathol 148(5):1445-1461, 1996. PMID: 8623916.
303. Wiener JR, Kassim SK, Yu Y, Mills GB, Bast RC. Transfection of human ovarian cancer cells with the HER-2/neu receptor tyrosine kinase induces a selective increase in PTP-H1, PTP-1B, PTP-alpha expression. Gynecol Oncol 61(2):233-240, 1996. PMID: 8626139.
304. Olt G, Soper J, Ramakrishnan S, Xu F, Berchuck A, Clarke-Pearson D, Dodge R, Bast RC. Preoperative evaluation of macrophage colony-stimulating factor levels in patients with endometrial cancer. Am J Obstet Gynecol 174(4):1316-1319, 1996. PMID: 8623863.
305. Vredenburgh JJ, Silva O, Tyer C, DeSombre K, Abou-Ghalia A, Cook M, Layfield L, Peters WP, Bast RC. A comparison of immunohistochemistry, two-color immunofluorescence, and flow cytometry with cell sorting for the detection of micrometastatic breast cancer in the bone marrow. J Hematother 5(1):57-62, 1996. PMID: 8646482.
306. Tyer CL, Vredenburgh JJ, Heimer M, Peters WP, Bast RC. Breast cancer cells are effectively purged from peripheral blood progenitor cells with an immunomagnetic technique. Clin Cancer Res 2(1):81-86, 1996. PMID: 9816094.
307. Nap M, Vitali A, Nustad K, Bast RC, O'Brien TJ, Nilsson O, Seguin P, Suresh MR, Børmer OP, Saga T, de Bruijn HW, Nozawa S, Kreutz FT, Jette D, Sakahara H, Gadnell M, Endo K, Barlow EH, Warren D, Paus E, Hammarström S, Kenemans P, Hilgers J. Immunohistochemical characterization of 22 monoclonal antibodies against the CA125 antigen: 2nd report from the ISOBM TD-1 Workshop. Tumour Biol 17(6):325-331, 1996. PMID: 8938947.
308. Woolas R, Xu FJ, Jacobs I, Oram D, Bast RC. Case Report: Elevated serum levels of macrophage colony stimulating factor and OVX1, 11 months prior to the diagnosis of stage IC ovarian cancer. Int J Gynecol Cancer 6:156-158, 1996. PMID: None.
309. Fayed S, Wu S, Lidor Y, Super M, Berchuck A, Jr BR, Wiener JR. Detection and partial purification of a 30 kDa ovarian carcinoma-associated protein. Cancer Mol Biol 3:915-926, 1996. PMID: None.
310. Nustad K, Bast RC, Brien TJ, Nilsson O, Seguin P, Suresh MR, Saga T, Nozawa S, Børmer OP, de Bruijn HW, Nap M, Vitali A, Gadnell M, Clark J, Shigemasa K, Karlsson B, Kreutz FT, Jette D, Sakahara H, Endo K, Paus E, Warren D, Hammarström S, Kenemans P, Hilgers J. Specificity and affinity of 26 monoclonal antibodies against the CA 125 antigen: first report from the ISOBM TD-1 workshop. International Society for Oncodevelopmental Biology and Medicine. Tumour Biol 17(4):196-219, 1996. PMID: 8685601.
311. Franklin WA, Shpall EJ, Archer P, Johnston CS, Garza-Williams S, Hami L, Bitter MA, Bast RC, Jones RB. Immunocytochemical detection of breast cancer cells in marrow and peripheral blood of patients undergoing high dose chemotherapy with autologous stem cell support. Breast Cancer Res Treat 41(1):1-13, 1996. PMID: 8932871.
312. Vredenburgh JJ, Peters WP, Rosner G, DeSombre K, Johnston WW, Kamel A, Wu K, Bast RC. Detection of tumor cells in the bone marrow of stage IV breast cancer patients receiving high-dose chemotherapy: the role of induction chemotherapy. Bone Marrow Transplant 16(6):815-821, 1995. PMID: 8750275.
313. Skates SJ, Xu FJ, Yu YH, Sjövall K, Einhorn N, Chang Y, Bast RC, Knapp RC. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer 76(10 Suppl):2004-2010, 1995. PMID: 8634992.
314. Hurteau JA, Woolas RP, Jacobs IJ, Oram DC, Kurman CC, Rubin LA, Nelson DL, Berchuck A, Bast RC, Mills GB. Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer. Cancer 76(9):1615-1620, 1995. PMID: 8635066.
315. Xu F, Yu Y, Bast RC Jr, Cornelissen G, Fujii S, Takagi M, O'Brien T, Halberg F. Toward salivary-urinary chronosensitivity testing: chronomes of OVX1, M-CSF and CA130. In Vivo 9(4):407-12, 1995. PMID: 8555442.
316. Portela A, Cornélissen G, Halberg F, Bast RC, Fujii S, Xu F, Yu Y, Takagi M, Halberg J, Halberg F. Spectral differences between epitopes in the cronomes of salivary CA130 and CA125. In Vivo 9(4):341-346, 1995. PMID: 8555433.
317. Havrilesky LJ, Hurteau JA, Whitaker RS, Elbendary A, Wu S, Rodriguez GC, Bast RC, Berchuck A. Regulation of apoptosis in normal and malignant ovarian epithelial cells by transforming growth factor β. Cancer Res 55(4):944-948, 1995. PMID: 7531618.
318. Woolas RP, Conaway MR, Xu F, Jacobs IJ, Yu Y, Daly L, Davies AP, O'Briant K, Berchuck A, Soper JT, Clarke-Pearson DL, Rodriguez G, Oram DH, Jr BR. Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecol Oncol 59:111-116, 1995. PMID: 7557595.
319. Elbendary A, Berchuck A, Davis P, Havrilesky L, Bast RC, Iglehart JD, Marks JR. Transforming growth factor β 1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells. Cell Growth Differ 5(12):1301-1307, 1994. PMID: 7696178.
320. Xu FJ, Boyer CM, Bae DS, Wu S, Greenwald M, O'Briant K, Yu YH, Mills GB, Bast RC. The tyrosine kinase activity of the C-erbB-2 gene product (p185) is required for growth inhibition by anti-p185 antibodies but not for the cytotoxicity of an anti-p185-ricin-A chain immunotoxin. Int J Cancer 59(2):242-247, 1994. PMID: 7927925.
321. McGeehan GM, Becherer JD, Bast RC, Boyer CM, Champion B, Connolly KM, Conway JG, Furdon P, Karp S, Kidao S. Regulation of tumour necrosis factor-α processing by a metalloproteinase inhibitor. Nature 370(6490):558-561, 1994. PMID: 8052311.
322. Hurteau J, Rodriguez GC, Whitaker RS, Shah S, Mills G, Bast RC, Berchuck A. Transforming growth factor-ß inhibits proliferation of human ovarian cancer cells obtained from ascites. Cancer 74(1):93-99, 1994. PMID: 8004589.
323. Shpall EJ, Stemmer SM, Hami L, Franklin WA, Shaw L, Bonner HS, Bearman SI, Peters WP, Bast RC, McCulloch W. Amifostine (WR-2721) shortens the engraftment period of 4-hydroperoxycyclophosphamide-purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support. Blood 83(11):3132-3137, 1994. PMID: 8193351.
324. Lukes AS, Kohler MF, Pieper CF, Kerns BJ, Bentley R, Rodriguez GC, Soper JT, Clarke-Pearson DL, Bast RC, Berchuck A. Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer. Cancer 73(9):2380-2385, 1994. PMID: 7909491.
325. Young TN, Rodriguez GC, Moser TL, Bast RC, Pizzo SV, Stack MS. Coordinate expression of urinary-type plasminogen activator and its receptor accompanies malignant transformation of the ovarian surface epithelium. Am J Obstet Gynecol 170(5 Pt 1):1285-1296, 1994. PMID: 8178854.
326. Wu S, Meeker WA, Wiener JR, Berchuck A, Bast RC, Boyer CM. Transfection of ovarian cancer cells with tumor necrosis factor-alpha (TNF-α) antisense mRNA abolishes the proliferative response to interleukin-1 (IL-1) but not TNF-α. Gynecol Oncol 53(1):59-63, 1994. PMID: 8175024.
327. Campbell IG, Nicolai HM, Foulkes WD, Senger G, Stamp GW, Allan G, Boyer C, Jones K, Bast RC, Solomon E. A novel gene encoding a B-box protein within the BRCA1 region at 17q21.1. Hum Mol Genet 3(4):589-594, 1994. PMID: 8069304.
328. Wiener JR, Hurteau JA, Kerns BJ, Whitaker RS, Conaway MR, Berchuck A, Bast RC. Overexpression of the tyrosine phosphatase PTP1B is associated with human ovarian carcinomas. Am J Obstet Gynecol 170(4):1177-1183, 1994. PMID: 8166206.
329. Xu FJ, Yu YH, Daly L, Anselmino L, Hass GM, Berchuck A, Rodriguez GC, Soper JT, Clarke-Pearson DL, Hollis D, Boyer C, Jr BR. OVX1 as a marker for early stage endometrial carcinoma. Cancer 73(7):1855-1858, 1994. PMID: 8137210.
330. Wiener JR, Kerns BJ, Harvey EL, Conaway MR, Iglehart JD, Berchuck A, Bast RC. Overexpression of the protein tyrosine phosphatase PTP1B in human breast cancer: association with p185c-erbB-2 protein expression. J Natl Cancer Inst 86(5):372-378, 1994. PMID: 7905928.
331. Moser TL, Young TN, Rodriguez GC, Pizzo SV, Bast RC, Stack MS. Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma. Int J Cancer 56(4):552-559, 1994. PMID: 8112891.
332. Kerns BJ, Jordan PA, Faerman LL, Berchuck A, Bast RC, Layfield LJ. Determination of proliferation index with MIB-1 in advanced ovarian cancer using quantitative image analysis. Am J Clin Pathol 101(2):192-197, 1994. PMID: 8116574.
333. Berchuck A, Kohler MF, Hopkins MP, Humphrey PA, Robboy SJ, Rodriguez GC, Soper JT, Clarke-Pearson DL, Bast RC. Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors. Gynecol Oncol 52(2):232-236, 1994. PMID: 7508877.
334. Liu FS, Kohler MF, Marks JR, Bast RC, Boyd J, Berchuck A. Mutation and overexpression of the p53 tumor suppressor gene frequently occurs in uterine and ovarian sarcomas. Obstet Gynecol 83(1):118-124, 1994. PMID: 8272291.
335. Berchuck A, Kohler MF, Marks JR, Wiseman R, Boyd J, Bast RC. The p53 tumor suppressor gene frequently is altered in gynecologic cancers. Am J Obstet Gynecol 170(1 Pt 1):246-252, 1994. PMID: 8296829.
336. Abou-Ghalia A, Silva O, Vredenburgh JJ, Jr BR. Advances in the detection of marrow micrometastases in breast cancer. Cancer Res Ther Control 4:43-47, 1994. PMID: None.
337. van den Brûle FA, Berchuck A, Bast RC, Liu FT, Gillet C, Sobel ME, Castronovo V. Differential expression of the 67-kD laminin receptor and 31-kD human laminin-binding protein in human ovarian carcinomas. Eur J Cancer 30A(8):1096-1099, 1994. PMID: 7654437.
338. Kassim SK, Wiener JR, Berchuck A, Jr BR. Protein tyrosine phosphatases: Biology and role in human cancers. Cancer Mol Biol 1:133-144, 1994. PMID: None.
339. Jacobs IJ, Rivera H, Oram DH, Bast RC. Differential diagnosis of ovarian cancer with tumour markers CA 125, CA 15-3 and TAG 72.3. Br J Obstet Gynaecol 100(12):1120-1124, 1993. PMID: 8297846.
340. Woolas RP, Xu FJ, Jacobs IJ, Yu YH, Daly L, Berchuck A, Soper JT, Clarke-Pearson DL, Oram DH, Bast RC. Elevation of multiple serum markers in patients with stage I ovarian cancer. J Natl Cancer Inst 85(21):1748-1751, 1993. PMID: 8411259.
341. Lidor YJ, O'Briant KC, Xu FJ, Hamilton TC, Ozols RF, Bast RC. Alkylating agents and immunotoxins exert synergistic cytotoxic activity against ovarian cancer cells. Mechanism of action. J Clin Invest 92(5):2440-2447, 1993. PMID: 8227359.
342. Kohler MF, Marks JR, Wiseman RW, Jacobs IJ, Davidoff AM, Clarke-Pearson DL, Soper JT, Bast RC, Berchuck A. Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst 85(18):1513-1519, 1993. PMID: 8360934.
343. Kohler MF, Nishii H, Humphrey PA, Saski H, Marks J, Bast RC, Clarke-Pearson DL, Boyd J, Berchuck A. Mutation of the p53 tumor-suppressor gene is not a feature of endometrial hyperplasias. Am J Obstet Gynecol 169(3):690-694, 1993. PMID: 8372881.
344. Gallion HH, Bast RC. National Cancer Institute Conference on Investigational Strategies for Detection and Intervention in Early Ovarian Cancer. Cancer Res 53(16):3839-3842, 1993. PMID: 8339296.
345. Lidor YJ, Xu FJ, Martínez-Maza O, Olt GJ, Marks JR, Berchuck A, Ramakrishnan S, Berek JS, Bast RC. Constitutive production of macrophage colony-stimulating factor and interleukin-6 by human ovarian surface epithelial cells. Exp Cell Res 207(2):332-339, 1993. PMID: 8344385.
346. F-J X, Y-A Y, Daly L, DeSombre K, Anselmino L, Hass GM, Berchuck A, Soper J, Clarke-Pearson D, Boyer C, Layfield LJ, Jr BR. OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures. J Clin Oncol 11(8):1506-1510, 1993. PMID: 8336189.
347. McKenzie SJ, DeSombre KA, Bast BS, Hollis DR, Whitaker RS, Berchuck A, Boyer CM, Bast RC. Serum levels of HER-2 neu (C-erbB-2) correlate with overexpression of p185neu in human ovarian cancer. Cancer 71(12):3942-3946, 1993. PMID: 8099528.
348. Peters WP, Ross M, Vredenburgh JJ, Meisenberg B, Marks LB, Winer E, Kurtzberg J, Bast RC, Jones R, Shpall E. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 11(6):1132-1143, 1993. PMID: 8501500.
349. Jordan PA, Kerns BJ, Pence JC, Kohler MF, Bast RC, Kinney RB, Berchuck A. Determination of proliferation index in advanced ovarian cancer using quantitative image analysis. Am J Clin Pathol 99(6):736-740, 1993. PMID: 8322710.
350. Kohler MF, Kerns BJ, Humphrey PA, Marks JR, Bast RC, Berchuck A. Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. Obstet Gynecol 81(5 Pt 1):643-650, 1993. PMID: 8469448.
351. Wu S, Boyer CM, Whitaker RS, Berchuck A, Wiener JR, Weinberg JB, Bast RC. Tumor necrosis factor alpha (TNF-α) as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and TNF-α expression. Cancer Res 53(8):1939-1944, 1993. PMID: 8385577.
352. Jacobs IJ, Smith SA, Wiseman RW, Futreal PA, Harrington T, Osborne RJ, Leach V, Molyneaux A, Berchuck A, Ponder BAJ, Jr BR. A deletion unit on chromosome 17q in epithelial ovarian tumors distal to the familial breast/ovarian cancer locus. Cancer Res 53(6):1218-1221, 1993. PMID: 8095178.
353. Xu F, Lupu R, Rodriguez GC, Whitaker RS, Boente MP, Berchuck A, Yu Y, DeSombre KA, Boyer CM, Bast RC. Antibody-induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185. Int J Cancer 53(3):401-408, 1993. PMID: 7679090.
354. Rodríguez GC, Boente MP, Berchuck A, Whitaker RS, O'Briant KC, Xu F, Bast RC. The effect of antibodies and immunotoxins reactive with HER-2/neu on growth of ovarian and breast cancer cell lines. Am J Obstet Gynecol 168(1 Pt 1):228-232, 1993. PMID: 8420332.
355. Woolas R, Xu FJ, Daly L, Soper JT, Berchuck A, Rodriguez G, Clarke-Pearson DL, Boyer CM, Jr BR. Screening strategies for ovarian cancer. Diagn Oncol 3:287-293, 1993. PMID: None.
356. Jacobs IJ, Kohler MF, Wiseman RW, Marks JR, Whitaker R, Kerns BA, Humphrey P, Berchuck A, Ponder BA, Bast RC. Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation. J Natl Cancer Inst 84(23):1793-1798, 1992. PMID: 1433368.
357. Boente MP, Berchuck A, Rodriguez GC, Davidoff A, Whitaker R, Xu FJ, Marks J, Clarke-Pearson DL, Bast RC. The effect of interferon gamma on epidermal growth factor receptor expression in normal and malignant ovarian epithelial cells. Am J Obstet Gynecol 167(6):1877-1882, 1992. PMID: 1361720.
358. Olt G, Berchuck A, Soisson AP, Boyer CM, Bast RC. Fibronectin is an immunosuppressive substance associated with epithelial ovarian cancer. Cancer 70(8):2137-2142, 1992. PMID: 1394043.
359. Pence JC, Deutsch MA, Kerns BJM, Huper G, Jordan LK III, Wolfe WG, Samuelson WM, Jr FW, Dodge RK, Plate CA, Jr BR, Iglehart JD. Sensitive and specific detection of the 4B5 antigen in bronchial lavage specimens from patients with primary bronchogenic carcinoma. Cancer 70(5):1115-1123, 1992. PMID: 1515986.
360. Jacobs IJ, Oram DH, Bast RC. Strategies for improving the specificity of screening for ovarian cancer with tumor-associated antigens CA 125, CA 15-3, and TAG 72.3. Obstet Gynecol 80(3 Pt 1):396-399, 1992. PMID: 1495694.
361. Daly L, Ferguson J, Cram GP, Hars V, George SL, McCarty KS, Bast RC. Comparison of a novel assay for breast cancer mucin to CA15-3 and carcinoembryonic antigen. J Clin Oncol 10(7):1057-1065, 1992. PMID: 1607912.
362. Einhorn N, Sjövall K, Knapp RC, Hall P, Scully RE, Bast RC, Zurawski VR. Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet Gynecol 80(1):14-18, 1992. PMID: 1603484.
363. Kerns BJ, Jordan PA, Moore MB, Humphrey PA, Berchuck A, Kohler MF, Bast RC, Iglehart JD, Marks JR. p53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry. J Histochem Cytochem 40(7):1047-1051, 1992. PMID: 1607637.
364. Cornelissen G, Halberg F, Halberg E, Bingham C, Haus E, Bast RC Jr, Fujii S, Long HJ 3rd, Halberg F, Tamura K. Toward a chronotherapy of ovarian cancer. Part III: Salivary CA125 for chronochemotherapy by efficacy. Chronobiologia 19(3-4):131-49, 1992. PMID: 1362146.
365. Deutsch MA, Pence JC, Kerns BJ, Plate CA, Kinney R, Gooch G, Iglehart JD, Bast RC. Detection of a novel marker in the bronchial secretions of patients with non-small cell lung cancer using the 4B5 monoclonal antibody. Cancer 69(12):2894-2904, 1992. PMID: 1375528.
366. O'Briant K, Chrysson N, Hunter V, Tyson F, Tanner M, Daly L, George S, Berchuck A, Soper J, Fowler W, Clarke-Pearson D, Jr BR. Ha-ras polymorphisms in epithelial ovarian cancer. Gynecol Oncol 45(3):229-302, 1992. PMID: 1351862.
367. Kohler MF, Berchuck A, Davidoff AM, Humphrey PA, Dodge RK, Iglehart JD, Soper JT, Clarke-Pearson DL, Bast RC, Marks JR. Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res 52(6):1622-1627, 1992. PMID: 1540970.
368. Wu S, Rodabaugh K, Martinez-Maza O, Watson JM, Silberstein DS, Boyer CM, Peters WP, Weinberg JB, Berek JS, Bast RC. Stimulation of ovarian tumor cell proliferation with monocyte products including interleukin-1, interleukin-6, and tumor necrosis factor-α. Am J Obstet Gynecol 166(3):997-1007, 1992. PMID: 1550178.
369. Berchuck A, Rodriguez G, Olt G, Whitaker R, Boente MP, Arrick BA, Clarke-Pearson DL, Bast RC. Regulation of growth of normal ovarian epithelial cells and ovarian cancer cell lines by transforming growth factor-ß. Am J Obstet Gynecol 166(2):676-684, 1992. PMID: 1536252.
370. Berchuck A, Boente MP, Kerns BJ, Kinney RB, Soper JT, Clarke-Pearson DL, Bast RC, Bacus SS. Ploidy analysis of epithelial ovarian cancers using image cytometry. Gynecol Oncol 44(1):61-65, 1992. PMID: 1370427.
371. Johnston CS, Shpall EJ, Williams S, Hami L, Jones RB, Bast RC, Ceriani RL, Franklin W. Detection of minimal residual breast cancer in bone marrow. Prog Clin Biol Res 377:637-642, 1992. PMID: 1438446.
372. Lidor YJ, Shpall EJ, Peters WP, Bast RC. Synergistic cytotoxicity of different alkylating agents for epithelial ovarian cancer. Int J Cancer 49(5):704-710, 1991. PMID: 1937956.
373. Xu FJ, Ramakrishnan S, Daly L, Soper JT, Berchuck A, Clarke-Pearson D, Bast RC. Increased serum levels of macrophage colony-stimulating factor in ovarian cancer. Am J Obstet Gynecol 165(5 Pt 1):1356-1362, 1991. PMID: 1957862.
374. Bast RC, Knauf S, Epenetos A, Dhokia B, Daly L, Tanner M, Soper J, Creasman W, Gall S, Knapp RC. Coordinate elevation of serum markers in ovarian cancer but not in benign disease. Cancer 68(8):1758-1763, 1991. PMID: 1913520.
375. Maier LA, Xu FJ, Hester S, Boyer CM, McKenzie S, Bruskin AM, Argon Y, Bast RC. Requirements for the internalization of a murine monoclonal antibody directed against the HER-2/neu gene product c-erbB-2. Cancer Res 51(19):5361-5369, 1991. PMID: 1680547.
376. Bast RC, Capizzi RL, Pagano JS, Wiley AL. Insurance coverage of screening mammography and Pap smears. The directors of North Carolina's University-based cancer centers speak out. N C Med J 52(10):496-498, 1991. PMID: 1944619.
377. O'Briant KC, Shpall EJ, Houston LL, Peters WP, Bast RC. Elimination of clonogenic breast cancer cells from human bone marrow. A comparison of immunotoxin treatment with chemoimmunoseparation using 4-hydroperoxycyclophosphamide, monoclonal antibodies, and magnetic microspheres. Cancer 68(6):1272-1278, 1991. PMID: 1873781.
378. Tyson FL, Boyer CM, Kaufman R, O'Briant K, Cram G, Crews JR, Soper JT, Daly L, Jr FW, Haskill JS, Jr BR. Expression and amplification of the HER-2/neu (c-erbB-2) protooncogene in epithelial ovarian tumors and cell lines. Am J Obstet Gynecol 165(3):640-646, 1991. PMID: 1679963.
379. Jerome KR, Barnd DL, Bendt KM, Boyer CM, Taylor-Papadimitriou J, McKenzie IF, Bast RC, Finn OJ. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res 51(11):2908-2916, 1991. PMID: 1709586.
380. Marks JR, Davidoff AM, Kerns BJ, Humphrey PA, Pence JC, Dodge RK, Clarke-Pearson DL, Iglehart JD, Bast RC, Berchuck A. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 51(11):2979-2984, 1991. PMID: 2032235.
381. Ozols RF, Hamilton TC, Hoskins WJ, Bast RC, Young RC. Summary of symposium: Biology and therapy of ovarian cancer. Semin Oncol 18(3):297-306, 1991. PMID: 2042066.
382. Rodriguez GC, Berchuck A, Whitaker RS, Schlossman D, Clarke-Pearson DL, Bast RC. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. II. Relationship between receptor expression and response to epidermal growth factor. Am J Obstet Gynecol 164(3):745-750, 1991. PMID: 2003535.
383. Shpall EJ, Bast RC, Joines WT, Jones RB, Anderson I, Johnston C, Eggleston S, Tepperberg M, Edwards S, Peters WP. Immunomagnetic purging of breast cancer from bone marrow for autologous transplantation. Bone Marrow Transplant 7(2):145-151, 1991. PMID: 2049558.
384. Berchuck A, Rodriguez GC, Kamel A, Dodge RK, Soper JT, Clarke-Pearson DL, Bast RC. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. Am J Obstet Gynecol 164(2):669-674, 1991. PMID: 1992720.
385. Yu YH, Schlossman DM, Harrison CL, Rhinehardt-Clark A, Soper JT, Klug TL, Zurawski VR, Bast RC. Coexpression of different antigenic markers on moieties that bear CA 125 determinants. Cancer Res 51(2):468-475, 1991. PMID: 1702359.
386. Shpall EJ, Jones RB, Bast RC, Rosner GL, Vandermark R, Ross M, Affronti ML, Johnston C, Eggleston S, Tepperburg M. 4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial. J Clin Oncol 9(1):85-93, 1991. PMID: 1985173.
387. Berchuck A, Rodriguez G, Kinney RB, Soper JT, Dodge RK, Clarke-Pearson DL, Bast RC. Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. Am J Obstet Gynecol 164(1 Pt 1):15-21, 1991. PMID: 1670908.
388. Harlozinska A, Bar JK, Rabczynski J, Bast RC, Richter R, Cislo M. Reactivity of polyclonal and two monoclonal antibodies with cell subsets isolated from cystic fluids of ovarian serous neoplasms. Tumori 76(5):505-510, 1990. PMID: 1701581.
389. Soper JT, Berchuck A, Olt GJ, Soisson AP, Clarke-Pearson DL, Bast RC. Preoperative evaluation of serum CA 125, TAG 72, and CA 15-3 in patients with endometrial carcinoma. Am J Obstet Gynecol 163(4 Pt 1):1204-1209, 1990. PMID: 2220931.
390. Hunter VJ, Daly L, Helms M, Soper JT, Berchuck A, Clarke-Pearson DL, Bast RC. The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction. Am J Obstet Gynecol 163(4 Pt 1):1164-1167, 1990. PMID: 2171337.
391. Berchuck A, Rodriguez G, Kamel A, Soper JT, Clarke-Pearson DL, Bast RC. Expression of epidermal growth factor receptor and HER-2/neu in normal and neoplastic cervix, vulva, and vagina. Obstet Gynecol 76(3 Pt 1):381-387, 1990. PMID: 1974342.
392. Westhoff C, Gollub E, Patel J, Rivera H, Bast R. CA 125 levels in menopausal women. Obstet Gynecol 76(3 Pt 1):428-431, 1990. PMID: 2381621.
393. Shpall EJ, Clarke-Pearson D, Soper JT, Berchuck A, Jones RB, Bast RC, Ross M, Lidor Y, Vanacek K, Tyler T. High-dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer. Gynecol Oncol 38(3):386-391, 1990. PMID: 2121627.
394. Jones RB, Shpall EJ, Shogan J, Affronti ML, Coniglio D, Hart L, Halperin E, Iglehart JD, Moore J, Gockerman J, Bast RC, Peters WP. The Duke AFM program. Intensive induction chemotherapy for metastatic breast cancer. Cancer 66(3):431-436, 1990. PMID: 2364358.
395. Leslie DS, Johnston WW, Daly L, Ring DB, Shpall EJ, Peters WP, Bast RC. Detection of breast carcinoma cells in human bone marrow using fluorescence-activated cell sorting and conventional cytology. Am J Clin Pathol 94(1):8-13, 1990. PMID: 2193508.
396. Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, Soper JT, Dodge R, Clarke-Pearson DL, Marks P, McKenzie S, Yin S, Bast RC. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 50(13):4087-4091, 1990. PMID: 1972347.
397. Welch WR, Niloff JM, Anderson D, Battaile A, Emery S, Knapp RC, Bast RC. Antigenic heterogeneity in human ovarian cancer. Gynecol Oncol 38(1):12-16, 1990. PMID: 2162315.
398. Montgomery RB, Kurtzberg J, Rhinehardt-Clark A, Haleem A, Ramakrishnan S, Olsen GA, Peters WP, Smith CA, Haynes BF, Houston LL, Jr BR. Elimination of malignant clonogenic T cells from human bone marrow using chemoimmunoseparation with 2'- deoxycoformycin, deoxyadenosine and an immunotoxin. Bone Marrow Transplant 5(6):395-402, 1990. PMID: 2369680.
399. Yu YH, Crews JR, Ramakrishnan S, Houston LL, Leslie DS, George SL, Lidor Y, Boyer CM, Ring DB, Jr BR. Use of immunotoxins in combination to inhibit clonogenic growth of human breast carcinoma cells. Cancer Res 50(11):3231-3238, 1990. PMID: 2334918.
400. Berchuck A, Olt GJ, Soisson AP, Kamel A, Soper JT, Boyer CM, Clarke-Pearson DL, Leslie DS, Bast RC. Heterogeneity of antigen expression in advanced epithelial ovarian cancer. Am J Obstet Gynecol 162(4):883-888, 1990. PMID: 2327461.
401. Zurawski VR, Sjovall K, Schoenfeld DA, Broderick SF, Hall P, Bast RC, Eklund G, Mattsson B, Connor RJ, Prorok PC. Prospective evaluation of serum CA 125 levels in a normal population, phase I: the specificities of single and serial determinations in testing for ovarian cancer. Gynecol Oncol 36(3):299-305, 1990. PMID: 2318438.
402. Hunter VJ, Weinberg JB, Haney AF, Soper JT, Lavin P, Metsch L, Knapp RC, Bast RC. CA 125 in peritoneal fluid and serum from patients with benign gynecologic conditions and ovarian cancer. Gynecol Oncol 36(2):161-165, 1990. PMID: 2404835.
403. Soper JT, Hunter VJ, Daly L, Tanner M, Creasman WT, Bast RC. Preoperative serum tumor-associated antigen levels in women with pelvic masses. Obstet Gynecol 75(2):249-254, 1990. PMID: 2300353.
404. Berchuck A, Olt GJ, Everitt L, Soisson AP, Bast RC, Boyer CM. The role of peptide growth factors in epithelial ovarian cancer. Obstet Gynecol 75(2):255-262, 1990. PMID: 2300354.
405. Shpall EJ, Anderson IC, Bast RC, Joines WT, Jones RB, Ross M, Edwards S, Eggleston S, Johnston C, Tepperberg M. Immunopharmacologic purging of breast cancer from bone marrow for autologous bone marrow transplantation. Prog Clin Biol Res 333:321-335; discussion 336, 1990. PMID: 2308989.
406. Soisson AP, Berchuck A, Lessey BA, Soper JT, Clarke-Pearson DL, McCarty KS, Bast RC. Immunohistochemical expression of TAG-72 in normal and malignant endometrium: correlation of antigen expression with estrogen receptor and progesterone receptor levels. Am J Obstet Gynecol 161(5):1258-1263, 1989. PMID: 2589448.
407. Berchuck A, Soisson AP, Olt GJ, Soper JT, Clarke-Pearson DL, Bast RC, McCarty KS. Epidermal growth factor receptor expression in normal and malignant endometrium. Am J Obstet Gynecol 161(5):1247-1252, 1989. PMID: 2480065.
408. Sallan SE, Niemeyer CM, Billett AL, Lipton JM, Tarbell NJ, Gelber RD, Murray C, Pittinger TP, Wolfe LC, Bast RC. Autologous bone marrow transplantation for acute lymphoblastic leukemia. J Clin Oncol 7(11):1594-1601, 1989. PMID: 2809677.
409. Berchuck A, Soisson AP, Soper JT, Clarke-Pearson DL, Bast RC, McCarty KS. Reactivity of epidermal growth factor receptor monoclonal antibodies with human uterine tissues. Arch Pathol Lab Med 113(10):1155-1158, 1989. PMID: 2802945.
410. Anderson IC, Shpall EJ, Leslie DS, Nustad K, Ugelstad J, Peters WP, Bast RC. Elimination of malignant clonogenic breast cancer cells from human bone marrow. Cancer Res 49(16):4659-4664, 1989. PMID: 2663144.
411. Boyer CM, Dawson DV, Neal SE, Winchell LF, Leslie DS, Ring D, Bast RC. Differential induction by interferons of major histocompatibility complex-encoded and non-major histocompatibility complex-encoded antigens in human breast and ovarian carcinoma cell lines. Cancer Res 49(11):2928-2934, 1989. PMID: 2497969.
412. Berchuck A, Soisson AP, Clarke-Pearson DL, Soper JT, Boyer CM, Kinney RB, McCarty KS, Bast RC. Immunohistochemical expression of CA 125 in endometrial adenocarcinoma: correlation of antigen expression with metastatic potential. Cancer Res 49(8):2091-2095, 1989. PMID: 2702650.
413. Ramakrishnan S, Xu FJ, Brandt SJ, Niedel JE, Bast RC, Brown EL. Constitutive production of macrophage colony-stimulating factor by human ovarian and breast cancer cell lines. J Clin Invest 83(3):921-926, 1989. PMID: 2646321.
414. Ciobanu N, Runowicz CD, Wiernik PH, Strauman T, Sheridan C, Bast RC. CA 125 levels in patients with ovarian carcinoma undergoing autologous bone marrow transplantation. Am J Obstet Gynecol 160(2):354-355, 1989. PMID: 2644834.
415. Boyer CM, Borowitz MJ, McCarty KS, Kinney RB, Everitt L, Dawson DV, Ring D, Bast RC. Heterogeneity of antigen expression in benign and malignant breast and ovarian epithelial cells. Int J Cancer 43(1):55-60, 1989. PMID: 2463226.
416. Peters WP, Stuart A, Klotman M, Gilbert C, Jones RB, Shpall EJ, Gockerman J, Bast RC, Moore JO. High-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. A clinical and pharmacologic study. Cancer Chemother Pharmacol 23(6):377-383, 1989. PMID: 2653660.
417. Zalutsky MR, Bast RC, Knapp RC. Pharmacokinetics of a radioiodinated monoclonal antibody F(ab')2 fragment in a xenograft model with circulating antigen. Int J Rad Appl Instrum B 16(4):405-411, 1989. PMID: 2777582.
418. Einhorn N, Knapp RC, Bast RC, Zurawski VR. CA 125 assay used in conjunction with CA 15-3 and TAG-72 assays for discrimination between malignant and non-malignant diseases of the ovary. Acta Oncol 28(5):655-657, 1989. PMID: 2590540.
419. Conkling PR, Chua CC, Nadler P, Greenberg CS, Doty E, Misukonis MA, Haney AF, Bast RC, Weinberg JB. Clinical trials with human tumor necrosis factor: in vivo and in vitro effects on human mononuclear phagocyte function. Cancer Res 48(19):5604-5609, 1988. PMID: 3046744.
420. Peters WP, Shpall EJ, Jones RB, Olsen GA, Bast RC, Gockerman JP, Moore JO. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 6(9):1368-1376, 1988. PMID: 3047332.
421. Malkasian GD, Knapp RC, Lavin PT, Zurawski VR, Podratz KC, Stanhope CR, Mortel R, Berek JS, Bast RC, Ritts RE. Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease. Am J Obstet Gynecol 159(2):341-346, 1988. PMID: 2457318.
422. Olsen GA, Gockerman JP, Bast RC, Borowitz M, Peters WP. Altered immunologic reconstitution after standard-dose chemotherapy or high-dose chemotherapy with autologous bone marrow support. Transplantation 46(1):57-60, 1988. PMID: 3293287.
423. Zurawski VR, Knapp RC, Einhorn N, Kenemans P, Mortel R, Ohmi K, Bast RC, Ritts RE, Malkasian G. An initial analysis of preoperative serum CA 125 levels in patients with early stage ovarian carcinoma. Gynecol Oncol 30(1):7-14, 1988. PMID: 2452773.
424. Brandt SJ, Peters WP, Atwater SK, Kurtzberg J, Borowitz MJ, Jones RB, Shpall EJ, Bast RC, Gilbert CJ, Oette DH. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N Engl J Med 318(14):869-876, 1988. PMID: 3281007.
425. Knauf S, Bast RC. Tumor antigen NB/70K and CA 125 levels in the blood of preoperative ovarian cancer patients and controls: a preliminary report of the use of the NB12123 and CA 125 radioimmunoassays alone and in combination. Int J Biol Markers 3(2):75-81, 1988. PMID: 3243980.
426. Endo K, Matsuoka Y, Nakashima T, Fujii S, Kunimatsu M, Saga T, Watanabe Y, Kawamura Y, Koizumi M, Konishi J, Torizuka K, Jr BR. Development of a new sensitive immunoradiometric assay for CA125: Mixed use of two monoclonal antibodies reactive with separate epitopes. J Tumor Marker Oncol 3:65-71, 1988. PMID: None.
427. Zalutsky MR, Knapp RC, Bast RC. Influence of circulating antigen on blood pool activity of a radioiodinated monoclonal antibody. Int J Rad Appl Instrum B 15(4):431-437, 1988. PMID: 3255739.
428. Kenemans P, Bast RC, Yedema CA, Price MR, Hilgers J. CA 125 and polymorphic epithelial mucin as serum tumor markers. Cancer Rev 11-12:119-144, 1988. PMID: None.
429. Koerner TJ, Hamilton TA, Introna M, Tannenbaum CS, Bast RC, Adams DO. The early competence genes JE and KC are differentially regulated in murine peritoneal macrophages in response to lipopolysaccharide. Biochem Biophys Res Commun 149(3):969-974, 1987. PMID: 3426621.
430. Peters WP, Henner WD, Grochow LB, Olsen G, Edwards S, Stanbuck H, Stuart A, Gockerman J, Moore J, Bast RC. Clinical and pharmacologic effects of high dose single agent busulfan with autologous bone marrow support in the treatment of solid tumors. Cancer Res 47(23):6402-6406, 1987. PMID: 2824032.
431. Leoni F, Bast RC, Canevari S, Menard S, Soper JT, Colnaghi MI. Immunochemical characterization and radioimmunometric detection of molecules shed by human ovarian cancer. Int J Cancer 40(5):592-597, 1987. PMID: 2445699.
432. Haleem A, Kurtzberg J, Olsen GA, Rhinehardt-Clark A, Leslie DS, Ray L, Smith CA, Peters WP, Haynes BF, Bast RC. Combined chemoseparation and immunoseparation of clonogenic T lymphoma cells from human bone marrow using 2'-deoxycoformycin, deoxyadenosine, 3A1 monoclonal antibody, and complement. Cancer Res 47(17):4608-4612, 1987. PMID: 3113721.
433. Introna M, Bast RC, Tannenbaum CS, Hamilton TA, Adams DO. The effect of LPS on expression of the early "competence" genes JE and KC in murine peritoneal macrophages. J Immunol 138(11):3891-3896, 1987. PMID: 3108379.
434. Zurawski VR, Broderick SF, Pickens P, Knapp RC, Bast RC. Serum CA 125 levels in a group of nonhospitalized women: relevance for the early detection of ovarian cancer. Obstet Gynecol 69(4):606-611, 1987. PMID: 2434895.
435. Introna M, Bast RC, Johnston PA, Adams DO, Hamilton TA. Homologous and heterologous desensitization of proto-oncogene cfos expression in murine peritoneal macrophages. J Cell Physiol 131(1):36-42, 1987. PMID: 3571335.
436. Lavin PT, Knapp RC, Malkasian G, Whitney CW, Berek JC, Bast RC. CA 125 for the monitoring of ovarian carcinoma during primary therapy. Obstet Gynecol 69(2):223-227, 1987. PMID: 2433652.
437. Lan MS, Bast RC, Colnaghi MI, Knapp RC, Colcher D, Schlom J, Metzgar RS. Co-expression of human cancer-associated epitopes on mucin molecules. Int J Cancer 39(1):68-72, 1987. PMID: 2432019.
438. Antman K, Eder JP, Elias A, Shea T, Peters WP, Andersen J, Schryber S, Henner WD, Finberg R, Wilmore D, Kaplan W, Lew M, Kruskall MS, Anderson K, Gorgone B, Bast R, Schnipper L, Frei E III. High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience. Cancer Treat Rep 71:119-125, 1987. PMID: 3542208.
439. Davis HM, Zurawski VR, Bast RC, Klug TL. Characterization of the CA 125 antigen associated with human epithelial ovarian carcinomas. Cancer Res 46(12 Pt 1):6143-6148, 1986. PMID: 2430690.
440. Introna M, Hamilton TA, Kaufman RE, Adams DO, Bast RC. Treatment of murine peritoneal macrophages with bacterial lipopolysaccharide alters expression of c-fos and c-myc oncogenes. J Immunol 137(8):2711-2715, 1986. PMID: 3760571.
441. Eder JP, Bast RC, Peters WP, Henner D, Sanchez E, Schryber S, Frei E, Schnipper LE. Prediction of the optimal timing of bone marrow reinfusion after high dose chemotherapy. Cancer Res 46(9):4496-4499, 1986. PMID: 3524814.
442. Niloff JM, Knapp RC, Lavin PT, Malkasian GD, Berek JS, Mortel R, Whitney C, Zurawski VR, Bast RC. The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer. Am J Obstet Gynecol 155(1):56-60, 1986. PMID: 3460341.
443. Peters WP, Eder JP, Henner WD, Schryber S, Wilmore D, Finberg R, Schoenfeld D, Bast R, Gargone B, Antman K. High-dose combination alkylating agents with autologous bone marrow support: a Phase 1 trial. J Clin Oncol 4(5):646-654, 1986. PMID: 3517240.
444. Berek JS, Knapp RC, Malkasian GD, Lavin PT, Whitney C, Niloff JM, Bast RC. CA 125 serum levels correlated with second-look operations among ovarian cancer patients. Obstet Gynecol 67(5):685-689, 1986. PMID: 3457330.
445. Barbieri RL, Niloff JM, Bast RC, Scaetzl E, Kistner RW, Knapp RC. Elevated serum concentrations of CA-125 in patients with advanced endometriosis. Fertil Steril 45(5):630-634, 1986. PMID: 3457709.
446. Bregni M, De Fabritiis P, Raso V, Greenberger J, Lipton J, Nadler L, Rothstein L, Ritz J, Bast RC. Elimination of clonogenic tumor cells from human bone marrow using a combination of monoclonal antibody: Ricin A chain conjugates. Cancer Res 46(3):1208-1213, 1986. PMID: 3510720.
447. Einhorn N, Bast RC, Knapp RC, Tjernberg B, Zurawski VR. Preoperative evaluation of serum CA 125 levels in patients with primary epithelial ovarian cancer. Obstet Gynecol 67(3):414-416, 1986. PMID: 2418395.
448. De Fabritiis P, Bregni M, Lipton J, Reynolds C, Nadler L, Ritz J, Bast RC. Antigenic heterogeneity among Burkitt's lymphoma cells surviving treatment with monoclonal antibody and complement. Leuk Res 10(1):35-42, 1986. PMID: 2935682.
449. Sekine H, Hayes DF, Ohno T, Keefe KA, Schaetzl E, Bast RC, Knapp R, Kufe DW. Circulating DF3 and CA125 antigen levels in serum from patients with epithelial ovarian carcinoma. J Clin Oncol 3(10):1355-1363, 1985. PMID: 2413181.
450. Mahvi DM, Meyers WC, Bast RC, Seigler HF, Metzgar RS. Carcinoma of the pancreas. Therapeutic efficacy as defined by a serodiagnostic test utilizing a monoclonal antibody. Ann Surg 202(4):440-445, 1985. PMID: 4051597.
451. Bast RC Jr, Siegal FP, Runowicz C, Klug TL, Zurawski VR Jr, Schonholz D, Cohen CJ, Knapp RC. Elevation of serum CA 125 prior to diagnosis of an epithelial ovarian carcinoma. Gynecol Oncol 22(1):115-20, 1985. PMID: 2410329.
452. Knauf S, Anderson DJ, Knapp RC, Bast RC. A study of the NB/7OK and CA 125 monoclonal antibody radioimmunoassays for measuring serum antigen levels in ovarian cancer patients. Am J Obstet Gynecol 152(7 Pt 1):911-913, 1985. PMID: 2411137.
453. Niloff JM, Knapp RC, Jones G, Schaetzl EM, Bast RC. Recombinant leukocyte α interferon in advanced ovarian carcinoma. Cancer Treat Rep 69(7-8):895-896, 1985. PMID: 4016797.
454. Bast RC, Knapp RC. Use of the CA 125 antigen in diagnosis and monitoring of ovarian carcinoma. Eur J Obstet Gynecol Reprod Biol 19(6):354-356, 1985. PMID: 4018373.
455. De Fabritiis P, Bregni M, Lipton J, Greenberger J, Nadler L, Rothstein L, Korbling M, Ritz J, Bast RC. Elimination of clonogenic Burkitt's lymphoma cells from human bone marrow using 4-hydroperoxycyclophosphamide in combination with monoclonal antibodies and complement. Blood 65(5):1064-1070, 1985. PMID: 3995166.
456. Niloff JM, Bast RC, Schaetzl EM, Knapp RC. Predictive value of CA 125 antigen levels in second-look procedures for ovarian cancer. Am J Obstet Gynecol 151(7):981-986, 1985. PMID: 3157319.
457. Greenberger JS, Rothstein L, DeFabritiis P, Bregni M, Bast R, Ritz J, Nadler LM, Lipton JM, Sakakeeny MA. Effects of monoclonal antibody and complement treatment of human marrow on hematopoiesis in continuous bone marrow culture. Cancer Res 45(2):758-767, 1985. PMID: 3967246.
458. Bast RC, De Fabritiis P, Lipton J, Gelber R, Maver C, Nadler L, Sallan S, Ritz J. Elimination of malignant clonogenic cells from human bone marrow using multiple monoclonal antibodies and complement. Cancer Res 45(2):499-503, 1985. PMID: 3967224.
459. Berek JS, Knapp RC, Hacker NF, Lichtenstein A, Jung T, Spina C, Obrist R, Griffiths CT, Berkowitz RS, Parker L, Zighelboim J, Jr BR. Intraperitoneal immunotherapy of epithelial ovarian carcinoma with Corynebacterium parvum. Am J Obstet Gynecol 152:1003-1010, 1985. PMID: 2992276.
460. Obrist R, Obrecht JP, Bast RC, Sandberg AL. Chemotactic anti-tumor antibodies - in vitro results with four different antibody preparations. Adv Exp Med Biol 186:827-832, 1985. PMID: 4050600.
461. Niloff JM, Knapp RC, Schaetzl E, Reynolds C, Bast RC. CA125 antigen levels in obstetric and gynecologic patients. Obstet Gynecol 64(5):703-707, 1984. PMID: 6208522.
462. Berek JS, Bast RC, Lichtenstein A, Hacker NF, Spina CA, Lagasse LD, Knapp RC, Zighelboim J. Lymphocyte cytotoxicity in the peritoneal cavity and blood of patients with ovarian cancer. Obstet Gynecol 64(5):708-714, 1984. PMID: 6493663.
463. Nadler LM, Takvorian T, Botnick L, Bast RC, Finberg R, Hellman S, Canellos GP, Schlossman SF. Anti-B1 monoclonal antibody and complement treatment in autologous bone-marrow transplantation for relapsed B-cell non-Hodgkin's lymphoma. Lancet 2(8400):427-431, 1984. PMID: 6147502.
464. Lichtenstein A, Berek J, Bast R, Spina C, Hacker N, Knapp RC, Zighelboim J. Activation of peritoneal lymphocyte cytotoxicity in patients with ovarian cancer by intraperitoneal treatment with Corynebacterium parvum. J Biol Response Mod 3(4):371-378, 1984. PMID: 6541243.
465. Bast RC, Klug TL, Schaetzl E, Lavin P, Niloff JM, Greber TF, Zurawski VR, Knapp RC. Monitoring human ovarian carcinoma with a combination of CA 125, CA 19-9, and carcinoembryonic antigen. Am J Obstet Gynecol 149(5):553-559, 1984. PMID: 6204531.
466. Masuho Y, Zalutsky M, Knapp RC, Bast RC. Interaction of monoclonal antibodies with cell surface antigens of human ovarian carcinomas. Cancer Res 44(7):2813-2819, 1984. PMID: 6202400.
467. Niloff JM, Klug TL, Schaetzl E, Zurawski VR, Knapp RC, Bast RC. Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix. Am J Obstet Gynecol 148(8):1057-1058, 1984. PMID: 6201072.
468. Klug TL, Bast RC, Niloff JM, Knapp RC, Zurawski VR. Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 125) associated with human epithelial ovarian carcinomas. Cancer Res 44(3):1048-1053, 1984. PMID: 6198078.
469. Feig LA, Bast RC, Knapp RC, Cooper GM. Somatic activation of rasK gene in a human ovarian carcinoma. Science 223(4637):698-701, 1984. PMID: 6695178.
470. Kabawat SE, Bast RC, Welch WR, Knapp RC, Bhan AK. Expression of major histocompatibility antigens and nature of inflammatory cellular infiltrate in ovarian neoplasms. Int J Cancer 32(5):547-554, 1983. PMID: 6358053.
471. Bast RC, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker L, Zurawski VR, Knapp RC. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 309(15):883-887, 1983. PMID: 6310399.
472. Berkowitz R, Kabawat S, Lazarus H, Colvin R, Knapp R, Bast RC. Comparison of a rabbit heteroantiserum and a murine monoclonal antibody raised against a human epithelial ovarian carcinoma cell line. Am J Obstet Gynecol 146(6):607-612, 1983. PMID: 6346879.
473. Bast RC, Reinherz EL, Maver C, Lavin P, Schlossman SF. Contrasting effects of cyclophosphamide and prednisolone on the phenotype of human peripheral blood leukocytes. Clin Immunol Immunopathol 28(1):101-114, 1983. PMID: 6409485.
474. Bast RC, Berek JS, Obrist R, Griffiths CT, Berkowitz RS, Hacker NF, Parker L, Lagasse LD, Knapp RC. Intraperitoneal immunotherapy of human ovarian carcinoma with Corynebacterium parvum. Cancer Res 43(3):1395-1401, 1983. PMID: 6825108.
475. Bast RC, Ritz J, Lipton JM, Feeney M, Sallan SE, Nathan DG, Schlossman SF. Elimination of leukemic cells from human bone marrow using monoclonal antibody and complement. Cancer Res 43(3):1389-1394, 1983. PMID: 6337707.
476. Kabawat SE, Bast RC, Welch WR, Knapp RC, Colvin RB. Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid, and clear cell types. Am J Clin Pathol 79(1):98-104, 1983. PMID: 6336888.
477. Valone FH, Obrist R, Tarlin N, Bast RC. Enhanced arachidonic acid lipoxygenation by K562 cells stimulated with 12-O-tetradecanoylphorbol-13-acetate. Cancer Res 43(1):197-201, 1983. PMID: 6401164.
478. Ritz J, Sallan SE, Bast RC, Lipton JM, Nathan DG, Schlossman SF. In vitro treatment with monoclonal antibody prior to autologous bone marrow transplantation in acute lymphoblastic leukemia. Haematol Blood Transfus 28:117-123, 1983. PMID: 6345287.
479. Obrist R, Reilly R, Leavitt T, Knapp RC, Bast RC. Monocyte chemotaxis mediated by formyl-methionyl-leucyl-phenylalanine conjugated with monoclonal antibodies against human ovarian carcinoma. Int J Immunopharmacol 5(4):307-314, 1983. PMID: 6629591.
480. Kabawat SE, Bast RC, Bhan AK, Welch WR, Knapp RC, Colvin RB. Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125. Int J Gynecol Pathol 2(3):275-285, 1983. PMID: 6196309.
481. Sang DN, Duncan J, Rodrick M, Steele G, Schepens CL, Jr BR. Circulating immune complex levels in peripheral uveitis: Discriminant analysis. Proceedings of the XXIV International Congress of Ophthalmology None(None):453-459, 1983. PMID: None.
482. Galli SJ, Bast RC, Bast BS, Isomura T, Zbar B, Rapp HJ, Dvorak HF. Bystander suppression of tumor growth: evidence that specific targets and bystanders are damaged by injury to a common microvasculature. J Immunol 129(2):890-899, 1982. PMID: 6282973.
483. Ritz J, Sallan SE, Bast RC Jr, Lipton JM, Clavell LA, Feeney M, Hercend T, Nathan DG, Schlossman SF. Autologous bone-marrow transplantation in CALLA-positive acute lymphoblastic leukemia after in-vitro treatment with J5 monoclonal antibody and complement. Lancet 2(8289):60-3, 1982. PMID: 6177990.
484. Bast RC, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 68(5):1331-1337, 1981. PMID: 7028788.
485. Feeney M, Knapp RC, Greenberger JS, Bast RC. Elimination of leukemic cells from rat bone marrow using antibody and complement. Cancer Res 41(9 Pt 1):3331-3335, 1981. PMID: 6942913.
486. Clavell LA, Lipton JM, Bast RC, Kudisch M, Pesando J, Scholssman SF, Ritz J. Absence of common ALL antigen on normal bipotent myeloid, erythroid, and granulocyte progenitors. Blood 58(2):333-336, 1981. PMID: 6941821.
487. Bast RC, Miller H, Rapp HJ, Gelboin HV. Aryl hydrocarbon (benzo[a]pyrene) hydroxylase in guinea pig lymphoid tissue. J Natl Cancer Inst 67(2):359-364, 1981. PMID: 6943374.
488. Berkowitz RS, Hornig-Rohan J, Martin-Alosco S, Klein S, Goldstein DP, Bast RC, DeWolf WC. HL-A antigen frequency distribution in patients with gestational choriocarcinoma and their husbands. Placenta Suppl 3:263-267, 1981. PMID: 6963960.
489. Zbar B, Canti G, Rapp HJ, Ashley MP, Sukumar S, Bast RC. Immunoprophylaxis of syngeneic methycholanthrene-induced murine sarcomas with Bacillus Calmette-Guerin and tumor cells. Cancer Res 40(4):1036-1042, 1980. PMID: 7357533.
490. Frei E, Blum RH, Pitman SW, Kirkwood JM, Henderson IC, Skarin AT, Mayer RJ, Bast RC, Garnick MB, Parker LM, Canellos GP. High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity. Am J Med 68(3):370-376, 1980. PMID: 6965819.
491. Bast RC, Knapp RC, Donahue VC, Thurston JG, Mitchell AK, Feeney M, Schlossman SF. Specificity of heteroantisera developed against purified populations of intact murine ovarian carcinoma cells. J Natl Cancer Inst 64(2):365-372, 1980. PMID: 6986493.
492. Bast RC, Knapp RC, Mitchell AK, Thurston JG, Tucker RW, Schlossman SF. Immunotherapy of a murine ovarian carcinoma with Corynebacterium parvum and specific heteroantiserum. I. Activation of peritoneal cells to mediate antibody-dependent cytotoxicity. J Immunol 123(5):1945-1951, 1979. PMID: 489967.
493. Okuda T, Vesell ES, Plotkin E, Tarone R, Bast RC, Gelboin HV. Interindividual and intraindividual variations in aryl hydrocarbon hydroxylase in monocytes from monozygotic and dizygotic twins. Cancer Res 37(11):3904-3911, 1977. PMID: 561657.
494. Okuda T, Bast RC, Miller H, Rapp HJ, Gelboin HV. The half-life of aryl hydrocarbon (benzo(a)pyrene) hydroxylase in human blood monocytes. Chem Biol Interact 14(3-4):379-382, 1976. PMID: 954153.
495. Bast RC, Okuda T, Plotkin E, Tarone R, Rapp HJ, Gelboin HV. Development of an assay for aryl hydrocarbon (benzo(a)pyrene) hydroxylase in human peripheral blood monocytes. Cancer Res 36(6):1967-1974, 1976. PMID: 1268850.
496. Detrick-Hooks B, Smith HG, Bast RC, Dunkel VC, Borsos T. Naturally soluble tumor antigens from guinea pig hepatomas: isolation and partial characterization. J Immunol 116(5):1324-1331, 1976. PMID: 178795.
497. Bast RC, Segerling M, Ohanian SH, Greene SL, Zbar B, Rapp HJ, Borsos T. Regression of established tumors and induction of tumor immunity by intratumor chemotherapy. J Natl Cancer Inst 56(4):829-832, 1976. PMID: 176411.
498. Borsos T, Bast RC, Ohanian SH, Segerling M, Zbar B, Rapp HJ. Induction of tumor immunity by intratumoral chemotherapy. Ann N Y Acad Sci 276(None):565-572, 1976. PMID: 194520.
499. Smith HG, Bast RC, Zbar B, Rapp HJ. Eradication of microscopic lymph nodes metastases after injection of living BCG adjacent to the primary tumor. J Natl Cancer Inst 55(6):1345-1352, 1975. PMID: 1107574.
500. Bast RC, Zbar B, Rapp HJ. Local antitumor activity of a primary and an anamnestic response to a syngeneic guinea pig hepatoma. J Natl Cancer Inst 55(4):989-994, 1975. PMID: 171435.
501. Bast RC, Zbar B, Miller TE, Mackaness GB, Rapp HJ. Antitumor activity of bacterial infection. II. effect of Listeria monocytogenes on growth of a guinea pig hepatoma. J Natl Cancer Inst 54(3):757-761, 1975. PMID: 164568.
502. Bast RC, Zbar B, Mackaness GB, Rapp HJ. Antitumor activity of bacterial infection. I. Effect of Listeria monocytogenes on growth of a murine fibrosarcoma. J Natl Cancer Inst 54(3):749-756, 1975. PMID: 804566.
503. Zbar B, Smith H, Jr BR, Rapp HJ. Immunotherapy with BCG: Approaches to human malignant melanoma based on a guinea pig model. Behring Inst Mitt 56:35-40, 1975. PMID: None.
504. Bast RC, Doos WG, Zbar B, Harmel RP, Dalgard DW, Steward AM. Intracolonic injection of BCG in the rhesus monkey. J Natl Cancer Inst 53(5):1423-1426, 1974. PMID: 4431061.
505. Bast RC, Whitlock JP, Miller H, Rapp HJ, Gelboin HV. Aryl hydrocarbon (benzo(a)pyrene) hydroxylase in human peripheral blood monocytes. Nature 250(5468):664-665, 1974. PMID: 4850643.
506. Dunkel VC, Bast RC, Gerwin BI, Heine U, Cottler-Fox M, Borsos T. Presence of A-type and absence of C-type virus particles in a chemically induced guinea pig hepatoma. J Natl Cancer Inst 53(2):591-593, 1974. PMID: 4135601.
507. Zwilling BS, Leonard EJ, Bast RC, Zbar B. Destruction of syngeneic tumors by tuberculin-stimulated peritoneal exudate cells from guinea pigs immunized to Mycobacterium bovis (strain BCG). J Natl Cancer Inst 53(2):541-546, 1974. PMID: 4367248.
508. Bast RC, Zbar B, Borsos T, Rapp HJ. BCG and cancer (first of two parts). N Engl J Med 290(25):1413-20, 1974. PMID: 4364286.
509. Bast RC, Zbar B, Borsos T, Rapp HJ. BCG and cancer (second of two parts). N Engl J Med 290(26):1458-1469, 1974. PMID: 4598691.
510. Bast RC, Cleveland RP, Littman BH, Zbar B, Rapp HJ. Acquired cellular immunity: extracellular killing of Listeria monocytogenes by a product of immunologically activated macrophages. Cell Immunol 10(2):248-259, 1974. PMID: 4218128.
511. Bast RC, Shears BW, Rapp HJ, Gelboin HV. Aryl hydrocarbon (benzo(a)pyrene) hydroxylase in guinea pig peritoneal macrophages: benz(a)anthracene-induced increase of enzyme activity in vivo and in cell culture. J Natl Cancer Inst 51(2):675-678, 1973. PMID: 4765380.
512. Dvorak AM, Bast RC, Dvorak HF. Morphologic changes in draining lymph nodes and in lymphocyte cultures after sensitization with complete or incomplete Freund's adjuvant. Correlation with immunologic events in vivo and in culture. J Immunol 107(2):422-435, 1971. PMID: 5568772.
513. Dvorak HF, Simpson BA, Bast RC, Leskowitz S. Cutaneous basophil hypersensitivity. III. Participation of the basophil in hypersensitivity to antigen-antibody complexes, delayed hypersensitivity and contact allergy. Passive transfer. J Immunol 107(1):138-148, 1971. PMID: 5091955.
514. Bast RC, Manseau EJ, Dvorak HF. Heterogeneity of the cellular immune response. I. Kinetics of lymphocyte stimulation during sensitization and recovery from tolerance. J Exp Med 133(2):187-201, 1971. PMID: 5316261.
515. Bast RC, Simpson BA, Dvorak HF. Heterogeneity of the cellular immune response. II. The role of adjuvant, lymphocyte stimulation in cutaneous basophil hypersensitivity. J Exp Med 133(2):202-215, 1971. PMID: 5316262.
516. Dvorak HF, Bast RC. Nature of the immunogen in crystalline serum albumins. Immunochemistry 7(1):118-124, 1970. PMID: 5416390.
517. Dvorak HF, Simpson BA, Bast RC. Immunologic unresponsiveness in the adult guinea pig. IV. Induction of unresponsiveness with aggregated serum proteins. J Immunol 102(5):1163-1171, 1969. PMID: 4181547.
518. Heilman DH, Bast RC. In vitro assay of endotoxin by the inhibition of macrophage migration. J Bacteriol 93(1):15-20, 1967. PMID: 5335889.
519. Heilman DH, Bast R. Effect of Endotoxin on Macrophages of the Adult Chicken. Proc Soc Exp Biol Med 116:1019-1022, 1964. PMID: 14230331.
520. Fahrmann JF, Mahmood MS, Han CY, Wu R, Dennison JB, Vykoukal J, Celestino J, Lu K, Lu Z, Drescher C, Do KA, Hanash S, Bast RC, Irajizad E. Validation of a blood based metabolite biomarker panel for early detection of ovarian cancer. Biomarker Research None(None):None. PMID: None.

Invited Articles

1. Finkler NJ, Bast RC, Knapp RC. Tumor markers in gynecologic cancer. Contemporary OB/GYN 30(None):29-42, 1987. PMID: None.
2. Knapp RC, StJohn E, Bast RC. A review of intraperitoneal therapy of human ovarian carcinoma. Peritoneal Dialysis Bull 3(None):59-62, 1983. PMID: None.
3. Bast RC, Rapp HJ. Immunotherapy of cancer - the skin is deep enough. Mod Med 43(None):45-51, 1975. PMID: None.

Other Articles

1. Bildik G, Liang X, Sutton MN, Bast RC, Lu Z DIRAS3: An Imprinted tumor suppressor gene that regulates RAS and PI3K-driven cancer growth, motility, autophagy and tumor dormancy. Mol Cancer Ther 21(1):25-37, 2022. PMID: 34667114.
2. Elias KM, Guo J, Bast RC Early Detection of Ovarian Cancer. Hematol Oncol Clin North Am 32(6):903-914, 2018. PMID: 30390764.
3. Kim J, Park EY, Kim O, Schilder JM, Coffey DM, Cho CH, Bast RC Cell Origins of High-Grade Serous Ovarian Cancer. Cancers (Basel) 10(11), 2018. PMID: 30424539.
4. Santiago, J, Bast RC, Lu Z Commentary: Autophagy and Cancer Chemotherapy – Inhibition or Enhancement?. Single Cell Biol 5(3):1000145, 2016. PMID: None.
5. Bast RC Molecular approaches to personalizing management of ovarian cancer. Ann Oncol 22 Suppl 8(None):viii5-viii15, 2011. PMID: 22180401.
6. Moore RG, MacLaughlan S, Bast RC Current state of biomarker development for clinical application in epithelial ovarian cancer. Gynecol Oncol 116(2):240-5, 2010. PMID: 19879639.
7. Bast RC Biomarkers for ovarian cancer: New technologies and targets to address persistently unmet needs. Cancer Biomark 8(4-5):161-166, 2010. PMID: 22045350.
8. Bast RC, Hennessy B, Mills GB The Biology of Ovarian Cancer: New Opportunities for Translation. Nat Rev Cancer 9(6):415-28, 2009. PMID: 19461667.
9. Badgwell D, Bast RC Early detection of ovarian cancer. Dis Markers 23(5-6):397-410, 2007. PMID: 18057523.
10. Bast RC, Brewer M, Zou C, Hernandez MA, Daley M, Ozols R, Lu K, Lu Z, Badgwell D, Mills GB, Skates S, Zhang Z, Chan D, Lokshin A, Yu Y Prevention and early detection of ovarian cancer: Mission impossible?. Recent Results Cancer Res 174:91-100, 2007. PMID: 17302189.
11. Fu S, Kavanagh JJ, Hu W, Bast RC Clinical application of oxaliplatin in epithelial ovarian cancer. Int J Gynecol Cancer 16(5):1717-1732, 2006. PMID: 17009963.
12. Fu S, Hu W, Kavanagh JJ, Bast RC Targeting Aurora kinases in ovarian cancer. Expert Opin Ther Targets 10(1):77-85, 2006. PMID: 16441230.
13. Bast RC, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, Baggerly KA, Atkinson EN, Skates S, Zhang Z, Lokshin A, Menon U, Jacobs I, Lu K New tumor markers: CA 125 and beyond. Int J Gynecol Cancer 15 Suppl 3:274-281, 2005. PMID: 16343244.
14. Bast RC, Lilja H, Urban N, Rimm DL, Fritsche H, Gray J, Veltri R, Klee G, Allen A, Kim N, Gutman S, Rubin MA, Hruszkewycz A Translational crossroads for biomarkers. Clin Cancer Res 11(17):6103-8, 2005. PMID: 16144908.
15. Kelloff GJ, Bast RC, Coffey DS, D'Amico AV, Kerbel RS, Park JW, Ruddon RW, Rustin GJ, Schilsky RL, Sigman CC, Vande Woude GF Biomarkers, surrogate endpoints, and the acceleration of drug development for cancer prevention and treatment: an update prologue. Clin Cancer Res 10(11):3881-3884, 2004. PMID: 15173097.
16. Rustin GJ, Bast RC, Kelloff GJ, Barrett JC, Carter SK, Nisen PD, Sigman CC, Parkinson DR, Ruddon RW Use of CA 125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. Clin Cancer Res 10(11):3919-3926, 2004. PMID: 15173101.
17. Bast RC Early detection of ovarian cancer: New technologies in pursuit of a disease that is neither common nor rare. Trans Am Clin Climatol Assoc 115(None):233-248, 2004. PMID: 17060970.
18. See HT, Kavanagh JJ, Hu W, Bast RC Targeted therapy for epithelial ovarian cancer: current status and future prospects. Int J Gynecol Cancer 13(6):701-734, 2003. PMID: 14675307.
19. Mills GB, Kohn E, Lu Y, Eder A, Fang X, Wang H, Bast RC, Gray J, Jaffe R, Hortobagyi G Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer. Semin Oncol 30(5 Suppl 16):93-104, 2003. PMID: 14613030.
20. Yu Y, Fujii S, Yuan J, Luo RZ, Wang L, Bao J, Kadota M, Oshimura M, Dent SR, Issa JP, Bast RC Epigenetic regulation of ARHI in breast and ovarian cancer cells. Ann N Y Acad Sci 983:268-277, 2003. PMID: 12724231.
21. Brewer MA, Johnson K, Follen M, Gershenson D, Bast R Prevention of ovarian cancer: intraepithelial neoplasia. Clin Cancer Res 9(1):20-30, 2003. PMID: 12538447.
22. Ozols RF, Daly MB, Klein-Szanto A, Hamilton TC, Bast RC, Brewer MA Specific keynote: chemoprevention of ovarian cancer: the journey begins. Gynecol Oncol 88(1 Pt 2):S59-66; discussion S67-70, 2003. PMID: 12586088.
23. Bast RC, Mills GB General keynote: molecular therapeutics and pharmacogenomics. Gynecol Oncol 88(1 Pt 2):S84-7; discussion S93-6, 2003. PMID: 12586093.
24. Bösze P, Bast RC, Berchuck A, Burke HB, Buller RE, Creasman WT, Dubeau L, Fox H, Geisler HE, Geisler JP, Henson DE, Rustin GJ, Vermorken JB, Wells M, Wilbanks GD Consensus statements on prognostic factors in epithelial ovarian carcinoma. Report of the Consensus Meeting organized by the European Society of Gynaecological Oncology, ESGO. Eur J Gynaecol Oncol 21(5):513-526, 2000. PMID: 11198047.
25. Brewer MA, Mitchell MF, Bast RC Prevention of ovarian cancer. In Vivo 13(1):99-106, 1999. PMID: 10218141.
26. Bast RC, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB CA 125: The past and the future. Int J Biol Markers 13(4):179-187, 1998. PMID: 10228898.
27. Pusztai L, Siddik ZH, Mills GB, Bast RC Physiologic and pathologic drug resistance in ovarian carcinoma--a hypothesis based on a clonal progression model. Acta Oncol 37(7-8):629-40, 1998. PMID: 10050979.
28. Bast RC SCC antigen. Summary remarks. Tumour Biol 19(6):527-8, 1998. PMID: 9817982.
29. Berek JS, Bast RC Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection. Cancer 76(10 Suppl):2092-2096, 1995. PMID: 8635006.
30. Berchuck A, Bast RC p53-based gene therapy of ovarian cancer: Magic bullet?. Gynecol Oncol 59(2):169-170, 1995. PMID: 7590466.
31. Bast RC, Boyer CM, Xu FJ, Wiener J, Dabel R, Woolas R, Jacobs I, Berchuck A Molecular approaches to prevention and detection of epithelial ovarian cancer. J Cell Biochem Suppl. 23:219-222, 1995. PMID: 8747399.
32. Bast RC Clinical and laboratory directions for ovarian cancer research. Gynecol Oncol 55(3 Pt 2):S164-167, 1994. PMID: 7835802.
33. Berchuck A, Elbendary A, Havrilesky L, Rodriguez GC, Bast RC Pathogenesis of ovarian cancers. J Soc Gynecol Investig 1(3):181-190, 1994. PMID: 9419769.
34. Jr BR, Boyer CM, Xu FJ, Wu S, Wiener JR, Kassim SK, Kohler MF, O'Briant K, DeSombre K, Bast RC, Dean S, Daly L, Berchuck A Selected molecular targets for diagnosis and therapy of epithelial ovarian cancer. Cancer Mol Biol 1(None):87-93, 1994. PMID: None.
35. Bast RC Perspectives on the future of cancer markers. Clin Chem 39(11 Pt 2):2444-2451, 1993. PMID: 8222257.
36. Boente MP, Hurteau J, Rodriguez GC, Bast RC, Berchuck A The biology of ovarian cancer. Curr Opin Oncol 5(5):900-907, 1993. PMID: 8218503.
37. Bast RC, Boyer CM, Jacobs I, Xu FJ, Wu S, Wiener J, Kohler M, Berchuck A Cell growth regulation in epithelial ovarian cancer. Cancer 71(4 Suppl):1597-1601, 1993. PMID: 8431895.
38. Berchuck A, Kohler MF, Boente MP, Rodriguez GC, Whitaker RS, Bast RC Growth regulation and transformation of ovarian epithelium. Cancer 71(2 Suppl):545-551, 1993. PMID: 8420675.
39. Wiener JR, Berchuck A, Bast RC Biology and therapy with biologic agents in gynecologic cancer. Curr Opin Oncol 4(5):946-954, 1992. PMID: 1457511.
40. Berchuck A, Kohler MF, Bast RC Oncogenes in ovarian cancer. Hematol Oncol Clin North Am 6(4):813-827, 1992. PMID: 1500387.
41. Berchuck A, Boente MP, Bast RC The use of tumor markers in the management of patients with gynecologic carcinomas. Clin Obstet Gynecol 35(1):45-54, 1992. PMID: 1544249.
42. Berchuck A, Bast RC Overexpression of HER-2/neu in gyn cancer. Contemp Obstet Gynecol 37(None):25-38, 1992. PMID: None.
43. Bookman MA, Bast RC The immunobiology and immunotherapy of ovarian cancer. Semin Oncol 18(3):270-291, 1991. PMID: 1710393.
44. Olt G, Berchuck A, Bast RC The role of tumor markers in gynecologic oncology. Obstet Gynecol Surv 45(9):570-577, 1990. PMID: 1697940.
45. Berchuck A, Bast RC New directions in diagnosing, monitoring and detecting epithelial ovarian cancer. Adv Oncol 6(None):18-22, 1990. PMID: None.
46. Olt GJ, Berchuck A, Bast RC Gynecologic tumor markers. Semin Surg Oncol 6(6):305-313, 1990. PMID: 2263805.
47. Jacobs I, Bast RC The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod 4(1):1-12, 1989. PMID: 2651469.
48. Lidor Y, Bast RC Serotherapy of ovarian cancer. Nat Immun Cell Growth Regul 7(4):193-215, 1988. PMID: 3070370.
49. Boyer CM, Lidor Y, Lottich SC, Bast RC Antigenic cell surfacemarkers in human solid tumors. Antibody Immunocon Radiopharm 1(None):105-162, 1988. PMID: None.
50. Berchuck A, Boyer CM, Bast RC The role of CA 125 in ovarian cancer. Postgrad Obstet Gynecol 8(None):1-7, 1988. PMID: None.
51. Bast RC, Hunter V, Knapp RC Pros and cons of gynecologic tumor markers. Cancer 60(8 Suppl):1984-1992, 1987. PMID: 2443235.
52. Greenberger JS, FitzGerald TJ, Rothstein L, Pierce J, Sakakeeny MA, Weichselbaum RR, Naparstek E, Newburger P, Griffin J, Bast RC Long-term culture of human granulocytes and granulocyte progenitor cells. Prog Clin Biol Res 211(None):159-185, 1986. PMID: 3008194.
53. Bast RC, Ritts RE Antigens shed by tumor cells. Hybridoma 5(None):171-172, 1986. PMID: None.
54. Bast RC, Knapp RC Monitoring epithelial ovarian cancer. Lab Med 16(None):315-318, 1985. PMID: None.
55. Bast RC, Klug T, Niloff JM, Knapp RC Clinical usefulness of CA 125. Cancer Bulletin 37(None):80-81, 1985. PMID: None.
56. Bast RC, Knapp RC Immunologic approaches to the management of ovarian carcinoma. Semin Oncol 11(3):264-274, 1984. PMID: 6207593.
57. Ritz J, Bast RC, Takvorian T, Sallan SE Clinical applications of monoclonal antibodies in acute leukemia. Ann N Y Acad Sci 428(None):308-317, 1984. PMID: 6234835.
58. Bast RC, Bast BS Critical review of previously reported animal studies of tumor immunotherapy with nonspecific immunostimulants. Ann N Y Acad Sci 277(00):60-93, 1976. PMID: 826208.

Editorials

1. Ahmed AA, Becker CM, Bast RC. The origin of ovarian cancer. BJOG 119(2):134-6, 2012. PMID: 22168761.
2. Bast RC, Mills GB. Dissecting PI3Kness: The complexity of personalized therapy for ovarian cancer. Cancer Discov 2(1):16-8, 2012. PMID: 22585163.
3. Bast RC, Spriggs DR. More than a biomarker: CA125 may contribute to ovarian cancer pathogenesis. Gynecol Oncol 121(3):429-30, 2011. PMID: 21601106.
4. Bast RC, Markman M. Chemotherapy: A new standard combination for recurrent ovarian cancer?. Nat Rev Clin Oncol 7(10):559-60, 2010. PMID: 20877420.
5. Bast RC, Mills GB. Personalizing therapy for ovarian cancer: BRCAness and beyond. J Clin Oncol 28(22):3545-8, 2010. PMID: 20547987.
6. Moore RG, Bast RC. How do you distinguish a malignant pelvic mass from a benign pelvic mass? Imaging, biomarkers, or none of the above. J Clin Oncol 25(27):4159-61, 2007. PMID: 17698803.
7. Bast RC, Hortobagyi GN. Individualized care for patients with cancer: A work in progress. N Engl J Med 351(27):2865-2867, 2004. PMID: 15591336.
8. Mills GB, Bast RC, Srivastava S. Future for ovarian cancer screening: novel markers from emerging technologies of transcriptional profiling and proteomics. J Natl Cancer Inst 93(19):1437-1439, 2001. PMID: 11584052.
9. Mills GB, Schmandt R, Gershenson D, Bast RC. Should therapy of ovarian cancer patients be individualized based on underlying genetic defects?. Clin Cancer Res 5(9):2286-2288, 1999. PMID: 10499594.
10. Fritsche HA, Bast RC. CA 125 in ovarian cancer: advances and controversy. Clin Chem 44(7):1379-1380, 1998. PMID: 9665412.
11. Bast RC. Progress in radioimmunotherapy. N Engl J Med 329(17):1266-1268, 1993. PMID: 8413396.
12. Bast RC, Jacobs I, Berchuck A. Malignant transformation of ovarian epithelium. J Natl Cancer Inst 84(8):556-558, 1992. PMID: 1556762.
13. McVie JG, Bast RC. Therapeutic modalities: Editorial overview. Curr Opin Oncol 1(None):171-173, 1989. PMID: None.

Book Chapters

1. Holland JF, Bast RC, Byrd JC, Croce C, Hawk ET, Khuri FR, Pollock RE, Tsimberidou AM, Willett CG, Wilman CL. Cardinal Manifestations of Cancer. In: Holland-Frei Cancer Medicine. 10th. John Wiley & Sons, Inc, 3-6, 2023.
2. Berek J, Renz M, Friedlander ML, Bast RC. Epithelial Ovarian, Fallopian Tube and Peritoneal Cancer. In: Holland-Frei Cancer Medicine. 10th. John Wiley & Sons, Inc, 1311-1328, 2023.
3. Berek J, Renz M, Bast RC. Nonepithelial Ovarian Malignancies. In: Holland-Frei Cancer Medicine. 10th. John Wiley & Sons, Inc, 1329-1342, 2023.
4. Coyne ZL, Kalakand RD, Hennessey BD, Bast RC, Mills GB. Molecular Diagnostics in Cancer. In: Holland-Frei Cancer Medicine. 10th. John Wiley & Sons, Inc, 505-518, 2023.
5. Tsimberidou AM, Bast RC, Khuri F, Byrd JC. Principles of Medical Oncology. In: Holland-Frei Cancer Medicine. 10th. John Wiley & Sons, Inc, 553-566, 2023.
6. Bast RC, Zalutsky MR. Monoclonal Antibody and Targeted Toxin Therapy. In: Holland-Frei Cancer Medicine, 10th Edition, eds. None. None, 755-780, 2023.
7. Holland JF, Hong, WK, Kufe DW, Bast RC, Hait WN, Pollock RE, Weichselbaum RR. Cardinal Manifestations of Cancer. In: Holland-Frei Cancer Medicine. 9th. John Wiley & Sons, Inc, 3-6, 2017.
8. Berek JS, Friedlander ML, Bast RC. Nonepithelial Ovarian Cancers. In: Holland-Frei Cancer Medicine. 9th. John Wiley & Sons, Inc, 1339-52, 2017.
9. Kalachand RD, Hennessy BD, Bast RC, Mills, GC. Molecular Diagnostics in Cancer. In: Holland-Frei Cancer Medicine. 9th. John Wiley & Sons, Inc, 469-80, 2017.
10. Bast RC, Zalutsky MR, Frankel AE. Monoclonal Serotherapy. In: Holland-Frei Cancer Medicine. 9th. John Wiley & Sons, Inc, 757-776, 2017.
11. Patriotis C, Simmons AR, Lu KH, Bast RC, Skates SJ. State-of the-Science in Biomarker Research–Ovarian Cancer. In: Biomarkers in Cancer Screening and Early Detection. None. John Wiley & Sons, Inc, 93-103, 2017.
12. Hait WN, Holland JF, Kufe DW, Bast RC, Hong WK, Piccart M. Principles of Medical Oncology. In: Holland-Frei Cancer Medicine. 9th. John Wiley & Sons, Inc, 511-20, 2017.
13. Berek JS, Friedlander ML, Bast RC. Epithelial Ovarian, Fallopian Tube and Peritoneal Cancer. In: Holland-Frei Cancer Medicine. 9th. John Wiley & Sons, Inc, 1317-38, 2017.
14. Bast RC, Markman M, Hawk, E. Preface. In: Targeted Therapy in Translational Cancer Research. None. John Wiley & Sons, Inc, xiii, 2016.
15. Bast RC, Romero I, Mills GB. Molecular pathogenesis of ovarian cancer. In: The Molecular Basis of Cancer. 4th. Elsevier Health, 531-47, 2015.
16. Sutton MN, Lu Z, Bast RC. The Role of Angiogenesis, Growth Arrest and Autophagy in Human Ovarian Cancer Xenograft Models for Tumor Dormancy. In: Tumor Dormancy, Quiescence, and Senescence. None. Springer Science+Business Media, 99-109, 2014.
17. Suh G, Hennessy B, Verhaak R, Yang JY, Mills GB, Bast RC. Molecular Targets for Ovarian Cancer. In: Molecular Oncology: Causes of Cancer and Targets for Treatment. None. Cambridge University Press, 600-18, 2014.
18. Bast RC, Markman M, Hawk E. Preface. In: Cancer Gene Therapy with Viral and Non-Viral Vectors. 1st. John Wiley & Sons, Inc, None, 2014.
19. Roux R, Romero I, Zweifel M, Rustin GM, Bast RC. Recurrent ovarian cancer: When to treat and how to assess. In: Controversies in the Management of Gynecological Cancers. None. Springer, None, 2014.
20. Le XF, Bast RC. Molecular and cellular alterations modified by HER2 inhibition and overexpression. In: Horizons in Cancer Research. None. Nova Science Publishers, 159-184, 2011.
21. Ahmed AA, Knapp S, Sood AK, Bast RC. Targeting therapy in ovarian cancer. In: Gynaecological Cancers - Biology and Therapeutics. None. 60th RCOG Study Group, Royal College of Obstetricians and Gynecologists, RCOG Press, 167-181, 2011.
22. Berek JS, Friedlander ML, Bast RC. Ovarian Cancer. In: Holland-Frei Cancer Medicine. 8th. PMPH-USA, 1344-1375, 2010.
23. Hait WN, Holland JF, Kufe DW, Bast RC, Hong WK, Piccart M. Principles of Medical Oncology. In: Holland-Frei Cancer Medicine. 8th. PMPH-USA, 541-9, 2010.
24. Holland JF, Frei E III, Hong WK, Kufe DW, Bast RC, Hait WN, Pollock RE, Weichselbaum RR. Cardinal manifestations of cancer. In: Holland-Frei Cancer Medicine. 8th. PMPH-USA, 1-3, 2010.
25. Keeler ER, Das P, Bast RC, Lu KH. Ovarian Cancer Screening. In: Early Diagnosis of Ovarian Cancer. None. Elsevier, 87-107, 2010.
26. Hennessy B, Bast RC, Mills GB. Molecular diagnostics in cancer. In: Holland-Frei Cancer Medicine. 8th. PMPH-USA, 335-346, 2010.
27. Bast RC, Zalutsky M, Kreitman RM, Frankel AE. Monoclonal Serotherapy. In: Holland-Frei Cancer Medicine. 8th. PMPH-USA, 710-724, 2010.
28. Le XF, Bast RC. p27Kip1 as a biomarker and target for treatment of cancer. In: Checkpoint Response in Cancer Therapy. None. Springer/Humana Press, 215-233, 2010.
29. Holland JF, Frei E III, Kufe DW, Bast RC, Pollock RE, Weichselbaum RR, Hong WK, Hait WN. Multidisciplinary management. In: Holland-Frei Cancer Medicine. 8th. PMPH-USA, 823-829, 2010.
30. Moore RG, Bast RC. Biomarkers and ovarian cancer. In: Ovarian Cancer: State of the Art. None. Remedica, 35-58, 2009.
31. Lu Z, Bast RC. Tumor suppressor genes. In: Cancer Treat Res. 2nd. Springer, 109-29, 2009.
32. Hennessy B, Bast RC, Gonzalez-Angulo AM, Mills GB. Early detection of cancer: Molecular Screening. In: The Molecular Basis of Cancer. 3rd. Saunders-Elsevier, 335-350, 2008.
33. Bast RC, Mills GB. Molecular pathogenesis of epithelial ovarian cancer. In: The Molecular Basis of Cancer. 3rd. Saunders-Elsevier, 441-454, 2008.
34. Lu Z, Feng W, Luo RZ, Liao WSL, Bast RC, Yu Y. E2F-HDAC complexes regulate tumor suppressor genes in cancer. In: Control of Cellular Physiology by E2F Transcription Factors. None. Research Signpost, 303-307, 2008.
35. Yu Y, Luo R, Lu Z, Wei Feng W, Badgwell D, Issa JP, Rosen DG, Liu J, Bast RC. Biochemistry and Biology of ARHI (DIRAS3), an Imprinted Tumor Suppressor Gene Whose Expression is Lost in Ovarian and Breast Cancers. In: Methods Enzymol. None. None, 455-68, 2006.
36. Holland JF, EIII F, Kufe DW, Bast RC, Pollack RW, Weichselbaum RR, Hong WK, Hait W. Principles of multidisciplinary management. In: Holland-Frei Cancer Medicine. 7th. B C Decker, Inc, 935-940, 2006.
37. Holland JF, Frei E III, Kufe DW, Bast RC, Pollock R, Weichselbaum RR, Hong WK, Hait WN. Cardinal manifestations of cancer. In: Holland-Frei Cancer Medicine. 7th. B C Decker, Inc, 3-8, 2006.
38. Hait WN, Holland JF, Frei E III, Kufe DW, Bast RC, Hong WK. Principles of Medical Oncology. In: Holland-Frei Cancer Medicine. 7th. B C Decker, Inc, 562-569, 2006.
39. Bast RC, Zalutsky M, Kreitman R, Frankel A. Monoclonal Serotherapy. In: Holland-Frei Cancer Medicine. 7th. B C Decker, Inc, 770-785, 2006.
40. Berek JS, Bast RC. Ovarian Cancer. In: Holland-Frei Cancer Medicine. 7th. B C Decker, Inc, 1543-1568, 2006.
41. Rosen DG, Yang G, Bast RC, Liu J. Use of ras-transformed human ovarian surface epithelial cells as a model for studying ovarian cancer. In: Methods Enzymol. None. None, 660-76, 2006.
42. Bast RC, Mills GB. Molecular mechanisms of pathogenesis and progression of epithelial ovarian cancer. In: The Ovary. 2nd. Elsevier Science, 425-445, 2004.
43. Berek J, Bast RC. Ovarian Cancer. In: Holland-Frei Cancer Medicine. 6th. B C Decker, Inc, 1831-1862, 2003.
44. Bast RC, Kousparou CA, Epenetos AA, Kreitman RJ, Sausville EA, Frankel AE. Monoclonal Serotherapy. In: Holland-Frei Cancer Medicine. 6th. B C Decker, Inc, 881-898, 2003.
45. Holland JF, Frei E III, Kufe DW, Bast RC, Pollock RE, Weichselbaum RR. Multidisciplinary management. In: Holland-Frei Cancer Medicine. 6th. B C Decker, Inc, 1079-1084, 2003.
46. Holland JF, Frei E III, Kufe DW, Bast RC. Principles of Medical Oncology. In: Holland-Frei Cancer Medicine. 6th. B C Decker, Inc, 637-644, 2003.
47. Bast RC, Urban N, Shridhar V, Smith D, Zhang Z, Skates S, Lu K, Liu J, Fishman D, Mills G. Early detection of ovarian cancer: promise and reality. In: Cancer Treat Res. None. Kluwer Publishers, (Cancer Treat Res 107:61-97), 2002.
48. Lu Y, Shayestri L, Lapushin R, Yu S, Cuevas B, Fang X, Eder A, Furui T, Plikoff D, Kuo WL, Baldocchi R, Vanhaesebroeck B, Jr BR, Pinkel D, Siminovitch K, Jaffe R, Gray J, Mills GB. Phosphatidylinositol 3' kinase in ovarian cancer: From genomics to therapeutics. In: Textbook of Ovarian Cancer. None. Oxford University Press, 565-578, 2001.
49. Bast RC, Mills GB. The molecular pathogenesis of ovarian cancer. In: The Molecular Basis of Cancer. 2nd. W.B. Saunders Co, 361-384, 2001.
50. Yu Y, Xu FJ, Peng H, Fang X, Zhao S, Xia W, Kuo WL, Gray JW, Siciliano M, Hogg D, Berchuck A, Hunt K, Mills GB, Bast RC. ARHI (NOEY2) an imprinted tumor suppressor gene in epithelial ovarian cancer. In: Textbook of Ovarian Cancer. None. None, 125-129, 2001.
51. Bast RC, Mills GB. Alterations in oncogenes, tumor suppressor genes and growth factors associated with epithelial ovarian cancers. In: Methods Mol Med. None. Humana Press, 37-48, 2001.
52. Jr BR. Comment: Clinical Practice Guidelines for the use of tumor markers in breast and colorectal cancer. In: Classic Papers and Current Comments: Evidence-Based Medicine and the Contribution of Guidelines. 4. Lippincott, Williams and Wilkins, 974-1009, 2000.
53. Jr BR, Zalutsky MR, Kreitman RR, Sausville EA, Frankel AE. Monoclonal Serotherapy. In: Holland Frei Cancer Medicine. 5th. B C Decker, Inc, 860-875, 2000.
54. Bookman MA, Boente MP, Jr BR. Immunology and Immunotherapy of Gynecologic cancers. In: Principles and Practice of Gynecologic-Oncology. 3rd. Lippincott-Raven Publishers, 129-164, 2000.
55. Holland JF, Frei E III, Kufe DW, Jr BR. Principles of Medical Oncology. In: Holland Frei Cancer Medicine. 5th. B C Decker, Inc, 503-510, 2000.
56. Jr BR, Morton DL. Immunostimulants. In: Holland Frei Cancer Medicine. 5th. B C Decker, Inc, 790-799, 2000.
57. Holland JF, Frei E III, Kufe DW, Jr BR, Pollock R, Weichselbaum RR. Principles of Multi-disciplinary Management. In: Holland Frei Cancer Medicine. 5th. B C Decker, Inc, 986-991, 2000.
58. Jr BR, F-J X, Yu Y, Fang X, Wiener J, Mills GB. Overview - The molecular biology of ovarian cancer. In: Ovarian Cancer 5. None. Isis Medical Media, 87-98, 1998.
59. Gallion HH, Kohn E, Mills GB, Jr BR. Clinical application of basic science investigation. In: Controversies in the Management of Ovarian Cancer. None. Churchill Livingston Publishing Co, 357-397, 1998.
60. Wolf JK, Mills GB, Jr BR, Roth JA, Gershenson DA. p53-mediated gene therapy. In: Ovarian Cancer 5. None. Isis Medical Media, 259-271, 1998.
61. Xu Y, Fang XJ, Furui T, Sasagawa T, Pustilnik T, Lu Y, Shen Z, Wiener JR, Shayesteh L, Gray JW, Jr BR, Mills GB. Regulation of growth of ovarian cancer cells by phospholipid growth factors. In: Ovarian Cancer 5. None. Isis Medical Media, 109-120, 1998.
62. Boente MP, Bookman M, Jr BR. Immunology and immunotherapy of gynecologic cancers. In: Gynecologic Oncology: Principles and Practice. 2nd. Lippincott-Raven, 149-176, 1997.
63. Jr BR. Foreword. In: What You Really Need to Know About Cancer. None. None, xiii-xiv, 1997.
64. Jr BR. An oncologist's perspective: Utility of tumor markers and the effectiveness of therapy. In: Tumor Markers: Reclassification, Reimbursement and Recent Advances. None. None, 23-37, 1997.
65. Jr BR, Frankel A, Zalutsky MR. Monoclonal Serotherapy. In: Cancer Medicine. 4th. Williams & Wilkins, 1245-1262, 1996.
66. Holland JF, Frei E III, Kufe DW, Jr BR, Morton DL, Weichselbaum RR. Principles of multidisciplinary management. In: Cancer Medicine. 4th. Williams & Wilkins, 1395-1401, 1996.
67. Berchuck A, Kohler MF, Bast RC. Molecular genetic features of ovarian cancer. In: Prog Clin Biol Res. None. John Wiley & Sons, Publishers, 269-284, 1996.
68. Holland JF, Frei E III, Kufe DW, Jr BR. Principles of Medical Oncology. In: Cancer Medicine. 4th. Williams & Wilkins, 755-765, 1996.
69. Soto-Wright V, Skates S, Berkowitz RS, Jr BR, Knapp RC. Natural history and detection of epithelial ovarian cancer. In: Gynecology and Obstetrics. None. Lippincott-Raven Publishers, 1-11, 1996.
70. Jr BR, Mills G, Gibson S, Boyer CM. Tumor Immunology. In: Cancer Medicine. 4th. Williams & Wilkins, 207-242, 1996.
71. Jr BR, Boyer CM, Dable RM, F-J X, Y-H Y, Berchuck A. New strategies for prevention and treatment. In: Ovarian Cancer 4. None. Chapman & Hall Medical, 199-204, 1996.
72. Jr BR, Morton DL. Immunostimulants. In: Cancer Medicine. 4th. Williams & Wilkins, 1169-1178, 1996.
73. Jr BR, Boyer CM, Xu FJ, Wiener J, Dabal R, Havrilesky L, Hurteau J, Elbendary A, Berchuck A. Cell growth regulation in human epithelial ovarian cancer. In: The Biology of Gynaecological Cancer. None. Royal College of Obstetricians and Gynaecologists Press, 119-127, 1995.
74. Berchuck A, Hurteau J, Jr BR. Oncogenes and tumor suppressor genes in ovarian cancer. In: Diagnosis and Management of Ovarian Disorders. None. Igaku-Shoin Medical Publishers, 208-227, 1995.
75. Elbendary AA, Berchuck A, Jr BR. Biology of epithelial ovarian cancer. In: Epithelial Cancer of the Ovary. None. British Medical Journal Publishing Group, 20-35, 1995.
76. Bast RC, Xu F, Yu Y, Crews J, Argon Y, Maier L, Lidor Y, Berchuck A, Boyer CM. Additive and synergistic interactions of monoclonal antibodies and immunotoxins reactive with breast and ovarian cancer. In: Immunol Ser. None. Marcel Dekker Inc, 23-30, 1994.
77. Berchuck A, Jr BR. Molecular genetic features of ovarian cancers: Potential for development of early detection strategies. In: Early Detection of Cancer: Molecular Markers. None. Futura Publishing Co., Inc, 279-288, 1994.
78. Jr BR, Wiener JR, Kassim S, Wu S, Boyer C, DeSombre K, Hurteau J, Rodriguez G, Mills G, Berchuck A. Cell growth regulation in ovarian cancer: Tyrosine kinases, tyrosine phosphatases and tumor necrosis factor-α. In: Ovarian Cancer 3. None. Chapman & Hall, 109-113, 1994.
79. Boyer CM, Knapp RC, Jr BR. Biology of gynecologic cancers. In: Practical Gynecologic Oncology. 2nd. Williams & Wilkins, 75-116, 1994.
80. Jr BR, F-J X, Woolas RP, Y-H Y, Conaway M, O'Briant K, Daly L, Oram D, Berchuck A, Clarke-Pearson DL, Soper JT, Rodriguez G, Jacobs I. Complementary and coordinate markers for detection of epithelial ovarian cancers. In: Ovarian Cancer 3. None. Chapman & Hall, 189-192, 1994.
81. Jr BR, Berchuck A. Ovarian Cancer. In: Harrison's Principles of Internal Medicine. 13th. McGraw-Hill Publishing, 1853-1858, 1994.
82. Holland JF, Frei EI, Jr BR, Kufe DW. Principles of medical oncology. In: Cancer Medicine. 3rd. Lea and Febiger, 588-597, 1993.
83. Jr BR, Morton DL. Immunostimulants. In: Cancer Medicine. 3rd. Lea and Febiger, 905-912, 1993.
84. Holland JF, Frei E III, Jr BR, Kufe DW, Morton D, Weichselbaum RR. Principles of multidisciplinary management. In: Cancer Medicine. 3rd. Lea and Febiger, 1073-1079, 1993.
85. Jr BR, Zalutsky MR, Frankel AE. Monoclonal Serotherapy. In: Cancer Medicine. 3rd. Lea and Febiger, 968-982, 1993.
86. Berchuck A, Jr BR. Oncogenes and tumor-suppressor genes. In: Ovarian Cancer. None. McGraw-Hill, 21-37, 1993.
87. Jr BR, Bookman MA, Knapp RC. Gynecologic tumor immunology. In: Gynecologic Oncology. 2nd. McGraw-Hill, 56-82, 1993.
88. Shpall EJ, Stemmer SM, Bearman SI, Jr BR, Peters WP, Ross M, Jones RB. High-dose chemotherapy with autologous bone marrow support for the treatment of epithelial ovarian cancer. In: Cancer of the Ovary. None. Raven Press, Ltd, 327-338, 1993.
89. Berchuck A, Jr BR. Use of CA 125 and other tumor markers for early diagnosis of epithelial ovarian cancer. In: Surgical Gynecologic Oncology. None. George Thieme Verlag Stuttgart, 440-442, 1993.
90. Berchuck A, Jr BR. Use of CA 125 and other markers for monitoring of epithelial ovarian cancer. In: Surgical Gynecologic Oncology. None. George Thieme Verlag Stuttgart, 449-450, 1993.
91. Berchuck A, Jr BR. Growth factors, oncogenes and tumor-suppressor genes. In: Cancer of the Ovary. None. Raven Press, 61-78, 1993.
92. Jr BR, Boyer CM. Tumor Immunology. In: Cancer Medicine. 3rd. Lea and Febiger, 171-197, 1993.
93. Jr BR, Xu FJ, Rodriguez GC, Whitaker R, Boente M, Berchuck A, McKenzie S, Houston LL, Boyer CM. Inhibition of breast and ovarian tumor cell growth by antibodies and immunotoxins reactive with distinct epitopes on the extracellular domain of HER-2/neu (c-erbB- 2). In: Ovarian Cancer 2: Biology, Diagnosis and Management. None. Chapman & Hall Medical, 67-72, 1992.
94. Jr BR, Boyer CM, Berchuck A, Xu FJ, Wu S, Lidor Y, Maier LA, Crews JR, Rosse M, Vredenburgh JJ, Shpall EJ, Peters WP. New strategies for the management of ovarian and breast cancer based on biology and pharmacology. In: Cancer Chemotherapy: Challenges for the Future, Volume 7. None. Excerpta Medica, 3-20, 1992.
95. Jacobs I, Jr BR. Tumor markers for ovarian cancer. In: Manual of Clinical Laboratory Immunology. 4th. American Society for Microbiology, 811-816, 1992.
96. Boente MP, Berchuck A, Jr BR. Immunology of gynecologic cancers. In: Principles and Practice of Gynecologic Oncology. None. JB Lippincott, 117-135, 1992.
97. Berchuck A, Marks JR, Jr BR. Expression of the epidermal growth factor receptor, HER-2/neu and p53 in ovarian cancer. In: Ovarian Cancer 2: Biology, Diagnosis and Management. None. Chapman & Hall Medical, 53-60, 1992.
98. Jr BR, Rodriguez GC, Wu S, Boyer CM, Berchuck A. Factors regulating the growth of normal and malignant ovarian epithelium. In: Ovarian Cancer 2: Biology, Diagnosis and Management. None. Chapman & Hall Medical, 61-66, 1992.
99. Sjövall K, Jr BR, Eklund G, Hall P, Knapp RC, Schoenfeld DA, Jr ZV, Einhorn N. Phase I investigation for early diagnosis of ovarian carcinoma: What problems are to be expected in a larger screening programme?. In: Cancer Screening. None. Cambridge University Press, 221-239, 1991.
100. Berchuck A, Rodriguez G, Jr BR. Recent advances in immunodiagnosis and immunotherapy. In: Gynecologic Oncology: Treatment Rationale and Techniques. None. Elsevier Science Publishing Co. Inc, 33-55, 1991.
101. Shpall EJ, Jr BR, Johnston CS, Peters WP, Jones RB. Combined purging approaches an autologous transplantation. In: Bone Marrow Processing and Purging: A Practical Guide. None. CRC Press, Inc, 307-328, 1991.
102. Rodriguez GC, Berchuck A, Jr BR. Monoclonal antibodies for immunodiagnosis and immunotherapy of epithelial ovarian cancer. In: Biologic Therapy of Cancer. None. JB Lippincott, 550-563, 1991.
103. Berek JS, Gritz ER, Jr BR, Kurman R, Rimer BK. Women's cancer screening: Guidelines and effect on mortality. In: Syntex Annual Women's Healthcare Roundtable Monograph 1991. None. Syntex Laboratories, 57-127, 1991.
104. Jerome KR, Barnd DL, Boyer CM, Taylor-Papadimitriou J, McKenzie IFC, Jr BR, Finn OJ. Adenocarcinoma reactive cytotoxic T lymphocytes recognize an epitope present on the protein core of epithelial mucin molecules. In: Cellular Immunity and the Immunotherapy of Cancer. UCLA Symposia on Molecular and Cellular Biology. New Series. None. Wiley-Liss Inc, 321-328, 1990.
105. Jacobs I, Bast RC. Immunodiagnosis of ovarian tumors. In: Immunol Ser. None. Marcel Dekker Inc, 323-38, 1990.
106. Jr BR, Boyer CM, Olt GJ, Berchuck A, Soper JT, Clarke-Pearson D, Xu FJ, Ramakrishnan S. Identification of markers for early detection of epithelial ovarian cancer. In: Ovarian Cancer. Biological and Therapeutic Challenges. None. Chapman & Hall Medical, 265-275, 1990.
107. Boyer CM, Knapp RC, Jr BR. Immunology and immunotherapy. In: Practical Gynecologic Oncology. None. Williams & Wilkins, 73-108, 1989.
108. Bast RC. Antigens associated with epithelial ovarian carcinomas. In: Prog Clin Biol Res. None. Alan R. Liss, 73-83, 1989.
109. Peters WP, Atwater S, Kurtzberg J, Borowitz M, Brandt SJ, Coleman RE, Kim CS, Gilbert C, Shpall EJ, Jones RB, Shogan J, Bast RC, Oette D, Stuart A, Coniglio D, Affronti ML, Evans S. The use of recombinant human granulocyte-macrophage colony-stimulating factor in autologous bone marrow transplantation. In: Autologous Bone Marrow Transplantation. Proc 4th Int Symp. None. The University of Texas M.D. Anderson Hospital and Tumor Institute, 657-667, 1989.
110. Jr MK, Kinney RB, Jr BR. Epithelial "tumor" markers in lesions of the breast. In: Hormones and Cancer 3. None. Raven Press Ltd, 282-289, 1988.
111. Finkler NJ, Knapp RC, Jr BR. Monoclonal Antibodies in Ovarian Cancer. In: Cancer Diagnosis in vitro Using Monoclonal Antibodies. None. Marcel Dekker Inc, 141-167, 1988.
112. Knapp RC, Berkowitz RS, Jr LT, Jr BR. Natural history and detection of ovarian cancer. In: Gynecology and Obstetrics. None. Harper & Row Publishers, 1-16, 1988.
113. Peters WP, Jones RB, Shpall EJ, Gockerman J, Kurtzberg J, Moore J, Bast RC, Gilbert C, Blackburn B, Coniglio D, Brophy L, Edwards S. Strategies in the treatment of breast cancer with intensive chemotherapy and autologous bone marrow support. In: Autologous Bone Marrow Transplantation. Proc 3rd Int Symp. None. The University of Texas MD Anderson Hospital and Tumor Institute, 465-474, 1987.
114. Kaizer H, Jr BR. Workshop summary: Autologous bone marrow transplantation in leukemia. In: UCLA Symposia on Molecular and Cellular Biology: Progress in Bone Marrow Transplantation. None. Alan R. Liss Inc, 779-785, 1987.
115. Frankel AE, Boyer CM, Bast RC. Immunobiology of Human Breast Cancer. In: Immunology of Malignant Disease. None. MTP Press, 167-224, 1987.
116. Bast RC, Knapp RC. The emerging role of monoclonal antibodies in the clinical management of epithelial ovarian carcinoma. In: Important Adv Oncol. None. JB Lippincott, 39-53, 1987.
117. Jr BR, Knapp RC. Humoral markers for epithelial ovarian carcinoma. In: Ovarian Malignancies: Diagnostic and Therapeutic Advances. None. Churchill Livingstone Publishing Co, 11-25, 1987.
118. Jr BR, Leslie D, Everitt L, Boyer C, Frankel A, Peters W, Ring D. Immunodetection of breast carcinoma cells in human bone marrow using multiple murine monoclonal antibodies and flow cytometry. In: Autologous Bone Marrow Transplantation. Proc 3rd Int Symp. None. The University of Texas MD Anderson Hospital and Tumor Institute, 485-487, 1987.
119. Antman K, Eder JP, Elias A, Shea T, Schryber S, Andersen J, Peters WP, Henner WD, Finberg R, Wilmore D, Kaplan W, Lew M, Kruskall MS, Anderson K, Bast R, Schnipper L, Frei E III. A preparative regimen of combination alkylating agent with autologous bone marrow transplant (ABMT) for solid tumors phase II. In: UCLA Symposia on Molecular and Cellular Biology: Progress in Bone Marrow Transplantation. None. Alan R. Liss Inc, 855-864, 1987.
120. Jr BR, Montgomery B, Haleem A, Kurtzberg J, Rhinehardt Clark A, Ramakrishnan S, Olsen G, Smith C, Leslie D, Peters W, Houston L. Chemoimmunoseparation of T lymphoma cells from human bone marrow. In: Autologous Bone Marrow Transplantation. Proc 3rd Int Symp. None. The University of Texas M.D. Anderson Hospital and Tumor Institute, 347-350, 1987.
121. Antman K, Peters WP, Eder JP, Schryber S, Andersen J, Henner WD, Elias A, Shea T, Finberg R, Wilmore D, Kaplan W, Lew M, Kruskall MS, Anderson K, Come S, Gorgone B, Bast R, Schnipper L, Frei E III. Treatment of 58 patients on a phase I and II protocol using a high-dose combination alkylating agent preparative regimen with autologous bone marrow support. In: Accomplishments in Cancer Research. None. JB Lippincott Co, 152-165, 1986.
122. Jr BR, Knapp RC. Monoclonal reagents in immunodiagnosis and immunotherapy of human epithelial ovarian carcinoma. In: Monoclonal Antibodies in Cancer: Advances in Diagnosis and Treatment. None. Futura Publishing Co, 61-86, 1986.
123. Peters WP, Shpall EJ, Jones RB, Olsen G, Gockerman J, Eder JP, Antman K, Kurtzberg J, Jr BR, Moore JO, Egorin MJ. Critical factors in the design of high dose combination chemotherapy regimens. In: Adv Cancer Chemother: High-Dose Thiotepa and Autologous Marrow Transplantation. Symposium Proceedings. None. None, 43-52, 1986.
124. Jr BR, Knapp RC. Concepts of gynecologic tumor immunology. In: Gynecologic Oncology. None. MacMillan Publishing Co, 97-118, 1986.
125. Jr BR, Knapp RC. Antigenic markers for ovarian carcinoma. In: Manual of Clinical Laboratory Immunology. 3rd. American Society for Micro-biology, 817-821, 1986.
126. Ritz J, Sallan SE, Jr BR, Takvorian T, Schlossman SF. Serotherapy and bone marrow transplantation. In: Hybridoma Technology in the Biosciences and Medicine. None. Plenum Publishing Co, 493-504, 1985.
127. Jr BR, DeFabritiis P, Bregni M, Raso V, Reynolds C, Lipton JM, Greenberger JS, Nadler LM, Sallan SE, Ritz J. Removal of malignant cells from human bone marrow using monoclonal antibodies and complement. In: Autologous Bone Marrow Transplantation. Proc 1st Int Symp. None. The University of Texas MD Anderson Hospital and Tumor Institute, 373-376, 1985.
128. Jr BR. Principles of cancer biology: Tumor immunology. In: Cancer: Principles and Practice of Oncology. 2nd. JB Lippincott, 125-150, 1985.
129. Jr BR, Sallan SE, Reynolds C, Lipton J, Ritz J. Autologous bone marrow transplantation for CALLA positive acute lymphoblastic leukemia: An Update. In: Autologous Bone Marrow Transplantation. Proc 1st Int Symp. None. The University of Texas MD Anderson Hospital and Tumor Institute, 3-6, 1985.
130. Nadler LM, Takvorian T, Botnick L, Bast R, Finberg R, Hellman S, Canellos GP, Schlossman SF. In vitro treatment with B1 monoclonal antibody prior to autologous bone marrow transplantation for relapsed B cell non Hodgkin's lymphoma. In: Immunopharmacology. Serono Symposia Publications. None. Raven Press, 129-139, 1985.
131. Jr BR, Knapp RC. Recent advances in the immunodiagnosis of epithelial ovarian carcinoma. In: Ovarian Cancer. None. Martinus Nijoff Publishers, 23-25, 1985.
132. Peters WP, Eder JP, Henner WD, Jr BR, Schnipper L, Frei E III. Novel toxicities associated with high-dose combination alkylating agents and autologous bone marrow support. In: Autologous Bone Marrow Transplantation. Proc 1st Int Symp. None. The University of Texas MD Anderson Hospital and Tumor Institute, 231-235, 1985.
133. Bast RC, Sallan SE, Nadler L, DeFabritiis P, Bregni M, Raso V, Reynolds C, Lipton J, Ritz J. Treatment of bone marrow with monoclonal antibodies in vitro prior to autologous bone marrow transplantation. In: Monoclonal Antibodies '84: Biological and Clinical Applications. None. Editrice Kurtis, 449-463, 1985.
134. Introna M, Jr BR. Epithelial ovarian carcinoma: Cell lines and antigenic tumor markers. In: Cancer of the Female Reproductive System. None. John Wiley and Sons, 153-180, 1985.
135. Jr BR, Zurawski VR, Knapp RC. Clinical application of monoclonal antibodies reactive with epithelial ovarian cancer. In: Monoclonal Antibodies and Cancer Therapy. None. Alan R. Liss, 37-51, 1985.
136. Jr BR, Knapp RC. Immunologic monitoring techniques and immunotherapy. In: Ovarian Cancer: New Approaches with Curative Intent. None. Sieber and McIntyre, 73-86, 1984.
137. Jr BR, Knapp RC. Monoclonal antibodies reactive with human ovarian carcinoma. In: Monoclonal Antibodies and Cancer. None. Marcel Dekker Inc, 241-252, 1984.
138. Jr BR, Knapp RC. CA 125 antigen for diagnosis and monitoring of epithelial ovarian carcinoma. In: Monoclonal Antibodies in Oncology: Clinical Applications. Proc Int Meeting. None. Conseil Regional Des Pays De Loire, 35-38, 1984.
139. Ritz J, Sallan SE, Bast RC, Lipton J, Hercend T, Nathan D, Schlossman SF. In vitro treatment with monoclonal antibody prior to autologous bone marrow transplantation in acute lymphoblastic leukemia. In: Quo Vadis. Flow Cytometry and Monoclonal Antibodies for Therapy Monitoring. None. Sanofi Recherche, 163-172, 1984.
140. Sallan SE, Jr BR, Lipton JM, Ritz J. Autologous bone marrow transplantation in CALLA positive acute lymphoblastic leukemia. In: Minimal Residual Disease in Acute Leukemia. None. Martinus Nijhoff Publishers, 255-264, 1984.
141. Jr BR, Ritz J. Application of monoclonal antibodies to autologous bone marrow transplantation. In: Biological Responses in Cancer: Progress Toward Potential Application, Volume 2. None. Plenum Press, 185-206, 1984.
142. Drebin JA, Schatten S, Tominaga A, Lefort S, Letvin NL, Bast R, Mizel SB, Greene MI. Characterization of ultraviolet radiation- induced impairment of antigen presenting cell function at the cellular and molecular levels. In: Effects of Ultraviolet Radiation on the Immune System. None. Academic Press, 123-127, 1983.
143. Jr BR, Knapp RC. The immunobiology of ovarian carcinoma. In: Gynecologic Oncology. None. Martinus Nijhoff Publishers, 187-226, 1983.
144. Ritz J, Sallan SE, Jr BR, Lipton JM, Nathan DG, Schlossman SF. In vivo and in vitro use of monoclonal antibodies for treatment of acute lymphoblastic leukemia. In: Leukemia Research: Advances in Cell Biology and Treatment. None. Elsevier Science Publishing Co. Inc, 281-294, 1983.
145. Jr BR. Effects of cancers and their treatment on host immunity. In: Cancer Medicine. 2nd. Lea and Febiger, 1134-1173, 1982.
146. Jr BR. Tumor immunology: An overview of future prospects. In: Cancer: A Manual for Practitioners. None. American Cancer Society, Massachusetts Division, 72-82, 1982.
147. Obrist R, Jr BR, Berkowitz R, Knapp RC. The immunology of gynecological malignancies. In: Current Problems in Obstetrics and Gynecology, Volume 5. None. Year Book Medical Publishers, Inc, 1-58, 1982.
148. Jr BR, Bast BS, Gelboin HV. Metabolism of polycyclic aromatic hydrocarbons by lymphoreticular cells. In: Extrahepatic Metabolism of Drugs and Other Foreign Compounds. None. MTP Press, 277-294, 1980.
149. Jr BR, Rapp HJ. The immunology of animal tumors. In: Immunological Diseases. 3rd. Little, Brown and Co, 359-388, 1978.
150. Gelboin HV, Selkirk J, Okuda T, Nemoto N, Yang SK, Wiebel FJ, Jr WJ, Rapp HJ, Jr BR. Benzo[a]pyrene metabolism: Enzymatic and liquid chromatographic analysis and application to human liver, lymphocytes and monocytes. In: Biological Reactive Intermediates. None. Plenum Press, 98-123, 1977.
151. Gelboin HV, Okuda T, Selkirk JK, Nemoto N, Yang SK, Rapp HJ, Jr BR. Benzo(a)pyrene metabolism: Enzymatic and liquid chromatographic analysis and application to human tissues. In: Fundamentals in Cancer Prevention. None. University Park Press, 167-190, 1976.
152. Gelboin HV, Okuda T, Selkirk J, Nemoto N, Yang SK, Wiebel FJ, Jr WJ, Rapp HJ, Jr BR. Benzo[a]pyrene metabolism: Enzymatic and liquid chromatographic analysis and application to human liver, lymphocytes and monocytes. In: Screening Tests in Chemical Carcinogenesis. None. IARC Scientific Publications, 225-247, 1976.
153. Zbar B, Smith HG, Jr BR, Rapp HJ. Immunologic eradication of lymph node metastases. In: BCG in Cancer Immunotherapy. None. Grune and Stratton, 361-366, 1976.

Books (edited and written)

1. Bast RC, Byrd JC, Croce C, Hawk ET, Khuri FR, Pollock RE, Tsimberidou AM, Willett CG, Wilman CL. Holland-Frei Cancer Medicine. Ed(s) 10th. John Wiley & Sons, 2023.
2. Cooper LJN, Mittendorf EA, Moyes J, Prabhakaran S. Immunotherapy in Translational Cancer Research. Ed(s) None. Wiley Blackwell, 2018.
3. Srivastava S, Bast RC, Markman M, Hawk E. Biomarkers Cancer Screening and Early Detection. Ed(s) None. Wiley Blackwell, 2017.
4. Bast RC, Hait WN, Hong WK, Kufe DW, Piccart-Gebart M, Pollock RE, Wang H, Weichselbaum RR, Holland JF. Holland-Frei Cancer Medicine. Ed(s) 9th. John Wiley & Sons, Inc, 2017.
5. Tsimberidou AM, Kurzrock R, Anderson K, Bast RC, Markman M, Hawk E. Targeted Therapy in Translational Cancer Research. Ed(s) None. Wiley-Blackwell, 2016.
6. Brenner M, Hung MC, Bast RC, Markman M, Hawk E. Cancer Gene Therapy by Viral and Non-Viral Vectors. Ed(s) None. Wiley-Blackwell, 2014.
7. Hong WK, Bast RC, Hait WN, Kufe DW, Pollock RE, Weichselbaum RR, Holland JF, Frei E III. Holland-Frei Cancer Medicine. Ed(s) 8th. PMPH-USA, 2010.
8. Bast RC, Markman M. Ovarian Cancer: State of the Art. Ed(s) None. Remedica, 2009.
9. Kufe DW, Bast RC, Hong WK, Hait W, Pollack RW, Weichselbaum RR, Holland JF, Frei E III. Holland-Frei Cancer Medicine. Ed(s) 7th. B.C. Decker, Inc, 2006.
10. Kufe DW, Pollock RE, Weichselbaum RR, Bast RC, Gansler TS, Holland JF, Frei E III. Holland-Frei Cancer Medicine. Ed(s) 6th. B.C. Decker, Inc, 2003.
11. Bast RC, Kufe DW, Pollock RE, Weichselbaum RR, Holland JF, Frei E III. Cancer Medicine. Ed(s) 5 Review. B.C. Decker, Inc, 2000.
12. Bast RC, Kufe DW, Pollock RE, Weichselbaum RR, Holland JF, Frei E III. Holland-Frei Cancer Medicine. Ed(s) 5th. B.C. Decker, Inc, 2000.
13. Sharp F, Blackett T, Berek J, Bast RC. Ovarian Cancer. Ed(s) 5th. Isis Medical Media, 1998.
14. Holland JF, Frei E III, Bast RC, Kufe DW, Morton DL, Weichselbaum RR. Cancer Medicine. Ed(s) 4th. Williams & Wilkins, 1996.
15. Holland JF, Frei E III, Bast RC, Kufe DW, Morton DL, Weichselbaum RR. Cancer Medicine. Ed(s) 3rd. Lea and Febiger, 1993.
16. Kimura K, Saito H, Carter SK, Bast RC. Cancer Chemotherapy: Challenges for the Future. Ed(s) None. Excerpta Medica, 1992.

Letters to the Editor

1. Harris L, Hayes D, Bast RC. 2007 ASCO Tumor Marker Guidelines, Reply to Letters from Cardoso et al and Bernards et al. J Clin Oncol 26: 2060-2061, 2008.
2. Kemeny N, Locker GY, Bast RC, Hayes DF. Carcinoembryonic Antigen Monitoring for Early Detection of Asymptomatic Incurable Metastatic Colorectal Cancer - Reply to the Letter-to-the-Editor. J Clin Oncol 25: 1294, 2007.
3. Bast RC. Tumor marker guidelines - Reply to the Letter-to-the-Editor. J Clin Oncol 15: 2175-2176, 1997.
4. Bast RC. Guidelines for the use of carcinoembryonic antigen in colorectal cancer - Reply to the Letter-to-the-Editor. J Clin Oncol 15: 864, 1997.
5. Bast RC, Woolas R. Screening for ovarian cancer. Multiple markers may outperform CA 125 alone. BMJ 306: 1684-5, 1993.